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Abstract 
 
Prostate cancer (PC) is the most common oncogenic malignancy in men in the UK, and is 
expected to affect 1 in 4 men throughout their lifetime. Whilst the treatment for organ 
confined PC is initially very effective, no successful therapies exist for patients where the 
disease has progressed to an advanced stage, and is reflected by the poor 5-year survival rate 
of 30%. Resistance to current treatment modalities, aimed at disrupting the androgen 
signalling axis, renders the disease what is termed castrate resistant PC (CRPC). Crucially, the 
primary target in the treatment of PC, the androgen receptor (AR), remains a key driver of 
disease survival and differentiation throughout disease progression.  
Activation of the AR at the post-translational level by aberrant co-activator activity is a well-
established resistance mechanism, however, the role of phosphatase enzymes on AR function 
represents a significant knowledge gap in AR regulation. To address this issue, phosphatase 
enzymes identified from a human phosphatome RNAi screen in the androgen responsive PC 
cell line, LNCaP, were characterised within the context of AR regulation. As such, myosin 
phosphatase (MLCP) was identified as a novel negative regulator of AR activity. Robust 
molecular biology techniques revealed that MLCP repressed AR function via indirect 
mechanisms involving the activation of the clinically relevant tumour suppressors RB1 and 
NF2. With this in mind, it was possible to identify the endogenous MLCP inhibitors, PPP1R14C 
and NUAK 1/2, as novel AR activators and potential therapeutic targets in both PC and CRPC. 
Disruption of either PPP1R14C or NUAK 1/2, via RNAi or small molecule inhibition, respectively, 
repressed AR transcriptional activity, characterised by reduced protein stability and impaired 
ligand induced nuclear translocation, culminating in reduced PC cell cycle progression, 
migration and proliferation, providing significant evidence for a novel, and therapeutically 
exploitable, AR regulatory mechanism. 
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1.1 Prostate Cancer 
1.1.1 Prostate Cancer Incidence 
Prostate cancer (PC) is the most common oncogenic malignancy in men in the UK (excluding 
non-melanoma skin cancer), accounting for approximately 25% of male diagnosed cancers 
(CRUK, 2016). This equates to 47,000 new cases being diagnosed each year, with current 
opinion suggesting that 1 in 8 men will be diagnosed with PC within their lifetime (CRUK, 2016; 
PCUK, 2016b). Diagnosis of PC has more than tripled since 1975, as demonstrated in figure 
1.1A. Amongst others, the advent and wide-spread implementation of the prostate-specific 
antigen (PSA) test, as well as an aging population, are considered major contributors to this 
phenomena (Schroder et al., 2014). Whilst little is known regarding risk factors for PC, 
incidence is significantly coupled with age, with the median age of diagnosis being between 
70 and 74 years. The rate of PC incidence for different age groups within the UK can be 
visualized in figure 1.1B. Indeed, the prevalence of histological PC upon post-mortem is 
significantly higher than the number of diagnosed cases (Klotz and Emberton, 2014), 
suggesting PC may be more prevalent in the elderly than currently thought. Unlike other 
cancer types, currently no highly penetrant inherited genes conferring the PC phenotype have 
been identified. However, men with a family history of PC are 2-3 times more likely to be 
diagnosed with PC. Furthermore, men with a mutation in BRCA2, a major genetic risk factor 
for breast and ovarian cancer, are up to 7 times more likely to be diagnosed with PC (Ostrander 
and Udler, 2008). Globally, rates vary dramatically as depicted in figure 1.2, and indeed, black 
British males are twice as likely to be diagnosed with PC as white British males (Ben-Shlomo 
et al., 2008), whereas British males of Asian descent are half as likely (CRUK, 2016), suggesting 
Figure 1.1 –Rate of Prostate Cancer Incidence A. Rate of PC incidence in the UK 1979-2011 B. Rate of PC 
incidence in the UK across different age groups C. Rate of PC incidence in the UK across different 
ethnicities. Data obtained from Cancer Research UK. 
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a genetic predisposition to PC development exists. The difference in PC incidence between 
British males of different ethnicity is represented in figure 1.1C.  
1.1.2 Prostate Cancer Grading and Staging 
Upon diagnosis of PC, the cancer is staged and graded in order to ascertain the risk of disease 
progression and to implement the appropriate disease management regime. Cancers are 
graded using the Gleason grading system, which is a morphological assessment of the cancer 
cells, performed microscopically by a pathologist, based on the extent of cancer cell 
differentiation from a normal prostate cell (CRUK, 2016; PCUK, 2016a). This is used to 
determine the aggressiveness of the cancer. The pattern is given a grade from 1-5, with scores 
of 1-2 being considered normal tissue, and 5 being the most differentiated cancer. Multiple 
tumour biopsies are taken, and the Gleason score is calculated from adding the most common 
biopsy grade with the highest biopsy grade, therefore PC must be defined by a Gleason score 
of between 6 and 10. The Gleason score is then used in combination with the stage and the 
PSA level of the patient to dictate treatment modality. Staging of the cancer is an assessment 
of how far the cancer has spread. Although different staging methods exist, the Tumour-
Nodes-Metastasis (TNM) system is employed in the UK and is represented in figure 1.3. This 
system determines the size and localization of the primary tumour, and the extent of 
metastasis to lymph nodes and/or distant sites. Taken together, tumour grade and stage 
allows patients to be stratified into 3 main categories; localized disease, locally advanced 
Figure 1.2 - Age standardised rate of PC across the world. Data obtained from GLOBOCAN 2012(Ferlay J, 
2013). Figure generated using publicly available medical art from www.servier.com. 
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disease, and advanced metastatic disease. The five year survival rate for patients classified 
into these cohorts is >90%, 70-80% and 30%, respectively, highlighting the need for early 
detection, appropriate risk stratification and more effective treatment options for advanced 
metastatic patients. 
 
 
 
 
1.1.3 Localized Prostate Cancer 
For localized prostate cancer the primary tumour is confined within the prostate organ. The 
majority of patients present with localized PC upon diagnosis, which are then further stratified 
according to their risk of disease progression (Klotz and Emberton, 2014). As localised PC is 
very often slow growing and has a low metastatic potential, it is crucial to identify which 
patients may benefit from treatment, and which patients may not require treatment at all. 
Low-risk PC is characterized by a PSA value lower than 10ng/ml and a Gleason score of 6 or 
less, whilst high-risk PC is defined by having a PSA level of 20ng/ml or higher, or, a Gleason 
score of 7 and above, or, if the stage is T2C, T3 or T4 (T3 and T4 staging means the tumour has 
broken through the prostate capsule, and as such will be reclassified as locally advanced). 
Radical prostatectomy has been the primary treatment option for all newly diagnosed PC 
cases over the last 30 years, however, following the introduction of the PSA test, a dramatic 
increase in the diagnosis of low-risk PC was observed, and as such, a large proportion of 
patients were over-diagnosed and subsequently over-treated. Recently, the general 
consensus for low-risk patients is to take a more cautious treatment approach termed active 
Figure 1.3 – TNM staging of PC. Data obtained from PCUK and table produced independently. PC 
is staged according to a TNM scoring system based on the extent of tumour spread and 
dissemination. 
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surveillance (Draisma et al., 2009). Active surveillance consists of serial PSA assessments and 
repeat biopsies and has been considered a successful intervention for risk reclassification, as 
the lead time between diagnosis and disease progression is often very long, or of no 
detrimental consequence. However, approximately one third of patients undergoing active 
surveillance will be reclassified as high risk and offered treatment (Klotz and Emberton, 2014). 
Again, avoidance of radical procedures is an emerging theme, and men will typically be offered 
focal therapy where applicable (Giannarini et al., 2014). Focal therapy involves excision of a 
solitary tumour target (>1.3cm3) following MRI guided identification, which may be performed 
in conjunction with repeat biopsies, resulting in minimally invasive surgery, and subsequently 
reduced morbidity. In cases where multiple positive cores have been identified, radical 
prostatectomy and/or radiotherapy will be recommended. Reclassification of low-risk PC to 
high-risk PC may occur following rising levels of PSA, or through increased tumour grading at 
repeat biopsy, or alternatively, up to 15% of patients present with high-risk disease at 
diagnosis (Chang et al., 2014).  
1.1.4 Locally Advanced Prostate Cancer 
Patients that undergo tumour reclassification from low-risk to high-risk PC are managed in the 
same way as patients diagnosed with locally advanced disease, whereby treatment of the 
primary tumour is crucial in delaying disease progression and gaining local control. Currently, 
a multi modal approach is considered the most efficacious including neo-adjuvant androgen 
deprivation therapy (ADT) with radical prostatectomy and/or external beam radiation (Bolla 
et al., 2002).  Radical prostatectomy requires complete removal of the gland itself, 
confirmation intraoperatively that surgical margins are negative for cancer, and more recently 
extended pelvic lymph node dissection. There are very few differences between 
prostatectomy and radiotherapy in relation to study end-points, and current practice is often 
dictated by the overall health and age of the patient. In patients where PSA continues to rise 
following radical treatment, salvage external beam radiation is employed and has shown 
significant survival advantages (Stephenson et al., 2007). Despite a 5-year survival rate of 70-
80% for patients with locally advanced PC, many patients will develop non-castrate metastasis, 
or rising PSA castrate resistant PC (CRPC), which will invariably lead to the development of 
castrate resistant metastatic PC (mCRPC), and ultimately death. 
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1.1.5 Advanced Metastatic Prostate Cancer 
Initially metastatic PC is characterized by a period of responsiveness to more advanced anti-
androgens, however, this period is short lived and the transition in disease progression to 
mCRPC is inevitable. The most frequent site of CRPC metastasis observed in patients is at the 
bone. This often results in what is termed ‘skeletal-related events’, consisting of bone pain, 
fracture and spinal cord compression, often resulting in the need for additional radiotherapy 
and/or orthopaedic surgery (Attard et al., 2016). Two drugs are currently employed to aid in 
the reduction of skeletal-related events, the first being zoledronic acid (Saad et al., 2002). 
Zoledronic acid is a bisphosphonate that inhibits osteoclast mediated bone resorption by 
approximately 10%. The second is the human monoclonal antibody denosumab that targets 
the RANKL protein, impeding osteoclast function (Fizazi et al., 2011). The addition of radium-
223 into treatment regimens has also proven to improve overall survival whilst reducing 
skeletal-related events in patients with mCRPC (Parker et al., 2013). However, currently no 
effective treatment regimens exist that significantly impede disease progression, with current 
therapy resulting in modest increases in survival and symptomatic relief (Gartrell et al., 2015). 
A number of cytotoxic agents have been investigated in the treatment of mCRPC, but only 
Advanced Metastatic Prostate Cancer
Anti-androgens Abiraterone
Docetaxel
Cabazitaxel
Radium 223 Sipuleucel-T
Locally Advanced Prostate Cancer
ADT Prostatectomy Radiotherapy
Localized Prostate Cancer
Active Surveillance
Figure 1.4 – Current Treatment Regimen of Prostate Cancer. Localized PC is initially monitored by active surveillance 
including regular PSA testing. Locally Advanced PC is primarily treated by radical prostatectomy, and/or 
radiotherapy, followed by androgen deprivation therapy. Advanced metastatic PC is treated with advanced anti-
androgens in combination with androgen biosynthesis inhibitor abiraterone. Radium 223 is frequently employed to 
combat associated bone metastasis and pain, whilst the implementation of cytotoxic agents, docetaxel or 
cabazitaxel, are employed as a last line of therapy. More recently, the immunotherapy sipuleucel-T has been in the 
treatment of advanced metastatic PC and shows modest benefit. 
27 
 
docetaxel and cabazitaxel have been FDA approved based on modest survival advantages 
(Attard et al., 2016). The implementation of immunotherapy in patient treatment is emerging, 
but remains highly costly, approximately £60,000/month(Simpson et al., 2015). Sipuleucel-T 
is an FDA approved active cellular immunotherapy with a reported 4.1 month survival 
advantage over placebo (Kantoff et al., 2010). The current treatment regimen employed 
within the UK throughout the progression of PC is represented in figure 1.4. 
1.1.6 Treatment Rationale 
The dependency of PC on circulating androgens was first demonstrated by Huggins et al in 
1941, where it was observed that tumour regression could be induced following the reduction 
of serum testosterone either by orchiectomy, or through the administration of exogenous 
estrogens (Huggins et al., 1941). Indeed, it was this discovery that provided the first successful 
treatment for PC, and prompted the emergence of therapeutics aimed at disrupting the 
androgen signalling axis. In 1971 Andrew Schally et al successfully characterised the luteinising 
hormone releasing hormone (LHRH) and his subsequent research focused on the development 
of LHRH agonists (Schally et al., 1971). Administration of LHRH agonists leads to stimulation 
of the hypothalamic signalling axis, resulting in the release of luteinising hormone (LH) and 
follicle stimulating hormone (FSH) and subsequent production of testosterone in the testes. 
However, when administered chronically, LHRH agonists render the pituitary gland refractory 
to further stimulation through down regulation of LHRH receptors, resulting in castrate levels 
of serum testosterone (Sandow et al., 1978). Due to the initial hyper-stimulation of LH release, 
use of LHRH agonists is associated with a surge in serum testosterone termed ‘testosterone 
flare’, which is associated with a number of unwanted side effects in patients such as hot 
flushes, fatigue and loss of libido (Rick et al., 2013). Nevertheless, LHRH agonists are 
associated with less morbidity than orchiectomy or estrogen administration whilst 
maintaining similar survival outcomes, and remain a crucial component of current ADT 
regimens (Byar and Corle, 1988; Ferraldeschi et al., 2015). More recently, LHRH antagonists 
have been developed that display very similar efficacy in relation to LHRH receptor 
downregulation, but do not exhibit the initial testosterone flare, thus providing a more 
favourable toxicity profile, at least in the short term (Wong et al., 2014). As such, it is likely 
LHRH antagonists will continue to be developed and may replace the use of LHRH agonists as 
the predominant agent in ADT (Klotz et al., 2014). In parallel, the discovery and 
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characterisation of the androgen receptor (AR) was being performed throughout the 1960’s 
(Anderson and Liao, 1968; Bruchovsky and Wilson, 1968; Mainwaring, 1969). As the 
understanding of AR regulation increased, the first generation of anti-androgens were 
developed. Cyproterone acetate is considered a ‘pure’ steroidal anti-androgen and acts as an 
AR antagonist, blocking the binding of endogenous AR ligands testosterone or the more 
potent metabolite dihydrotestosterone (DHT) (Isurugi et al., 1980; Pavone-Macaluso et al., 
1986). Cyproterone acetate was successfully used in PC patients resulting in tumour 
regression, reduction in serum testosterone, LH and FSH, and displayed similar survival 
advantages to estrogen administration. However, cyproterone acetate had affinity for other 
steroidal receptors and resulted in systemic progestational side effects including loss of libido 
and impotence, therefore the development of non-steroidal anti-androgens ensued (Wong et 
al., 2014). In the 1970s flutamide was characterised by Shutsung Liao and colleagues as a 
competitive non-steroidal antiandrogen, and received FDA approval for use in advanced PC 
patients in 1989 (Liao et al., 1974; Labrie et al., 1982; FDA, 1989). Subsequent compounds 
were generated with higher affinity for the ligand binding domain of the AR including 
bicalutamide (Casodex) which is still widely used today (Rathkopf and Scher, 2013). However, 
as sequencing techniques advanced, it emerged that as many as 30% of patients present with 
mutations within the AR ligand binding domain following treatment courses, allowing for anti-
androgens to act as agonists, and thus stimulate the AR signalling axis (Taplin et al., 2003). In 
addition, first-generation anti-androgens exhibit significantly lower binding affinity for the AR 
than endogenous androgens, and have recently been outclassed by second-generation anti-
androgens (Simard et al., 1997; Kolvenbag et al., 1998). In 2010, enzalutamide, formerly MDV-
3100, was developed by Jung et al, which through further characterisation demonstrated a 
significantly higher AR binding affinity over bicalutamide of approximately seven-fold and 
resulted in xenograft tumour shrinkage as opposed to retardation (Tran et al., 2009; Jung et 
al., 2010). Enzalutamide showed considerable efficacy in phase I and II trials, including over a 
50% reduction in PSA levels in 43-56% of patients, enabling it to rapidly progress to phase III 
trials (Scher et al., 2010). In the phase III trial AFFIRM, enzalutamide treatment significantly 
increased patient survival (18.4 months vs. 13.6 months, HR 0.63, 95% CI 0.53–0.75; P <0.001) 
as well as displaying superiority in all secondary end-points (Scher et al., 2012), and was 
subsequently FDA approved for the treatment of CRPC in patients with prior administration 
of chemotherapy (FDA, 2012). It has since been included in trials for use prior to 
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chemotherapy, notably the PREVAIL trial (Beer et al., 2014). The rapid progression of 
enzalutamide through clinical trials, combined with the high demand for increased treatment 
efficacy in CRPC, has driven the development of a number of additional AR targeting agents 
currently in preliminary trials. One such compound is ARN-509, an AR antagonist derived from 
the same chemical series as enzalutamide (Bambury and Rathkopf, 2015) that provides 
comparable in-vitro efficacy characterised by AR degradation and impaired nuclear 
localization. Another AR antagonist is ODM-201, but this compound has a distinct structure to 
enzalutamide and ARN-509, and does not cross the blood brain barrier. Both novel AR 
antagonists have demonstrated promising results in phase I/II trials and are currently being 
employed in phase III trials (clinicaltrials.gov, 2016a; Clinicaltrials.gov, 2016b). Similarly other 
regions of the AR protein are crucial for AR transactivation, and may represent a novel 
approach to treating patients where resistance has arisen, or delaying resistance in the first 
instance. EPI-001 targets the N-terminal domain of the AR as opposed to the C-terminal ligand 
binding domain for which all previously mentioned AR antagonists have affinity. Development 
of EPI-001 remains in very early stages, but it is hoped this compound or a sister compound 
will progress to further studies shortly (Brand et al., 2015). Similarly EZN-4176 works by 
targeting the AR via a distinct mechanism, the AR mRNA (Bianchini et al., 2013). EZN-4176 is 
considered a third-generation anti-androgen and is in fact a locked anti-sense oligonucleotide 
that binds the hinge region of AR mRNA leading to degradation and is currently in phase I trials. 
Directly targeting the AR has proven an effective strategy thus far, but similarly to the very 
first effective PC treatments, minimising circulating androgens provides an equally successful 
approach, and as such our greater understanding of testosterone production and conversion 
has led to the development of additional androgen biosynthesis inhibitors. Despite the 
effectiveness of LHRH agonists and antagonists at reducing circulating androgens produced in 
the testes, the adrenal glands are still capable of producing circulating pro-androgens through 
two independently regulated reactions catalysed by the cytochrome P450 enzyme CYP17. 
Firstly, CYP17 is responsible for the 17-α-hydroxylation of progesterone and pregnenolone, 
and secondly the lyase cleavage of 17-α-hydroxyprogesterone and 17-α-
hydroxypregnenolone resulting in the formation of androstenedione and DHEA respectively 
(Attard et al., 2005). These two products can then be converted to testosterone via a reaction 
catalysed by the enzyme 17-keto reductase (Hellerstedt and Pienta, 2002). Understanding this 
route of androgen production led to the development of the highly selective and potent CYP17 
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inhibitor abiraterone, a compound of similar structure to pregnenolone that has a binding 
affinity for CYP17 of <1nM (Attard et al., 2009). Abiraterone was approved for treatment of 
mCRPC patients in 2011(FDA, 2011) following success in a phase III trial where it displayed a 
significant increase in overall survival (14.8 months vs. 10.9 months; HR 0.65; 95% CI 0.54 to 
0.77; P<0.001) (de Bono et al., 2011). Novel compounds targeting the androgen biosynthesis 
pathway include but are not limited to TAK-700, TOK-001 and VT-464 and are under clinical 
development demonstrating that exploitation of the androgen biosynthesis pathway remains 
an approach of continued refinement (Molina and Belldegrun, 2011; Gomez et al., 2015; Bird 
and Abbott, 2016). As such, targeting the androgen signalling axis has proven to be a 
successful intervention in the treatment of PC over the last 60 years, and crucially, through 
the development of more advanced molecular biology techniques, data from clinical and 
experimental model systems not only demonstrate that the AR is still essential for driving 
disease progression under castrate conditions, but remains a viable therapeutic target in the 
future treatment of both PC and CRPC (Buchanan et al., 2001; Feldman and Feldman, 2001), 
and thus there is a great need to enhance our knowledge on AR regulation and function. 
 
1.2 The Androgen Receptor 
1.2.1 The Androgen Receptor Structure and Function 
In order to continue developing more effective AR targeting agents it is crucial we enhance 
our knowledge on the intricate regulation of the AR. The AR gene is located on chromosome 
Xq11-12 in males, existing as a single allele (Gelmann, 2002). Whilst not being 
developmentally lethal, complete loss of the AR gene results in complete androgen 
insensitivity syndrome, whereas missense mutations that result in impaired activity result in 
partial androgen insensitivity syndrome. Phenotypically, retardation or loss of male sexual 
development is observed despite the production of normal physiological levels of androgens 
(Quigley et al., 1995). This is due to the fact that androgens require a biologically active AR in 
order to exert their effects at a cellular level. The AR is therefore defined as a member of the 
steroid hormone receptor family of transcription factors (Heinlein and Chang, 2004). 
Furthermore, it has been shown that the conversion of testosterone to DHT is essential for 
complete prostate morphogenesis, confirming DHT as the more potent AR ligand (Wilson et 
al., 1993). Aside from normal prostate development, the AR is essential for cell differentiation, 
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secretory function, metabolism, morphology, proliferation and survival (Dehm and Tindall, 
2006). The AR is expressed in both the prostate epithelial and stromal cells, with androgen 
depletion resulting in apoptosis of the prostate epithelia (Litvinov et al., 2003). This process 
can be reversed following the reintroduction of androgens, resulting in the rapid proliferation 
and differentiation of basal epithelial stem cells, and subsequently reinstating the secretory 
function of the prostate (Kurita et al., 2001). In turn, transcription of the AR gene is regulated 
by androgens amongst other steroid hormones, as well as being shown to be tissue and age 
specific. Studies of the AR gene promotor have revealed a broad range of transcription factor 
binding sites including palindromic DNA binding sites recognized by the AR, the glucocorticoid 
receptor and the progesterone receptor (Baarends et al., 1990). Interestingly, the androgen 
signalling axis forms an auto-regulatory negative feedback loop whereby androgen 
stimulation results in reduced AR mRNA expression, and castration results in increased AR 
mRNA expression (Quarmby et al., 1990). Like other steroid hormone receptors, the exons of 
the AR gene code for functionally distinct domains of the ~919 amino acid AR protein, with 
exon 1 coding for the N-terminal domain (NTD), exons 2 and 3 coding for the DNA binding 
domain (DBD), exon 4 the hinge region, and exons 5 through 8 coding for the C-terminal 
domain (CTD) which contains the ligand-binding domain (LBD) (Lubahn et al., 1988; Jenster et 
al., 1992; Bain et al., 2007). Additionally, the NTD and CTD harbour co-activator binding 
Figure 1.5 – Schematic representation of the Androgen Receptor gene and protein. The AR gene is located on chromosome 
Xq11-12 and spans 8 exons. The AR protein possesses 4 distinct domains, the N-terminal domain, DNA binding domain, 
hinge region, and the C-terminal domain. The N and C-terminal domains can functionally interact through the ‘FxxLF’ and 
‘WxxLF’ motifs located in the N-terminus. The nuclear localization signal (NLS) spans both the DNA binding domain and the 
hinge region. 
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grooves termed transcriptional activation function 1 (AF-1) and transcriptional activation 
function 2 (AF-2) respectively (Jenster et al., 1995; Dehm and Tindall, 2006). A schematic 
diagram representing the genomic and protein structure of the AR can be found in figure 1.5. 
 Despite being highly conserved throughout evolution, the complexity of the structural and 
functional elements of the AR remain to be fully elucidated (Thornton and Kelley, 1998). 
Whilst it has been possible to solve the crystal structures of the CTD and DBD, the same cannot 
be said for the NTD (Matias et al., 2000; Sack et al., 2001). The AR CTD is organised as three 
antiparallel helical sheets, comprised of 11 rather than 12 α-helices like other hormone 
receptors (Sack et al., 2001). Each of the α-helices contains 18 amino acids that form a central 
LBD cavity, and create direct interactions with the ligand. Upon ligand binding, the ultimate α-
helix of the LBD undergoes a conformational change, causing it to stabilize the ligand within 
the cavity. This conformational change leads to the formation and exposure of the AF-2 
coactivator binding surface (Dehm and Tindall, 2006). Exposure of the hydrophobic AF-2 
groove allows for docking of proteins containing an ‘LxxLL’ motif (Hur et al., 2004). Despite 
extensive crystallography, the consequence of such interactions remains unclear, with AR 
peptide based studies revealing the AR CTD displays minimal intrinsic transcriptional activity 
(Bevan et al., 1999; He et al., 1999; Hur et al., 2004). As such, subsequent studies identified 
that the CTD was capable of binding ‘FxxLF’ and ‘WxxLF’ peptide sequences present in the AR 
NTD (He et al., 2000). Furthermore, the CTD displayed significantly higher binding affinities for 
NTD derived peptides compared with ‘LxxLL’ containing proteins. Additional studies were able 
to demonstrate that the NTD-CTD (N/C) interaction was more commonly associated with 
mobile AR following androgen stimulation, but was also lost upon DNA binding, suggesting the 
N/C interaction may serve as a means of preventing protein binding until the AR is deposited 
at the chromatin (Li et al., 2006; van Royen et al., 2007). The DBD of the AR is highly conserved 
with other nuclear hormone receptors and plays an important role in mediating AR 
dimerization, nuclear localization and DNA binding (Shaffer et al., 2004). This domain 
encompasses 2 zinc fingers and a loosely structured carboxy-terminal extension (CET) (Dehm 
and Tindall, 2006). The first zinc finger is termed the P-box, which forms the recognition helix 
that binds the DNA major groove at androgen response elements (AREs). Interestingly, the P-
box shares perfect homology with that found in the glucocorticoid receptor, progesterone 
receptor and mineralocorticoid receptor, and thus the AR constitutes a member of the Class I 
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of nuclear hormone receptors (Claessens et al., 1996; Schoenmakers et al., 2000; Verrijdt et 
al., 2000). AREs are hexameric half-sites arranged as either direct-repeat or inverted-repeat 
sequences split by a 3bp spacer recognised by AR homodimers arranged in a head to head 
orientation (Claessens et al., 2008). The head to head dimerization is unique to the AR 
amongst the steroid receptor family and is mediated through D-box, the second zinc finger, 
interactions (Shaffer et al., 2004). However, this does raise fundamental issues on the 
specificity of AR DNA binding, which to date is still unclear. There are speculations that the 
CET or an additional interface results in increased AR/ARE stability. In addition to harbouring 
the P-box, D-box and CET, the DBD also encompasses a proportion of the nuclear localization 
sequence (NLS). The NLS also spans into the hinge region and comprises the bipartite 
sequence 617-RKCYEAGMTLGARKLKK-634 that possesses 2 basic motifs at either flank (Jenster 
et al., 1993). The NLS is believed to be exposed upon ligand binding, allowing for the binding 
of α-importin and nuclear translocation (Ni et al., 2013). In addition to containing the NLS, 
mutagenesis studies have revealed that the hinge region also has roles in AR dimerization and 
ultimately the transcriptional output of the AR (Haelens et al., 2007; Clinckemalie et al., 2012). 
The NTD accounts for over 50% of the total AR protein and is encoded entirely by exon 1. 
Within the NTD are two poly-amino acid stretches of significantly variable length throughout 
the human population. These are made up of poly-glutamine (poly-Gln) and poly-glycine (poly-
Gly) sequences respectively (Chang et al., 1988; Hsing et al., 2000; Sasaki et al., 2003). The 
exact function of these repeats is largely unknown, but there is considerable evidence for 
them acting as docking sites for protein-protein interactions (Palazzolo et al., 2008). 
Additionally it has been shown that the length of the poly-Gln repeat inversely correlates with 
AR transcriptional activity and may in fact be a risk factor for the development of PC 
(Chamberlain et al., 1994). Indeed, there is modest evidence for males of African-American 
descent possessing shorter poly-Gln stretches and an increased incidence of PC compared to 
white American males (Platz et al., 2000). As previously mentioned, the NTD is structurally 
disordered and described as possessing a molten-globule like structure and therefore likely to 
be heavily influenced through protein-protein interactions, adding to the complexity of its role 
and function, as well as adding dynamic context specific factors to its regulation (Lavery and 
McEwan, 2006). Independently of this, the NTD has been shown to be a potent transcriptional 
activator in the absence of the CTD (Reid et al., 2002). This transcriptional activity was mapped 
to two distinct regions within the AF-1 binding groove termed transcriptional activation unit 
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1 (TAU1) and transcriptional activation unit 5 (TAU5) (Callewaert et al., 2006). Both TAU 
regions have been shown to be indispensable for AR transcriptional activity through 
mutagenesis studies, whilst TAU1 and TAU5 also possess the ‘FQNLF’ and ‘WHTLF’ motifs 
respectively, required for the ligand dependent N/C interaction (Doesburg et al., 1997; He et 
al., 2000; Wilson, 2011). 
1.2.2 Androgen Receptor Transactivation 
In the absence of ligand the AR is found predominantly in the cytoplasm (Cardozo et al., 2003), 
maintained in complex with a range of heat shock (HSP), chaperone and co-chaperone 
proteins, in a high ligand binding affinity conformation (Cano et al., 2013). Circulating 
androgens can freely diffuse through the cell membrane where testosterone is metabolized 
to the more potent AR binding metabolite, DHT. Ligand binding then triggers a series of 
conformational changes within the AR and partial dissociation from the unbound protein 
complex (Cano et al., 2013). The conformational changes lead to exposure of the NLS and 
subsequent nuclear translocation via a classical import mechanism involving recognition by 
importin α and β, followed by movement through the nuclear pore complex (Black and Paschal, 
2004). The AR homodimer is then capable of engaging its transcriptional program through 
Figure 1.6 - AR Transactivation. 
Testosterone freely enters 
prostate cells by passive diffusion 
where it is metabolised to the 
more potent metabolite, DHT, by 
5α-reductase. DHT then binds to 
the AR causing dissociation of the 
AR from the foldosome and 
leading to homodimerization. AR 
homodimers then translocate to 
the nucleus where they are able 
to bind to AREs, recruit additional 
transcriptional regulators, and 
initiate gene transcription. 
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association with AREs and interaction with co-activators and co-repressors. Figure 1.6 
represents a simplified visualization of AR transactivation. However, post-translational 
modifications (PTMs) of the AR, including phosphorylation, ubiquitination, sumoylation and 
acetylation invariably add extra layers to the structural and functional complexity of the AR 
(van der Steen et al., 2013), and as such represent an invaluable area to expand our knowledge 
on AR regulation.  
1.2.3 Post-Translational Modifications of the Androgen Receptor 
It has been well documented in the literature that AR activity is heavily influenced by the 
activity of co-activators and co-repressors in a dynamic and context specific manner, but 
crucially, many of these co-activators and repressors impact AR function through direct PTM. 
Indeed, PTM of the AR is capable of regulating protein stability, interactions with additional 
proteins, subcellular localization and structure (Coffey and Robson, 2012). Many of these 
modifications have been extensively studied and their functional consequences identified, and 
as such, their respective modulators have been evaluated as novel therapeutic targets in 
diseases where aberrant AR activation plays a significant role in disease initiation and 
progression. This section will introduce the impact of acetylation, methylation, ubiquitination 
and sumoylation (depicted in figure 1.7) on AR function, but will focus primarily on 
phosphorylation of the AR. 
As a transcription factor, the impact of histone acetylation on the AR transcriptional program 
has been extensively studied (Li et al., 2005), but it wasn’t until 2000 when acetylation was 
first described as a direct modification of the AR (Fu et al., 2000). Specifically, three lysines 
within the ‘KLKK’ motif flanking the DBD (K630, K632, K633) were shown to be acetylated by 
histone acetyltransferase P300 and lysine acetyltransferase 2B. Subsequent research also 
identified lysine acetyltransferase 5 and N-acetyltransferase arrest-defect 1 protein as direct 
acetyl transferases of the AR (Gaughan et al., 2002; Wang et al., 2012). Through the 
implementation of mutagenesis studies, it was shown that acetylation of the AR plays a pro-
androgenic role, contributing to the transactivation of the AR through the recruitment of 
additional co-activators (Gaughan et al., 2002). It was shown that the AR can be acetylated in 
response to androgen, but also through additional stimuli such as bombesin and interleukin 4 
(Fu et al., 2000; Gong et al., 2006; Lee et al., 2009). In turn, acetylated AR can be de-acetylated 
by histone deacetylase (HDAC) enzymes, thus providing a context specific means of AR 
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modulation. Indeed, upon inhibition of HDAC1, an increase in acetylation of the AR is observed, 
and this correlates with increases in AR transcriptional activity (Gaughan et al., 2002; Faus and 
Haendler, 2008). Conversely, overexpression of the HDAC sirtuin 1 reduces AR transactivation, 
and it was identified that de-acetylation of the AR within the ‘KLKK’ motif disrupts the AR N/C 
terminal interaction and subsequent nuclear translocation and chromatin binding, providing 
substantial evidence for the impact of AR acetylation on receptor structural rearrangements 
and interactions (Fu et al., 2006). 
 
The ‘KLKK’ motif within the AR known to be acetylated also displays significant sequence 
homology with the consensus sequence for methylation by SET9. Despite strong but 
conflicting evidence for the exact residue of modification, it was shown that lysine N-
methyltransferase 7 (SET9) is capable of methylating the AR by two independent research 
groups (Gaughan et al., 2011; Ko et al., 2011). Similarly to acetylation, methylation of the ‘KLKK’ 
motif was shown to be important for N/C interaction and subsequent transcriptional activity 
of the AR. Expression of SET9 in clinical PC samples demonstrated elevated expression in 
cancerous tissue vs non-cancerous tissue and provides evidence of its activity as an AR co-
activator in the progression of PC (Gaughan et al., 2011). Similarly, methylation is a reversible 
process, and the characterisation of de-methylation enzymes on AR activity has ensued 
(Coffey et al., 2013). 
Ubiquitination is the process of covalently modifying lysine residues with the addition of 
ubiquitin, a small 8.5 kDa protein. Ubiquitination has been linked to signal transduction as well 
as protein recognition and degradation. Ring finger protein 6 (RNF6) and seven in abstentia 
Figure 1.7 – Acetylation, Methylation, Ubiquitination and Sumoylation of the AR. The AR can be acetylated and methylated 
at residues K630, K632 and K633, whilst ubiquitination occurs on resideus K845 and K847 and sumoylation occurs on K386 
and K520. 
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homolog 2 (SIAH2) have been shown to promote the mono-ubiquitination of the AR on 
residues K845 and K847 resulting in increased transcriptional activity, whereas poly-
ubiquitination mediated by double minute 2 protein (MDM2) and STIP1 homology and u-box 
containing protein 1 (CHIP) have been shown to promote AR protein turnover (Lin et al., 2002; 
Xu et al., 2009; Qi et al., 2013; Sarkar et al., 2014). Preventing de-ubiquitination of the AR by 
the ubiquitin specific peptidase (USP) family of proteins has emerged as a promising 
therapeutic approach to destabilize the AR protein. USP7 and USP12 have both been 
described as AR co-activators and are capable of influencing the ability of the AR to bind to 
AREs (Burska et al., 2013; Chen et al., 2015). 
Similarly to ubiquitination, sumoylation is the process of covalently modifying lysine residues 
with the addition of a small protein, in this instance, small ubiquitin-like modifier (SUMO). 
There are 4 SUMO protein members, with SUMO 1 being the most frequently observed AR 
sumoylation conjugate (van der Steen et al., 2013). AR sumoylation was first described in 2000 
after the sumo conjugating enzyme ubiquitin conjugating enzyme E2 I was co-
immunoprecipitated with the AR (Poukka et al., 2000). The AR contains 2 sumolyation motifs, 
(I-L-V)-K-x-D/E, encompassing K386 and K520 residues. Androgen stimulation leads to 
increased sumoylation and was shown to be inhibitory to AR activity by impeding the AR N/C 
interaction (Kaikkonen et al., 2009). It also became apparent that sumoylation of the AR elicits 
a distinct transcriptional program to non-sumoylated AR (Sutinen et al., 2014). Despite the 
induction of sumoylation of the AR by androgens, and the distinct downstream effects of gene 
transcription, sumoylation does not appear to be localization dependent and sumoylated AR 
exists equally between the nucleus and cytoplasm (Nishida and Yasuda, 2002). 
Phosphorylation is the most extensively studied PTM of the AR to date, and many of the 
phosphorylation sites have been functionally annotated and their respective kinase identified 
(Gioeli and Paschal, 2012). Phosphorylation occurs on serine, threonine and tyrosine residues 
across all of the AR’s functional domains, and these have been shown to occur in both the 
presence and absence of androgen, and indeed through the stimulation of alternative 
signalling cascades, demonstrating the complexity of AR regulation. This becomes of 
increasing relevance in relation to the function of the AR throughout the progression of PC to 
CRPC, and through further understanding of the biological consequences of AR 
phosphorylation, it may be possible to identify novel therapeutic targets for the treatment of 
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patients where resistance to antiandrogens has emerged. Figure 1.7 illustrates the 
phosphorylation sites identified thus far and are subsequently described below. 
 
Serine 16 was found to be phosphorylated in response to androgen and lies within a consensus 
sequence for both protein kinase A (PKA) and calcium calmodulin II (Gioeli et al., 2002). 
However, upon stimulation of PKA with forskolin no observable increase in the 
phosphorylation of serine 16 was observed, raising some doubts as to the responsible kinase. 
Interestingly, upon deletion of the LBD, serine 16 was phosphorylated in the absence of 
androgens suggesting it may play a role in the cross-talk between domains and may be of 
functional importance in androgen splice variants that lack the LBD (Gioeli et al., 2002).  
Serine 81 was found to display the highest stoichiometric phosphorylation in response to 
androgen, and also displayed the most prolonged phosphorylation (Gioeli et al., 2002). 
Multiple kinases belonging to the cyclin dependent family of kinases (CDK) have been 
described to phosphorylate this site, each under distinct contexts. CDK1 has been shown to 
phosphorylate the AR in a cell cycle specific manner, whereas CDK9 has been shown to 
phosphorylate the AR in the nucleus during transcription (Chen et al., 2006; Gordon et al., 
2010). In addition it was reported that CDK5 is also responsible for the phosphorylation of the 
AR at this residue (Hsu et al., 2011). Functionally, it was found that CDK1 stabilizes the AR 
protein throughout the G2/M phase of the cell cycle, when CDK1 is most active, and had the 
Figure 1.8 - Phosphorylation sites of the AR. The AR has been described to be phosphorylated on 17 sites thus far spanning 
all four domains of the AR protein. These have been shown to result in distinct regulatory outcomes in relation to AR 
function. Phosphorylation has been attributed to a range of kinases from distinct signalling cascades. 
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most profound impact on AR stabilization in the absence of androgen (Chen et al., 2006). 
Interestingly, CDK1 was also found to be expressed at higher levels in androgen independent 
tumours, suggesting a potential role in AR activation under androgen depleted conditions. 
However, it was also observed that serine 81 is phosphorylated outside of the G2/M phase of 
the cell cycle when CDK1 is inactive, leading to the observations that CDK5 and CDK9 were 
also capable of phosphorylating this site. Upon over-expression of CDK9, a marked increase in 
serine 81 phosphorylation was observed, and this coincided with an increase in AR nuclear 
localization, chromatin deposition and retention, and gene transcription (Chen et al., 2012). 
Similarly, upon over-expression of CDK5, increases in serine 81 phosphorylation were 
identified, correlating with increases in AR transcriptional activity. Conversely, siRNA 
depletion of CDK5 leads to a reduction in the phosphorylation of serine 81, and subsequent 
repression of AR regulated gene transcription (Hsu et al., 2011). Crucially, it has been 
demonstrated through mutagenesis studies that loss of serine 81 phosphorylation limits PC 
cell growth (Gordon et al., 2010).  
 
Figure 1.9 – AR serine 81 phosphorylation. Phosphorylation of AR serine 81 by CDK1 occurs in a cell cycle dependent manner, 
specifically during G2/M phase of the cell cycle when CDK1 is most active. In addition, CDK5 and CDK9 have been shown to 
phosphorylate the AR in the nucleus throughout all phases of the cell cycle. Phosphorylation of serine 81 has been shown to 
induce AR transcriptional activity characterised by increased nuclear localization and chromatin binding. 
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There is evidence for serine 94 being constitutively phosphorylated and does not increase in 
response to androgen (Yang et al., 2007). Currently the kinase responsible for modification of 
this residue and its biological relevance remains unknown. 
The impact of serine 213 phosphorylation on AR function has been extensively studied, and a 
number of kinases have been identified as the conjugating enzymes responsible for this 
modification. It has emerged that phosphorylation of this site by the distinct kinases results in 
different functional outcomes (Koryakina et al., 2014). Indeed, the kinases responsible for the 
phosphorylation of this site belong to independent signalling cascades, both of which have 
been identified as possessing clinical significance in the progression of PC. The first kinase, 
protein kinase B (AKT), was demonstrated to induce serine 213 phosphorylation following 
stimulation of the phosphoinositide 3-kinase (PI3K) pathway, whilst inhibition of this pathway 
diminishes phosphorylation of serine 213 (Lin et al., 2001; Palazzolo et al., 2007). Subsequent 
in-vitro phosphorylation assays went on to prove that AKT was capable of phosphorylating this 
site. Functionally, phosphorylation by AKT results in the recruitment of MDM2, followed by 
subsequent ubiquitination and degradation, and thus is regarded as a repressive 
phosphorylation site (Lin et al., 2002). Indeed, it was demonstrated that the AR forms a 
complex with both AKT and MDM2 upon phosphorylation of serine 213 (Deep et al., 2008). 
The AKT mediated AR degradation can be rescued following addition of the proteasomal 
inhibitor MG132 confirming phosphorylation of serine 213 results in proteasomal degradation. 
Despite the repressive impact of AKT on AR signalling observed throughout these studies, the 
PI3K pathway is frequently dysregulated in advanced PC due to genomic deletion of the PI3K 
repressor phosphatase and tensin homolog (PTEN), and as such the interplay between these 
two signalling cascades may be more complex than initially thought (Lin et al., 2004). Indeed, 
AKT is also capable of phosphorylating serine 791 resulting in the proteasomal degradation of 
the AR via the same mechanisms involving MDM2 (Gioeli et al., 2002). Pim-1 proto-oncogene, 
serine/threonine kinase (PIM1) is also capable of phosphorylating the AR at serine 213, but its 
two transcript variants, PIM1-S and PIM1-L differentially impact on AR function (Ha et al., 
2013). PIM1-S induces similar functional outcomes whereby upon phosphorylation of S213 
MDM2 is recruited and the AR undergoes proteasomal degradation, and as a result AR 
transcriptional activity is reduced. PIM1-L on the other hand does not impact on AR 
proteasomal degradation, and over-expression of this kinase results in increased 
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transcriptional activity despite increased phosphorylation of serine 213. However, PIM1-L is 
also capable of phosphorylating threonine 850 which is associated with increased activity, 
suggesting there may be some degree of cross-talk between the two events. Phosphorylation 
of threonine 850 by PIM1-L leads to AR stabilization and increased transcriptional activity, 
particularly in the presence of low concentrations of androgens. This was found to be due to 
the recruitment of RNF6 as opposed to MDM2, leading to subsequent ubiquitination, but 
favoured enhanced stability as opposed to degradation. In the presence of androgens the 
interaction between PIM1-L and the AR is enhanced (Linn et al., 2012). 
 
 
Another phosphorylation site with unknown functional consequence is serine 256, which is 
phosphorylated in response to androgen stimulation and lies within a calcium calmodulin 
kinase II consensus sequence (Gioeli and Paschal, 2012).  
Aurora A is a kinase that has been implicated with the progression of PC to CRPC and is 
responsible for the phosphorylation of 2 residues in the AR, threonine 280 and serine 291 (Shu 
et al., 2010).  Both sites were demonstrated to be phosphorylated in the presence and absence 
of androgen leading to the potentiation of AR transcriptional activity through enhanced DNA 
binding. Aurora A expression has been shown to increase between localized PC and advanced 
Figure 1.10 – AR serine 213 and serine 791 phosphorylation. Activation of tyrosine kinase receptors by growth factors leads 
to the initiation of the PI3K signalling cascade, culminating in the activation of AKT. AKT is then capable of phosphorylating 
the AR on serine 213 and serine 791. Phosphorylation of these residues leads to the recruitment of MDM2, subsequent AR 
ubiquitination and ultimately proteasomal degradation.  
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PC in clinical samples, and correlates with PSA expression, Gleason score, and survival 
(Buschhorn et al., 2005; Furukawa et al., 2007; Beltran et al., 2011; Mosquera et al., 2013), 
reinforcing its viability as a potential therapeutic target. 
Serine 308 is phosphorylated by CDK11P58 throughout the G2/M phase of the cell cycle (Zong 
et al., 2007; Chi et al., 2011). Modification of this residue results in repression of the AR 
signalling axis and repression of cell growth. Upon siRNA depletion of CDK11P58, increases in 
AR transcriptional activity are observed, whereas overexpression results in repression of AR 
transactivation. Indeed, expression of CDK11P58 inversely correlates with the Gleason score 
and proliferative capacity of PC when quantified by Ki67 staining (Olshavsky et al., 2008). More 
recently, it was shown that CDK1 also phosphorylates serine 308, which raises the possibility 
that CDK1 acts as both a co-activator and co-repressor (Koryakina et al., 2015). The authors 
went on to show that phosphorylation of serine 308 directed the AR to a distinct subset of 
androgen regulated genes which would suggest that the AR is capable of driving distinct 
transcriptional programs throughout different phases of the cell cycle, based on the 
stimulation and activity of co-activators. 
Genomic sequencing of a male with AIS led to the discovery of serine 405 as a phosphorylation 
site (Lagarde et al., 2012). Mutation of this residue to alanine leads to impaired AR activity 
and in the case of this patient, AIS.  
Serine 424 is another residue identified as being androgen dependent, but the functional 
impact of this modification remains to be elucidated. The kinase responsible also remains 
unknown (Gioeli et al., 2002). 
Serine 515 is another residue where multiple kinases have been successfully identified as 
modulators of this residue. CDK7 was proven to phosphorylate serine 515 through in-vitro 
biochemical assays, further compounded through the incorporation of serine-515-alanine 
mutants in to in-vitro phosphorylation assays (Chymkowitch et al., 2011). Functionally, it was 
shown that phosphorylation by CDK7 occurred at the promotor regions of androgen target 
genes, resulting in the recruitment of the ubiquitin ligase MDM2, and promoting AR turnover. 
However, impaired phosphorylation of this residue by CDK7 was shown to reduce the overall 
transactivation potential of the AR, suggesting AR protein turnover is a crucial step in the 
androgen signalling axis. Secondly, significant evidence for the phosphorylation of serine 515 
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by the mitogen-activated protein kinase (MAPK) signalling cascade exists (Gregory et al., 2004; 
Mellinghoff et al., 2004). It was demonstrated that following epidermal growth factor (EGF) 
stimulation, an increase in AR transcriptional activity is observed, and this is recapitulated by 
an increase in PC cell growth. Upon treatment with MAPK inhibitors, a clear reduction in the 
phosphorylation of serine 515 is observed. Indeed, future mutagenesis studies successfully 
identified serine 515 as the site of AR phosphorylation in response to EGF (Ponguta et al., 
2008). In contrast, a more recent study demonstrated that elevated levels of phosphorylated 
serine 515 at diagnosis by immuno-histochemistry correlated with PSA expression and a 
decreased time to biochemical relapse (Willder et al., 2013). However, phosphorylation of 
serine 515 did not correlate with MAPK or phosphorylated MAPK expression, but rather, CDK1 
and phosphorylated CDK1 expression. Additional in-vitro studies using the pan-CDK inhibitor 
roscovitine demonstrated that a reduction in the phosphorylation of CDK1 correlated with a 
reduction in the phosphorylation of serine 515. Furthermore, phosphorylation of serine 515 
appears to be co-regulated with phosphorylation of serine 578 following EGF stimulation. 
Mutagenesis studies revealed that phosphorylation of serine 515 is maximal when serine 578 
is not phosphorylated (Ponguta et al., 2008). This cross-talk becomes increasingly complex 
when it was identified that both protein kinase C (PKC) and p21 protein-activated kinase 6 
(PAK6) can phosphorylate serine 578 (Ponguta et al., 2008; Liu et al., 2013). Phosphorylation 
by PKC drives increased transcriptional activity and mediates cross-talk with serine 515 
phosphorylation, whereas phosphorylation by PAK6 results in the recruitment of MDM2 and 
repression of AR transactivation. As such, the impact of EGF stimulation on AR function 
remains a point of interest for future research as it is also well documented that the MAPK 
signalling cascade is frequently dysregulated in the progression of PC and poses a viable 
therapeutic target (Gioeli et al., 1999; Kinkade et al., 2008).  
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Another signalling cascade capable of impacting on AR phosphorylation is that of the stress-
activated protein kinase pathway, highlighting once again the convergence of multiple 
pathways on the AR (Gioeli et al., 2006). Both C-Jun N-terminal kinase 1 (JNK) and p38 MAPK 
were shown to phosphorylate the AR on serine 650 upon activation with phorbol 12-myristate 
13-acetate. Conversely, inhibition of JNK and p38 MAPK with SP600125 and SB203580 
respectively resulted in a reduction of phosphorylated serine 650. Phosphorylation of serine 
650 was demonstrated to be repressive to AR function when either kinase was over-expressed, 
whereas increases in AR transcriptional activity was observed following siRNA depletion of 
either kinase. Repression of AR activity following phosphorylation of this mark was attributed 
to enhanced nuclear export. 
Similar to threonine and serine, there are a number of tyrosine residues that are able to be 
phosphorylated. Once again, the phosphorylation of these residues is mediated through a 
number of independent signalling cascades. Tyrosine 267 and tyrosine 363 were identified as 
Figure 1.11 – AR serine 515 phosphorylation. Activation of tyrosine kinase receptors by growth factors leads to the induction 
of the MAPK signalling cascade culminating in activation of the ERK kinases. The ERK kinases are then capable of 
phosphorylating the AR on serine 515 resulting in enhanced nuclear localisation and transcriptional activity. In addition, 
CDK1 and CDK7 can also phosphorylate serine 515. 
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being phosphorylated by tyrosine kinase non-receptor 2 (ACK) through mass spectrometry 
and site directed mutagenesis (Mahajan et al., 2007). Mutation of both tyrosine residues 
independently with phenylalanine reduced AR transcription and chromatin binding in both 
the presence and absence of androgen. It was also shown that activated ACK stimulated 
growth of PC xenograft tumours, whilst mutation of tyrosine-267-phenylalanine blocked the 
growth of castrate resistant xenografts. In addition, it was shown that stimulation of ACK with 
EGF, heregulin and Gas6 also resulted in increased tyrosine phosphorylation. More recently, 
it was shown that stimulation of ACK with EGF directed the tyrosine phosphorylated species 
of AR to distinct gene promotors when compared to androgen stimulation, specifically the 
ATM gene promotor (Mahajan et al., 2012). This not only highlights the ability of ACK to 
phosphorylate and stimulate AR activity, but also the ability of ACK to direct a distinct 
transcriptional program, even in the absence of androgen, whilst also implicating a role for 
ACK in driving resistance to radiotherapy in PC. 
Tyrosine 534 has been identified as a SRC proto-oncogene non-receptor tyrosine kinase (SRC) 
phosphorylation site (Guo et al., 2006). This residue is phosphorylated by SRC following 
stimulation by EGF, bombesin and interleukin 6. Site-directed mutagenesis demonstrated that 
phosphorylation of tyrosine 534 enhances AR transcriptional activity and the growth of PC 
xenografts. Immunohistochemical analysis also demonstrated that levels of phosphorylated 
tyrosine 534 correlated with SRC activity as well as disease progression. Interestingly, it was 
observed that tyrosine 534 phosphorylation also correlated with epithelial and endothelial 
tyrosine kinase (ETK) expression in human prostate tumours (Dai et al., 2010). Over-expression 
of either ETK or SRC results in increased Y534 phosphorylation and subsequent AR stabilization 
(DaSilva et al., 2009). Although similar observations can be made between AR tyrosine 
phosphorylation by SRC and ETK, it is likely their impact remains stimulus and context 
dependent.  
Finally, it has also been shown that the tyrosine kinase FER (FER) phosphorylates tyrosine 223 
in the presence of interleukin 6, leading to the formation of AR-FER complexes in the nucleus, 
resulting in enhanced AR gene transcription (Rocha et al., 2013). 
Crucially, phosphorylation of the AR is a highly complex regulatory mechanism, with many of 
the modulators in question regarded as oncogenes both in the context of PC and in additional 
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cancers. As described, phosphorylation events can occur both in the presence and absence of 
androgen, are both enhancing and repressive to AR function, and can be stimulated by 
alternative signalling cascades. With this in mind, elucidating the role of phosphatases on AR 
dephosphorylation poses an unmet need in our understanding of AR regulation.  
The role of phosphatases on AR function represents a significant knowledge gap when 
compared to the role of kinases on AR function, and as such there are only a handful of known 
phosphatases capable of impacting on AR function both directly and indirectly. PTEN is one of 
the most widely studied prognostic markers for PC. Loss of PTEN is known to drive PC 
progression to a more aggressive and castrate resistant phenotype, and genomic loss is 
observed in up to 40% of mCRPC cases (Shen and Abate-Shen, 2007; Dan et al., 2015). Loss of 
PTEN has been shown to be independently associated with increased risk of lethal progression 
and decreased survival (Ahearn et al., 2016). Through de-repression of the PI3K-AKT pathway, 
PTEN loss results in a reduction in AR transcriptional activity, characterised by increased AKT 
mediated phosphorylation and degradation (Carver et al., 2011b). With the prominent role of 
PTEN loss established within the progression of PC, a number of additional phosphatases that 
feed into the PI3K-AKT pathway have also been identified within the context of PC progression. 
These include the AKT phosphatases PH domain and leucine rich repeat protein phosphatase 
(PHLPP) 1 and PHLPP2, capable of antagonising the PI3K pathway by direct dephosphorylation 
of AKT, and inositol polyphosphate-4 phosphatase type II B, a phosphatase capable of 
dephosphorylating the phosphatidylinositol (3,4,5)-trisphosphate that accumulates following 
PTEN loss (Chen et al., 2011; Kofuji et al., 2015). All 3 of these phosphatases have been shown 
to be down-regulated in the progression of PC (Chen et al., 2014; Rynkiewicz et al., 2015). 
Protein tyrosine phosphatase 1B (PTP1B) is a well-established regulator of metabolic signalling, 
and has recently been identified as being an androgen regulated gene (Lessard et al., 2012). 
Although its reciprocal role in AR signalling has not been assessed, PTP1B was shown to be 
required for optimal cell migration of PC cells in an androgen independent manner. 2 
additional phosphatases, protein tyrosine phosphatase of regenerating liver 3 (PRL-3) and 
low-molecular weight protein tyrosine phosphatase (LMWPTP), have also recently been 
shown to positively impact on PC proliferation and migration (Ruela-de-Sousa et al., 2016; 
Vandsemb et al., 2016).  
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However, to date only 3 phosphatases have been described to directly interact with the AR. 
The first, small CTD phosphatase 2 (SCP2), interacts with the AR, but no evidence exists for 
direct modulation of the AR phosphorylation status by SCP2 (Thompson et al., 2006). Rather, 
SCP2 binds to the AR and translocates with the AR upon androgen stimulation to the AREs of 
androgen regulated genes, such as PSA, where it is able to repress AR transcriptional activity. 
It is believed that repression of AR transcriptional activity occurs through dephosphorylation 
of the recruited transcriptional machinery, such as RNA polymerase II. The second 
phosphatase known to interact with the AR is protein phosphatase 2A (PP2A) (Yang et al., 
2005a). PP2A binds to the AR in a ligand-dependent manner, suggesting phosphorylation of 
androgen responsive residues enhances the affinity of PP2A for the AR. Preliminary evidence 
would suggest that PP2A is capable of dephosphorylating serine 81, serine 256, serine 308 and 
serine 424, subsequently reducing AR transcriptional activity. As such, PP2A is considered an 
AR co-repressor. Indeed, ectopic expression of the PP2A catalytic subunit, PPP2CA, prevents 
epithelial to mesenchymal transition, and potently supresses PC tumour growth and 
metastasis in-vivo (Bhardwaj et al., 2014). Furthermore, protein phosphatase 2 regulatory 
subunit B (PPP2R2C), the substrate specifying subunit of PP2A, is frequently lost in PC (Bluemn 
et al., 2013). It was found that down-regulation of PPP2R2C promotes androgen-independent 
growth of PC cells, albeit not by AR mediated mechanisms, and is tightly correlated with the 
increased likelihood of disease recurrence, and ultimately PC-specific mortality.  
Protein phosphatase 1 (PP1) on the other hand, first identified to directly interact with the AR 
in 2009, is considered an AR co-activator (Chen et al., 2009). Initial studies first demonstrated 
that inhibition of PP1 with okadaic acid led to cell type-dependent effects on AR activity and 
expression. Subsequent studies using the more specific PP1 inhibitor tautomycin, or indeed 
RNAi depletion of the catalytic subunit of PP1, PP1α, led to enhanced proteasomal 
degradation of the AR. Conversely, over-expression of PP1α led to increases in AR protein 
expression and transcriptional activity. Using phospho-specific antibodies, depletion of PP1α 
resulted in a marked increase in the phosphorylation status of the AR at serine 650. As 
previously described, phosphorylation of serine 650 by either JNK or p38 MAPK leads to 
reduced AR transcriptional activity characterised by reduced nuclear localisation and 
enhanced degradation. In support of this, PP1α depletion led to significant impairment in the 
nuclear localisation of a wild-type AR construct, but not a serine 650-alanine mutant construct. 
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Subsequent studies have identified that PP1 also mediates AR stabilisation through additional 
mechanisms. PP1 is capable of dephosphorylating and inhibiting the AR ubiquitin ligase MDM2, 
and it was demonstrated that PP1 contributes to enhanced AR stabilisation, particularly in the 
absence of androgen, via this mechanism leading to the prevention of proteasomal 
degradation (Liu et al., 2016a; Liu et al., 2016b). Recently, it was also demonstrated that the 
opposing impact on AR stabilization between PP1 and AKT is also extended to the 
constitutively active AR splice variant, AR-V7 (Li et al., 2015). It was shown that PP1 enhanced 
AR-V7 stabilization via a reduction in the phosphorylation of serine 213, however, no evidence 
was presented for the direct dephosphorylation of serine 213 by PP1, suggesting the impact 
is likely to be mediated through repression of either AKT or MDM2 as previously described 
(Xiao et al., 2010; Liu et al., 2016a).  
The lack of understanding into the role of phosphatases in PC disease progression, and more 
specifically, the contribution of phosphatase enzymes to AR activity, led our research group 
to investigate the role of phosphatase enzymes on AR transcriptional activity. In order to gain 
a greater insight into the role of phosphatase enzymes on the regulation of AR activity, both 
directly and indirectly, our research group performed an RNAi screen targeting 291 
phosphatase enzymes and phosphatase interacting proteins with 3 individual RNAi oligos, in 
the androgen responsive, AR positive cell line, LNCaP-7B7 (Clayton, 2011). The LNCaP-7B7 cell 
line used also contained a chromosomally integrated luciferase reporter under the control of 
the ARE3 element from the PSA promotor. This enabled subsequent luciferase activity 
measurements to be used as a surrogate for AR activity and ranking of the RNAi targets as AR 
co-activators or co-repressors. As the targets were depleted through RNAi transfection, 
increases in luciferase activity were considered to be attributed to the depletion of a 
repressive phosphatase, whereas a reduction in luciferase activity was considered to be 
attributed to the depletion of a pro-androgenic phosphatase, when compared to the 
scrambled control.  
Although potential hits were observed throughout all of the major classes of phosphatases, 
the impact of PP1 regulatory subunit depletion particularly stood out from what is known in 
the literature. PP1 belongs to the serine/threonine protein phosphatase family (Virshup and 
Shenolikar), which collectively have been described to catalyse approximately 90% of all 
eukaryotic dephosphorylation events, reversing the modifications imposed by hundreds of 
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serine/threonine kinases (Heroes et al., 2013). Indeed, PP1 is encoded by 3 independent genes, 
collectively resulting in the formation of 6 alternatively spliced isoforms, all displaying ~90% 
amino acid sequence homology and resulting in very broad yet highly overlapping substrate 
specificity in-vitro (Cohen, 1988; Sasaki et al., 1990; Dombradi et al., 1993; Cohen, 2002). 
However, it is now becoming widely understood that PP1 catalytic subunits rely on the 
hundreds of mutually exclusive PP1 interacting proteins to govern their promiscuous activity 
in a spatio-temporal manner, thus allowing for the independent regulation of protein 
dephosphorylation (Korrodi-Gregorio et al., 2014). As such, PP1 catalytic subunits never exist 
as monomeric subunits in-vivo, but through association with their regulatory subunits, form 
multimeric PP1 holoenzymes with distinct subcellular localizations, substrate specificity and 
catalytic activity (Peti et al., 2013). A graphical representation of this process is depicted in 
figure 1.12. Furthermore, the association of PP1 with its regulatory subunits is a dynamic 
Figure 1.12 – Regulation of the PP1 catalytic subunit. The PP1 catalytic subunit displays very broad substrate 
specificity in-vitro, however, does not exist as a monomeric subunit in-vivo. The PP1 catalytic subunit associates 
with upto 100 mutually exclusive regulatory subunits, all of which have an affinity for the catalytic subunit in 
the nM range. The association of the catalytic subunit with regulatory subunits results in the formation of 
functionally distinct PP1 holoenzymes, all of which possess distinct subcellular localizations, substrate specific, 
and catalytic activity. 
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process, governed by the intracellular concentration of the regulatory subunits, which varies 
significantly between cell type, and their independent affinity for PP1, which in turn can also 
be modulated at the post-translational level, allowing for signalling cues to impact on 
dephosphorylation events, creating the pathway sensitivity required to counteract the action 
of serine/threonine kinases in a biologically relevant manner (Shi, 2009; Virshup and 
Shenolikar, 2009; Bollen et al., 2010; Choy et al., 2012). With this in mind, a highly variable 
response in AR activity following RNAi depletion of specific PP1 regulatory subunits was 
observed upon analysis of the RNAi screen, depicted in figure 1.13. This is in contrast to what 
is currently known in the literature regarding the role of PP1 on AR activity. Crucially, it was 
the identification of protein phosphatase 1 regulatory inhibitor subunit 14C (PPP1R14C) as a 
potent activator of the AR (luciferase activity vs scrambled control, 0.4 fold-change), and that 
of protein phosphatase 1 regulatory subunit 12A (PPP1R12A) as a repressor of the AR 
(luciferase activity vs scrambled control, 1.38 fold-change) that led to the subsequent 
characterisation and validation studies presented in this thesis. The rationale underlying the 
pursuit of PPP1R14C and PPP1R12A characterisation is that both proteins are components of 
the same PP1 holoenzyme, myosin phosphatase (MLCP), providing preliminary evidence for 
cross-talk between the dynamic regulation of MLCP activity and AR transactivation.  
 
Figure 1.13 – The impact of PP1 regulatory subunit 
RNAi depletion on AR transcriptional activity. PP1 
regulatory subunits were depleted by RNAi as part of a 
phosphatase RNAi screen (Clayton, et al.). Luciferase 
activity (Fold-Change vs Scrambled control) was 
measured as a surrogate for AR activity. Analysis 
revealed that depletion of PP1 regulatory subunits 
results in distinct outcomes in relation to AR 
transcriptional activity (Clayton, 2011).   
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2.1 Mammalian cell culture and storage 
2.1.1 Cell Lines 
Cell lines purchased from ATCC (Virginia, US): 
LNCaP (ATCC® CRL-1740™) – First isolated from the lymph node metastasis of a 50 year old 
male in 1980 (Horoszewicz et al., 1980), the LNCaP cell line represents an androgen-responsive 
model of PC. 
CWR22RV1 (ATCC® CRL-2505™) – Is a subclone of the CWR22 cell line serially propagated in 
mice under castrate conditions. This cell line expresses AR splice variants and represents an 
androgen-independent model of PC. 
HEK293T (ATCC® CRL-3216™) – Originally derived from human embryonic kidney cells, this cell 
line is readily transfected and as such will be used for over-expression studies within this thesis. 
LNCaP, CWR-22RV1 and HEK293T cells were maintained in RPMI-1640 (R5886, Sigma Aldrich) 
supplemented with 10% (v/v) foetal bovine serum (HyClone) and 2 mM L-glutamine (Sigma 
Aldrich), and will be referred to as full media throughout this thesis. For steroid-depleted 
media, RPMI-1640 was supplemented with 10% (v/v) dextran-coated charcoal-stripped foetal 
bovine serum (HyClone) and 2 mM L-glutamine and is referred to as DCC media. Cell lines were 
cultured at 37°C in a 5% CO2 humidified incubator (MCO-20AIC, Sanyo). 
Cell line subclones generated in-house: 
LNCaP-Androgen Independent (LNCaP-AI) – Generated from serial passage of the parental 
LNCaP cell line under steroid-depleted conditions. LNCaP-AI cells are maintained in DCC media. 
The LNCaP-AI cell line represents a model of androgen-independence. 
LNCaP-Casodex Resistant (LNCaP-CdxR) – Generated from serial passage of the parental 
LNCaP cell line in full media and escalating doses of casodex until a final concentration of 
10µM is reached. LNCaP-CdxR cells are maintained in full media + 10µM casodex. The LNCaP-
CdxR cell line represents a model of resistance to current anti-androgens.  
LNCaP-Enzalutamide Resistant (LNCaP-EnzR) – Generated from serial passage of the parental 
LNCaP cell line in full media and escalating doses of enzalutamide until a final concentration 
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of 10µM is reached. LNCaP-EnzR cells are maintained in full media + 10µM enzalutamide. The 
LNCaP-EnzR cell line represents a model of resistance to next generation anti-androgens. 
2.1.2 Cell Passaging 
Cell culture was carried out in a BioMat class II microbiological safety cabinet. To passage cells, 
culture media was removed from the culture flask and cells gently washed two times with 
phosphate buffered saline (PBS) (Invitrogen) and incubated with 1 x Trypsin-EDTA (Sigma 
Aldrich) solution and incubated for 5 minutes at 37°C. Following cell detachment, the trypsin 
was neutralised by the addition of culture media to the flask and the cell suspension was 
transferred to a sterile universal tube (Thermo scientific) and centrifuged at 400 x g for 5 
minutes. The cell pellet was resuspended and cells seeded into new flasks at a 1:3 to 1:10 
dilution. Mycoplasma tests were carried out every 2 months in-house. 
2.1.3 Cell Storage 
When required, cells would be stored at -80°C following resuspension in full media spiked with 
10% DMSO in 1ml cryovial aliquots. If cells needed to be thawed, cryovials were warmed to 
37°C in a water bath and added to 10ml of 37°C full media. The cells were then centrifuged at 
400 x g for 5 mins, resuspended in 10ml of 37°C full media and transferred to a T25 cell culture 
flask. 
2.1.4 Cell Counting 
Cells were detached from culture flasks as previously described and resuspended in fresh 37°C 
media. 10µl of the cell suspension was then pipetted onto a haemocytometer (Fisher Scientific) 
and the cells within a 1mm2 area were counted and then multiplied by 10,000 in order to 
obtain cells/ml. Cells would then be diluted as required. 
2.2 Compounds 
2.2.1 5α-Dihydrotestosterone (DHT) 
Dihydrotestosterone (DHT), a potent androgen receptor agonist (Kd=0.25-0.5nM (Ferner, 
2012)), was supplied from Sigma Aldrich in powder form, resuspended in ethanol (Fisher 
Chemicals) at a concentration of 10 mM, and subsequently stored at -80°C.  
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2.2.2 Casodex  
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-
methylpropanamide is an AR antagonist (IC50=160nM) that is marketed under the name 
casodex and developed by AstraZeneca. Casodex was supplied by AstraZeneca in powder form 
which was dissolved in endotoxin free anhydrous DMSO (Sigma Aldrich) to a stock 
concentration of 20mM. Stock solutions of casodex were stored at -80oC and dilutions were 
made in DMSO and stored at -20oC. 
2.2.3 Enzalutamide  
Enzalutamide (chemical name: 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-
2-thioxo-1-imidazolidinyl]-2-fluoro-N-methyl-benzamide, brand name Xtandi), a potent anti-
androgen (IC50=36nM) was purchased in powder form (Selleckchem), resuspended in 
dimethyl sulfoxide (DMSO) (Sigma Aldrich) at a concentration of 30 mM and stored at -80°C 
for no more than 6 months. 
2.2.4 Cycloheximide 
Cycloheximide (chemical name: 3-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2-
hydroxyethyl]glutarimide), an antibiotic that inhibits translation, was purchased in powder 
form (Sigma Aldrich) and suspended in molecular grade water (Life Technologies) to a final 
concentration of 5 mg/ml. Cycloheximide solution was made fresh when required. 
2.2.5 MG-132 
MG-132 (chemical name: benzyl (S)-4-methyl-1-1((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-
2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbarmate), a membrane permeable 
proteasome inhibitor (IC50=100nM) was purchased as a readymade solution in DMSO at a 
concentration of 10 mM (Sigma Aldrich) and stored at -20°C. 
2.2.6 MK2206 
MK2206 (chemical name: 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-
f][1,6]naphthyridin-3(2H)-one), a potent AKT1/2/3 inhibitor (IC50=8nM, 12nM, 65nM 
respectively, Selleckchem) and suspended in DMSO at a concentration of 5mM and stored at 
-80°C for no more than 6 months. 
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2.2.7 ML-7 
ML-7 (chemical name: Hexahydro-1-[(5-iodo-1-naphthalenyl)sulfonyl]-1H-1,4-diazepine 
hydrochloride) is a potent inhibitor of myosin light chain kinase (MLCK, IC50=300nM) 
purchased in powder form (TOCRIS), resuspended in DMSO at a final concentration of 5mM, 
and stored at -80°C for no more than 6 months. 
2.2.8 Y-27632 
Y-27632 (chemical name: (1R,4r)-4-((R)-1-aminoethyl)-N-(pyridin-4-
yl)cyclohexanecarboxamide dihydrochloride) is a selective Rho associated coiled-coil 
containing protein kinase (ROCK) I/II inhibitor (IC50=140nM, 300nM respectively) purchased 
in powder form (Selleckchem), resuspended in DMSO at a final concentration of 5mM, and 
stored at -80°C for no more than 6 months. 
2.2.9 WZ-4003 
WZ-4003 (chemical name: Propanamide, N-[3-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-
piperazinyl)phenyl]amino]-4-pyrimidinyl]oxy]phenyl]-) is a selective NUAK family kinase 
(NUAK)1/2 inhibitor (IC50=20nM, 100nM respectively) purchased in powder form 
(Selleckchem), resuspended in DMSO at a final concentration of 10mM, and stored at -80°C 
for no more than 6 months. 
2.3 RNAi Transfection 
The RNAi sequences used throughout this thesis have been generated according to Tuschl’s 
rules of design and have been cross checked using the siRNA check software available from 
the National Cancer Institute. RNAi sequences used are presented in Table 2.1. RNAi oligos 
were stored at 20°C in aliquots at a concentration of 50µM. Lipofectamine® RNAiMAX 
transfection reagent (Thermo Fisher) was used for delivery of RNAi into cell lines. Transfection 
mixes were prepared in Eppendorf tubes under sterile conditions by adding the appropriate 
amount of siRNA to give a final concentration of 25nM in the desired cell culture vessel. 
Dilution was performed using basal media (RPMI-1640 + 2mM L-glutamine, no serum). 
Transfection mixtures were incubated for 30 minutes at room temperature and then added 
directly to the cell culture plate in a dropwise fashion over pre-seeded cells. Pre-seeded cells 
were typically grown for 24 hours prior to transfection. Transfections were incubated for 24-
96 hours at 37°C to acquire optimal gene knockdown.  
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Table 2.1 - RNAi Targets and Sequences 
RNAi Target RNAi sense sequence 
PPP1R12A AGUACUCAACCAUAAUUAATT 
PPP1R14C-1 GAUAUCAUGACUCUAGCCATT 
PPP1R14C-2 CAAAGGAGGUGGACACUCATT 
PPP1R14C-3 CAGCCUAACCAAGGAUUAUTT 
AR CCAUCUUUCUGAAUGUCCU 
Scrambled Control (Non-targeting RNAi) UUCUCCGAACGUGUCACGUTT 
 
2.4 Plasmid DNA Transfection 
Mammalian expression plasmids were transfected into cells using TransIT®-LT1 transfection 
reagent (Mirus) according to the manufacturer’s protocol. The required amount of plasmid 
DNA was added to basal media in an Eppendorf tube. 3µl of TransIT®-LT1 transfection reagent 
was added to the tube for every 1µg plasmid DNA to be transfected. The TransIT®-LT1 reagent 
and DNA mixture was incubated at room temperature for 30 minutes. TransIT®-LT1 
reagent:DNA complexes were added in a dropwise fashion over pre-seeded cells. Cells were 
typically grown for 24 hours prior to transfection. The transfection was typically incubated for 
48-96 hours before harvesting for the required assay. 
The AR plasmid DNA was a kind gift from Professor Ralf Janknecht, University of Oklahoma. 
The PPP1R14C cDNA construct was purchased from the Harvard Medical School plasmid 
repository.  
2.5 Bacterial Transformation of Plasmid DNA 
Propagation of the PPP1R12A plasmid DNA was carried out by transforming NEB® 5-alpha E. 
coli chemically competent cells (New England BioLabs). Competent cells were stored at -80°C 
before gently thawing out on ice for 10 minutes when required. Approximately 500 ng of 
plasmid DNA was added to the competent cells, very gently mixed, and incubated on ice for 
30 minutes before a 30 second 42°C heat-shock. Cells were placed back on ice for 2-5 minutes 
followed by the addition of 950 µl SOC medium (2% (w/v) peptone, 0.5% (w/v) yeast extract, 
10 mM NaCl, 20 mM glucose, 10 mM MgCl2, 2.5 mM KCl, 10 mM MgSO4) and incubated at 
37°C, with agitation (200 rpm in a Thermotron incubator shaker (Infors HT)) for 1 hour. Cell 
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cultures were gently mixed and then 50-200µl culture was spread onto pre-warmed LB agar 
plates (1% (w/v) NaCl, 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1.5% (w/v) agar) containing 
100 µg/ml ampicillin.  
2.6 Culture of Transformed Bacteria 
For DNA mini-prep cultures, single bacterial colonies were picked from LB agar plates using 
sterile pipette tips and incubated in 3 ml LB medium (1% (w/v) NaCl, 1% (w/v) tryptone, 0.5% 
(w/v) yeast extract) containing 100 µg/ml ampicillin for selection overnight at 37°C with 
rotation at 200 rpm. For maxi-prep cultures, a single bacterial colony was incubated in 5 ml LB 
medium containing 100 µg/ml ampicillin for 8 hours at 37°C with rotation at 200 rpm and then 
transferred to a conical flask containing 200 ml of pre-warmed antibiotic-containing LB 
medium and incubated overnight with rotation at 37°C. 
2.7 Plasmid DNA Extraction 
Plasmid DNA extraction from bacteria was performed using commercially available extraction 
and purification kits. For mini-prep cultures, the GenElute™ Plasmid Miniprep Kit (Sigma 
Aldrich) was used according to manufacturer’s instruction. For maxi-prep cultures, the 
PureLink® HiPure Plasmid Filter Maxiprep Kit (Life Sciences, Invitrogen) was used according to 
the manufacturer’s protocol. Extracted and purified DNA was resuspended in a suitable 
volume of TE buffer and DNA concentration measured using a Nanodrop spectrophotometer 
(Thermo Scientific). 
2.8 SDS-PAGE 
Cell lysates were generated by adding SDS sample buffer (125 mM Tris-HCl, pH6.8, 5% SDS, 
10% glycerol, 10% β-mercaptoethanol and 0.01% bromophenol blue) directly to cultured cells 
washed with PBS. Samples were then boiled for 10 minutes at 100°C prior to loading into a 
gel. Various percentage gels were made using the quantities outlined in Table 2.2 using a mini-
PROTEAN® tetra casting system (Bio-Rad) dependent upon the size of the protein of interest. 
Gels were loaded with pre-boiled protein samples alongside a prestained gel ladder mixture 
of recombinant protein of known sizes (Spectra Multicolor Broad Range Protein Ladder, 
Thermo). Protein samples were separated using a Mini-PROTEAN® Tetra Vertical 
Electrophoresis Cell (Bio-Rad) filled with running buffer (25 mM Tris, 190 mM glycine, 0.1% 
SDS) at a voltage between 100-200V. 
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Table 2.2 - SDS-PAGE Gel Recipes 
 
 
 
 
 
 
 
 
 
 
 
2.9 Western blotting 
Following protein separation by gel electrophoresis, proteins were transferred to Hybond ECL 
Nitrocellulose membrane (GE healthcare) using the Mini Trans-Blot Electrophoretic Transfer 
Cell system (Bio-Rad) according to manufacturer’s instruction. The transfer was carried out 
using transfer buffer (25 mM Tris-HCl, pH8.3, 150 mM glycine, 10% methanol) at 100V for 1 
hour or 30V overnight. Following the transfer of proteins from the acrylamide gel to 
nitrocellulose, the membrane was blocked using 5% (w/v) milk (Marvel)/ TBS (500 mM NaCl, 
200 mM Tris-HCl pH7.5) for 1 hour at room temperature or overnight at 4°C with gentle 
rocking. Primary antibodies outline in Table 2.3 were typically made up to a final concentration 
of 200ng/ml. Membranes were then washed 3 times in TTBS (500 mM NaCl, 200 mM Tris-HCl, 
pH7.5, 0.001% Tween-20) for 5 minutes with gentle rocking and then incubated with specific 
primary antibody diluted in a volume of 4 ml 1% (w/v) milk/TTBS for 1 hour at room 
temperature or overnight at 4°C. The following day, membranes were washed 3 times for a 
total of 15 minutes with TTBS followed by incubation with a horse-radish peroxidase-
conjugated secondary antibody, raised against the species of the primary antibody, for an 
hour at room temperature. After incubation, membranes were washed twice with TTBS for 5 
minutes each and once in TBS for 10 minutes and then incubated with prepared ECL western 
blotting detection reagent (GE healthcare) for one minute with gentle agitation prior to X-ray 
 10% Gel 15% Gel 
Running Running Stacking 
Acrylamide (30%) 3.33ml 5ml 1.25ml 
Water (distilled) 1.67ml - 1.25ml 
2X Buffer A (750mM Tris-HCl, pH8.8, 
0.2% SDS) 
5ml 5ml - 
2X Buffer B (250mM Tris-HCl, pH 6.8, 
0.2% SDS) 
- - 2.5ml 
N,N,N’,N’-tetramethylethane-1,2-
diamine (TEMED) 
20µl 20µl 6µl 
Ammonium persulphate (10%) 100µl 100µl 50µl 
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film (FujiFilm, SuperRX) exposure for signal detection. Films were developed using an 
automatic X-ray film processor model JP-33 (JPI Healthcare).  
Table 2.3 - List of Antibodies, species, suppliers and applications 
Antibody Species Supplier Applications 
AR (N-20) (sc-816) Rabbit Santa Cruz WB, IP, IF 
Phosphorylated AR 
S81 (07-1375) 
Rabbit Merck Millipore WB 
Phosphorylated AR 
S213 (ab47562) 
Rabbit Abcam WB 
Phosphorylated AR 
S515 
Rabbit Gift from Dr Joanne 
Edwards 
University of Glasgow 
WB 
PPP1R12A 
(DU34962) 
Sheep University of Dundee - 
commercial 
WB 
Phosphorylated 
PPP1R12A S472 
(S509C) 
Sheep University of Dundee- 
commercial 
WB 
Phosphorylated 
Myosin Light Chain 
S19 (#3675) 
Mouse Cell Signaling WB, IF 
PARP-1 (H-250) (sc-
7150) 
Rabbit Santa Cruz WB 
MAPK1 (D-2) (sc-
1647) 
Mouse Santa Cruz WB 
Phosphorylated 
MAPK1/MAPK3 
T202/Y204 (sc-
101760) 
Rabbit Santa Cruz WB 
α-tubulin (T9026) Mouse Sigma Aldrich WB 
Phosphorylated 
AKT S473 (sc-7985) 
Rabbit Santa Cruz WB 
AKT (H-136) (sc-
8312) 
Rabbit Santa Cruz WB 
NF2 (A-19) (sc-331) Rabbit Santa Cruz WB 
Phosphorylated 
PLK-1 T210 (sc-
135706) 
Rabbit Santa Cruz WB 
PLK-1 (F-8) (sc-
17783) 
Mouse Santa Cruz WB 
Phosphorylated 
RB1 S807/811 
(9308) 
Rabbit Cell Signaling WB 
RB1 (554140) Mouse BD Pharmingen WB 
Anti-Mouse-HRP Rabbit Dako WB 
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Anti-Rabbit-HRP Swine Dako WB 
Anti-Sheep-HRP Rabbit ThermoFisher Scientific WB 
Anti-Rabbit-HRP Swine Dako WB 
Rabbit IgG Rabbit Diagenode IP 
Anti-Rabbit-Alexa 
Fluor 488 
(ab150077) 
Goat Abcam IF 
Anti-Mouse-Alexa 
Fluor 594 
(ab150116) 
Goat Abcam IF 
 
2.10 Live cell imaging 
Cell growth was measured using the IncuCyte® ZOOM system (Essen BioSciences) which 
incorporates live cell imaging and analysis to provide quantification of cell proliferation over 
a given time period. As long as the morphology of the cells following treatment remains 
consistent, nor do the cells reach 100% confluency, this method of quantification provides an 
accurate surrogate for cell proliferation. Briefly, cells were seeded in the appropriate culture 
vessel and allowed to adhere for 24 hours where they would be 5-10% confluent. Following 
seeding, cells would be subjected to DNA/siRNA transfection or compound treatments and 
placed into the IncuCyte® ZOOM system. Images would then be taken from multiple fields per 
well every 4 hours over the desired period of time required for the assay. Proliferation was 
calculated by a measure of cell confluency and provided as a percentage. Raw percentage was 
normalised to the confluency of time point zero for each particular well and then calculated 
as fold changes. 
2.11 Cell cycle analysis 
Cell cycle analysis was carried out using fluorescence activated flow cytometry (FACs) in order 
to assess the percentage of cells in a particular phase of the cell cycle following target 
modulation. Propidium iodide (PI), a DNA intercalating dye, is incorporated into cells and upon 
excitation produces a quantifiable fluorescent signal corresponding to cellular DNA content as 
a result of stoichiometric binding. As such, cells in G2/M phase will have twice as much DNA 
as cells in G0/G1 phase, whilst cells in S-phase will possess an intermediary value. Excitation 
and fluorescent measurement of samples was carried out using the FACSCalibur™ (BD 
biosciences) with subsequent data analysis performed using Cyflogic 1.2.1 (CyFlo Ltd.).  Cells 
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were seeded onto 6-well plates at an appropriate confluency that they would be exponentially 
growing at the time of harvest. 
2.11.1 Cell harvest and staining 
At the time of harvest, culture media was transferred to 5 ml round-bottom tubes (BD 
biosciences), cells washed once in PBS, retaining the PBS and adding to the previously 
removed culture media in tubes. Cells were detached as described in section 2.1.2 and added 
to the aforementioned tubes. Tubes were centrifuged at 400 x g for 5 minutes at 4°C and cell 
pellets washed with PBS before a second round of centrifugation after which the pellet was 
resuspended in 100 µl citrate buffer (250 mM sucrose, 40 mM sodium citrate, pH7.6). 400 µl 
of DNA staining buffer (20 µg/ml PI, 0.5 mM EDTA, 0.5% NP40, 10 µg/µl RNase A) was added 
to the cell suspension mix and incubated for 1 hour at 4°C in the dark. 
2.11.2 Flow cytometry and data analysis 
Samples were briefly mixed and passed through a Microlance hypodermic needle, 21G (BD 
biosciences) and loaded into the FACSCalibur™ machine using BD CellQuest™ to acquire data 
of 10,000 events (cells). Cell aggregates were discriminated and removed from analysis by 
gating only single cell populations. Histogram plots were generated using cell counts Vs FL2-A 
(fluorescent emission from a cell) and % of cells in cell cycle phases analysed from the 
histogram by the Cyflogic software. 
2.12 RNA extraction 
RNA was isolated from cells using TRIzol® Reagent (Life Sciences, Invitrogen) according to the 
manufacturer’s protocol. Briefly, media was removed from the culture vessel (typically a 6-
well plate) and cells washed once in PBS. 1 ml of TRIzol® Reagent was added directly to the 
cells and the homogenized sample was transferred to an Eppendorf tube and incubated at 
room temperature for 5 minutes. 0.2 ml of chloroform (Sigma Aldrich) was then added to each 
sample and shaken vigorously and incubated at room temperature for 3 minutes before 
centrifugation for 15 minutes at 12,000 x g at 4°C. The upper aqueous phase was transferred 
to a fresh tube and 0.5 ml of isopropanol (Fisher Chemicals) was added followed by incubation 
at room temperature for 10 minutes before centrifugation at 12,000 x g for 10 minutes at 4°C. 
The resultant RNA pellet was washed in 75% ethanol in nuclease-free water (Life Sciences, 
Invitrogen) and centrifuged at 7,500 x g for 5 minutes at 4°C. The ethanol wash was removed 
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and the RNA pellet was allowed to air dry. The pellet was resuspended in 20 µl of water and 
incubated at 55°C for 10 minutes to remove any secondary structures. RNA concentration was 
then quantified using the Nanodrop (Thermo Scientific) prior to reverse transcription. RNA 
was stored at -20°C. 
2.13 Reverse transcription 
RNA was reverse transcribed to cDNA using moloney murine leukaemia virus reverse 
transcriptase (M-MLV RT) (Promega) according to the manufacturer’s protocol. Briefly, 1 µg 
RNA was made up to a final volume of 12.7µl with DEPC water. Seperately, a reverse 
transcription master mix was made up for the appropriate number of samples by adding 4 µl 
M-MLV 5X reaction buffer, 2µl 4mM dNTPs, 100µg Oligo(dT) and 0.3µl M-MLV RT enzyme to 
a final volume of 7.3µl. Samples were then incubated with the reverse transcription master 
mix for 1 hour at 37°C, followed by 5 minutes at 95°C to inactivate the RT enzyme. Resultant 
cDNA was further diluted 1:5 with nuclease-free water. Samples were stored at -20°C until 
required. 
2.14 Quantitative real time polymerase chain reaction (qPCR) 
Gene expression was quantified by subjecting cDNA samples to qPCR in 384-well format using 
a 7900HT Fast Real-Time PCR thermocycler (Applied Biosystems). Samples were run in 
triplicate using PCR reaction master mixes prepared for each gene target of interest in a total 
volume of 9 µl per well with the following components: 5µl Fast SYBR Green Master Mix (2X) 
(Thermo Fisher), 0.4µl forward primer (see Table 2.4), 0.4µl reverse primer and 3.2µl DEPC 
water.  
Reaction master mixes were loaded onto a 384-well plate (Applied biosciences), followed by 
1µl of sample cDNA. Using an absolute quantification method, a standard curve was generated 
by loading master mix reaction followed by the addition of serial dilutions of a cDNA sample 
(1, 0.5, 0.05, 0.005, 0.005 and a H2O (no template only control) onto the plate. The prepared 
microplate was covered with an optical adhesive cover, briefly centrifuged (Labnet MPS 1000) 
and ran using the following PCR parameters: 95°C for 10 minutes followed by 40 cycles of 95°C 
for 15 seconds, 60°C for 1 minute. 
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Table 2.4 Primer sequences used for qPCR. Primers were diluted to a concentration of 25ng/µl in nuclease free water prior 
to qPCR reaction setup. 
 
 
Data acquired was analysed using Sequence Detection System (SDS) software version 2.3 
(Applied Biosystems). Relative quantities for each gene of interest was calculated from the 
standard curve generated, these values were subsequently normalised using the relative 
quantity HPRT1 gene expression values for each sample. 
2.15 Luciferase reporter assay 
Luciferase reporter assays were performed in HEK293T cells due to their high transfection 
efficiency. Cells were seeded at a density of 2x104 per well of 24-well plate in DCC media and 
were reverse transfected with 100ng/well p3xARE-luc, 100ng/well pCMV-β-galactosidase 
construct and 50ng/well androgen receptor expressing plasmids. Cells were the incubated 
with the transfection mix for 48 hours with DHT treatments (if required) applied for an 
additional 24 hours prior to harvesting in 100µl 1x reporter lysis buffer (Promega) per well. 
Plates were incubated at 37°C for 15 minutes and then stored at -80°C until required. When 
needed, cells were thawed on ice, scraped, and pipetted up and down. 10µl of lysate was 
transferred to a 96 well white, flat bottom microplate (Greiner bio-one) containing 40µl DEPC 
water, which was then inserted into a FLUOstar Omega plate reader (BMG Labtech). The plate 
reader injected and mixed 50 µl luciferase assay substrate (Promega) into each well and 
measured luminescence before injecting into the next well. Data acquired was presented as 
light counts per second (LCPS). The transfection efficiency between experimental arms was 
measured using a β-galactosidase assay. To measure enzymatic activity, 10 µl of cell lysates 
Gene Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) 
PSA GCAGCATTGAACCAGAGGAG AGAACTGGGGAGGCTTGAG 
TMPRSS2 CTGCTGGATTTCCGGGTG TTCTGAGGTCTTCCCTTTCTCCT 
KLK2 AGCATCGAACCAGAGGAGTTCT TGGAGGCTCACACACCTGAAGA 
PPP1R14C GGAAGAAGAAATGCCAGAGGTAGA 
 
GCATCAAGAAGATCATCAATGTCAAT 
 
AR AAGAGAAGTACCTGTGCGCC TTCAGATTACCAAGTTTCTTCAG 
HPRT1 TTGCTTTCCTTGGTCAGGCA AGCTTGCGACCTTGACCATCT 
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were transferred to a clear bottom 96 well plate (Corning) and mixed with 10 µl of β-
galactosidase substrate (2mM MgCl2, 100mM β-mercaptoethanol, 1.33mg/ml o-nitrophenyl- 
β-D- galactopyranoside, 100mM sodium phosphate buffer, pH7.3) at 37°C for 5 minutes until 
the lysate/substrate mix turned from colourless to yellow. 50 µl of 1M Na2CO3 was added to 
terminate the enzymatic reaction and the plate was then read on a microplate reader (Model 
680, Bio-Rad) at Abs480. Results of luciferase assays were presented as normalised LCPS 
(LCPS/β-gal). 
2.16 Immunofluorescence 
LNCaP cells were grown in 6-well plate format (Corning) upon glass coverslips. Following RNAi 
modulation, cells were fixed with 2mls paraformaldehyde (2%v/v) overnight at 4°C. The next 
day cells were washed twice with PBS prior to being permeabilised with 0.1% Trition-X-100 
(PBS) for 15 minutes. Cells were then blocked for 1 hour at room temperature in 0.1% Triton-
X-100, 1% BSA – PBS. Coverslips were then incubated with blocking solution containing 4µg/ml 
primary antibody overnight at 4°C. Coverslips were then washed 3 times with room 
temperature PBS before addition of the secondary antibody, 1µg/ml in blocking solution, for 
1 hour at room temperature. Coverslips were then washed twice with PBS and mounted to 
glass slides with DAPI mounting medium (Vectashield), air-dried, and visualised using a Leica 
DMR fluorescent microscope. 
2.17 Immunoprecipitation 
HEK293T cells were cultured as described in section 2.1.2 and underwent AR plasmid DNA 
transfection as described in section 2.4. Following a 48 hour period, cells were washed with 
4°C PBS and lysed with 1ml immunoprecipitation buffer (0.5ml 1M Tris-HCl pH7.5, 0.375ml 
4M NaCl, 100µl 0.1M phenylmethane sulfonyl fluoride (in methanol), 1X cOmplete mini 
protease inhibitor tablet (Roche), 10µl 1M dithiothreitol, 100µl 10mM sodium orthavanadate, 
100µl nonyl phenoxypolyethoxylethanol, 8.9ml water). Cells were scraped and collected in an 
Eppendorf Tube and gently agitated for 30 minutes by rotation at 4°C. In parallel, protein-G 
sepharose (PGS) beads were prepared by resuspending 20µl of PGS slurry in 500µl 
immunoprecipitation lysis buffer, followed by centrifugation at 12,000 x g for 3 minutes. The 
supernatant was then discarded and the PGS beads resuspended in 500µl 
immunoprecipitation buffer. This wash process was repeated 3 times and the PGS beads were 
then stored at 4°C. 50µl cell lysate was then removed to be used as an input control for 
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western blot analysis. The remaining 950µl was then incubated with 20µl of the prepared PGS 
solution at 4°C for 1 hour. The samples were then centrifuged for 3 minutes at 12,000 x g, with 
the supernatant being split evenly (475µl per tube) between fresh Eppendorf tubes containing 
10µg of either AR (N20) antibody, or Rabbit IgG. Samples were then gently rotated overnight 
at 4°C. The following day samples were centrifuged for 3 minutes at 12,000 x g and the 
supernatant discarded. PGS Samples were washed once with immunoprecipitation wash 
buffer A once, and twice with wish buffer B, centrifuged at 12,000 x g for 3 minutes between 
each wash. Final PGS samples were then boiled for 10 minutes in 100µl SDS sample buffer. 
Immunoprecipitation samples were then ready to be analysed by western blot.  
2.18 Boyden Chamber Assay 
A migration assay employing the Boyden chamber transwell approach was performed as 
previously described (Chen, 2005). Briefly, LNCaP cells were grown as described in section 
2.1.1 and transfected with siPPP1R14C-1 as previously described for 48 hours. Cells were 
collected and resuspended in basal media prior to counting. 10x102 cells in 50µl basal media 
were then placed within the Boyden chamber (8µm pore size polycarbonate membrane, 
Merck Millipore) in 24 well plate format positioned within 250µl full media and incubated for 
24 hours at 37°C. Cells were then fixed with 0.5mls paraformaldehyde (2%v/v) for 30 minutes 
at room temperature prior to washing 3 times with PBS. Migrated cells were then stained with 
crystal violet and visualized using an EVOS XL Core Cell Imaging System (Thermo Scientific). 
The cells within 8 independent fields of view were counted for each experimental repeat.  
2.19 Nuclear-Cytoplasmic Fractionation 
Nuclear-cytoplasmic fractionation was performed using the NE-PER Nuclear and Cytoplasmic 
Extraction Kit (Thermo Scientific) according to the manufacturer’s protocol. Briefly, LNCaP 
cells were cultured as previously described in DCC media and transfected with siPPP1R14C-1 
or the scrambled control RNAi oligo. Cells were incubated for 72 hours prior to a 30 minute 
10nM DHT stimulation. Cells were then harvested according to the manufacturer’s protocol, 
with the isolated nuclear and cytoplasmic lysates stored at -20°C until analysis by western blot.  
2.20 RNA sequencing 
LNCaP cells were cultured as previously described in section 2.1.1 and underwent RNAi 
depletion as described in section 2.3. RNAi knockdown was performed in LNCaP cells grown 
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for at least 5 passages independently of each other. Briefly, RNA extraction was performed by 
column filtration using the commercially available RNeasy Plus Kit (Qiagen) according to 
manufacturer’s protocol. Isolated RNA was then quantified by Nanodrop (Thermo Scientific) 
and validated by qPCR as described in sections 2.13 and 2.14. Once the level of knockdown 
for each sample was established, RNA samples were subject to analysis through use of the 
2100 Bioanalyzer (Agilent Technologies) to ascertain the integrity of the RNA sample. The RNA 
integrity number (RIN) value ranges between 0-10, with 10 representing the maximum 
integrity. Only samples with a RIN value >9 were taken forward for RNA sequencing. RNA 
sequencing was performed by Aros Applied Biotechnology, Denmark on the Illumina HiSeq 
2500 platform. RNA samples were prepared using Stranded Total RNA Sample Prep kit 
(Illumina), depleted of ribosomal RNA using the RiboZero Gold kit (Illumina) and sequenced 
with 100bp paired end reads resulting in an estimated ~80 million reads per sample. Reads 
were mapped to human genome hg19 using the RNA-sequence alignment tool STAR (Dobin 
et al., 2013). Raw read counts were then calculated for each gene using HTSeq (Anders et al., 
2015) prior to differential gene expression analysis using DEseq2 (Love et al., 2014). 
Differential gene expression enrichment analysis was performed using the gene set 
enrichment analysis (GSEA) software (Broad Institute) and publicly available datasets from the 
molecular signatures database (MSigDB, Broad Institute). 
Figure 2.1 – RNA sequencing work-flow. The work-flow for generating the PPP1R14C RNAi depletion dataset was performed 
as shown above. Tasks bordered in blue were performed by myself, whilst tasks bordered in red were performed by the in-
house bioinformatition Dr. S. Nakjang, and the task in green performed by Aros Applied Biotechnology. 
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2.21 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software, California, 
USA) implementing paired and unpaired student t-tests where applicable.  
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Chapter 3. 
Myosin Phosphatase is a Dynamic Regulator of Androgen 
Receptor Transcriptional Activity 
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3.1 Introduction 
Myosin Phosphatase (MLCP) is heterotrimeric protein comprising the PP1δ catalytic subunit 
isoform, PPP1R12A regulatory subunit, and M20, a small 20 kDa protein that binds to the C-
terminus of PPP1R12A (Ito et al., 2004). It has been demonstrated that M20 does not impact 
on the phosphatase activity of MLCP, but as of yet, its exact role remains to be elucidated 
(Hartshorne et al., 1998). For this reason, the implication of M20 will not be discussed in this 
thesis in the context of AR signalling. PPP1R12A is a 110 kDa protein expressed by a single 
gene on chromosome 12q15-q21.2 (Takahashi et al., 1997).  The N-terminus of PPP1R12A 
contains the PP1 binding motif (K/R-I/V-x-F/W) and a 7 ankyrin repeat domain, both of which 
have been shown to be involved in the interaction between PP1δ and PPP1R12A (Hirano et 
al., 1997; Tanaka et al., 1998; Toth et al., 2000). A schematic representation of the PPP1R12A 
protein can be found in figure 3.1. Mutation of the ‘KVKF’ sequence in PPP1R12A 
demonstrated that this motif is essential for PP1δ binding. Using PPP1R12A peptide fragments 
of varying lengths it was demonstrated that MLCP had enhanced affinity for its substrate, 
phosphorylated myosin light chain serine 19 (pMLC-S19), compared to purified PP1δ, and that 
the NTD was sufficient to induce allosteric regulation of the catalytic activity (Johnson et al., 
1997). In addition, inclusion of the ankyrin repeat domain was shown to be required for 
maximal affinity toward pMLC-S19 (Tanaka et al., 1998). Indeed, the ankyrin repeat domain 
has since been reported to act as a docking platform for interacting proteins and additional 
substrates (Ito et al., 2004). PPP1R12A also contains 2 nuclear localization signals in the C-
terminus, and whilst unbound to PP1δ it is predominantly found in the nucleus, however, 
Figure 3.1 – Schematic Representation of the PPP1R12A Protein. The PPP1R12A gene is located on chromosome 
12q15-21.2 and encodes the 110kDa PPP1R12A protein. PPP1R12A contains the PP1 binding motif ‘KVKF’ at its N-
terminus adjacent to the ankyrin repeat domain, whilst the C-terminus possesses a leucine zipper.  
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when in complex as MLCP, it is found equally distributed throughout all cellular compartments 
(Wu et al., 2005). PPP1R12A can be expressed as 2 alternatively spliced isoforms, representing 
the presence or absence of a 123 nucleotide centrally located exon (Shimizu et al., 1994). The 
inclusion or exclusion of this exon dictates the presence or absence of 2 leucine zipper motifs 
in the C-terminus. Presence of this exon leads to a frameshift, leading to the inclusion of a 
premature stop codon and exclusion of the leucine zipper motifs (Khatri et al., 2001). It was 
demonstrated that the presence of the leucine zipper motifs did not mediate an interaction 
between MLCP and protein kinase G (PKG), but did result in repressive modulation of MLCP in 
a cyclic guanosine monophosphate and PKG dependent manner (Huang et al., 2004). 
The catalytic activity of MLCP is heavily influenced through a number of different mechanisms, 
principally PTM and through association with endogenous inhibitory proteins (Eto et al., 2007; 
Matsumura and Hartshorne, 2008). In this section I will introduce the concept of MLCP 
inhibition via interaction with endogenous inhibitory proteins, whilst PTM of MLCP will be 
discussed in section 9.1. 
Protein phosphatase regulatory inhibitor subunit 14A (PPP1R14A) was the first MLCP 
inhibitory protein to be identified, and it was demonstrated to act as a signal transduction 
protein, responding to G-protein coupled receptor (GPCR) stimulation, and resulting in MLCP 
inhibition (Eto et al., 1995). Subsequent studies identified PPP1R14-B, C, D through sequence 
homology and were successfully characterised as MLCP inhibitors (Eto et al., 1999; Liu et al., 
2002; Liu et al., 2004). Indeed, there is a very high degree of sequence homology between all 
MLCP inhibitory proteins, but no sequence homology with any other known PP1 inhibitory 
proteins (e.g. Inhibitor-1) despite similar mechanisms of inhibition (Eto et al., 2007). All the 
members contain a conserved central PP1 holoenzyme inhibitory (PHIN) domain containing a 
pseudo palindromic motif incorporating an inhibitory threonine (Eto et al., 2007). Solution 
NMR studies of PPP1R14A has revealed the 3D structure of the PHIN domain when both 
phosphorylated and dephosphorylated (Eto et al., 2007). The PHIN domain consists of a loop 
structure surrounding the inhibitory threonine termed the ‘P loop’ followed by a 4-helix 
bundle that acts to stabilize the ‘P loop’. Upon phosphorylation of the inhibitory threonine a 
conformational change occurs whereby a hydrophobic core is created, causing the phospho-
threonine to be displayed on the surface of the protein. In addition, a tyrosine residue flanking 
the threonine anchors the phospho-threonine in place. Mutagenesis studies proved that the 
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tyrosine residue is essential in the prevention of hydrolysis of the phosphorylated threonine 
(Hayashi et al., 2001). As such, a stable complex is formed between MLCP and the inhibitory 
protein, resulting in transient inhibition of MLCP catalytic activity (Eto et al., 2004). Indeed, 
the electrostatic surface potentials from MLCP inhibitory proteins appear to complement the 
acidic cluster formed by PP1δ and the PPP1R12A ankyrin repeat domain providing evidence 
for interactions between the inhibitory proteins with both the catalytic and regulatory 
subunits of MLCP (Terrak et al., 2004). Furthermore, the MLCP inhibitory proteins can be 
dephosphorylated by purified PP1δ and indeed PP1δ containing holoenzymes, and as such, 
their specificity towards MLCP is more a question if they behave as inhibitors or substrates 
(Eto, 2009).    
 
More specifically, the PPP1R14C gene is located on chromosome 6q24.3-q25.3 and spans 4 
exons coding for a 165 amino acid protein with a mass of 19kDa as depicted in figure 3.2 (Liu 
et al., 2002). Phosphorylation of threonine 73, located within the PHIN domain, dramatically 
increases the binding affinity of PPP1R14C to MLCP by 600-fold, resulting in an IC50 of 0.1nM 
(Eto and Brautigan, 2012). Multiple kinases have been demonstrated to directly phosphorylate 
PPP1R14C, or have been inferred through sequence homology surrounding the inhibitory 
threonine in the PHIN domain of PPP1R14A. These include PKC, integrin linked kinase (ILK), 
death-associated protein kinase 3 (ZIPK), rho-associated coiled-coil containing protein kinase 
(ROCK) I/II, protein kinase N (PKN) and p21-activated kinase (Hamaguchi et al., 2000; Koyama 
et al., 2000; MacDonald et al., 2001; Deng et al., 2002; Liu et al., 2002; Takizawa et al., 2002; 
Figure 3.2 – Schematic Representation of the PPP1R14C Protein. The PPP1R14C gene is located on chromosome 
6q24.3-25.3 and spans 4 exons. The encoded protein contains an N-terminal PP1 binding motif, ‘KVFF’, and a 
central phosphatase inhibitory (PHIN) domain. Within the PHIN domain resides threonine 73, which upon 
phosphorylation, enhances the affinity of PPP1R14C for myosin phosphatase by 600-fold, where it behaves as a 
pseudosubstrate and inhibits subsequent myosin phosphatase activity. 
72 
 
Erdodi et al., 2003; Liu et al., 2013). Crucially, phosphorylation of threonine 73 by any of the 
aforementioned kinases results in the same functional output, i.e. inhibition of MLCP. In 
addition, PPP1R14C also contains the classical ‘KVFF’ PP1 binding motif within its N-terminus, 
and has been shown to bind PP1δ when dephosphorylated, albeit with a highly reduced 
affinity (Eto and Brautigan, 2012). However, this cannot rule out additional mechanisms of 
inhibition or indeed additional signalling roles. PPP1R14C was initially identified as an MLCP 
inhibitory protein regulated by morphine, and the understanding of its role in cancer remains 
limited (Liu et al., 2002). However, ectopic expression of PPP1R14C in the breast cancer cell 
line MCF-7 results in activation of the MAPK signalling cascade, a pathway frequently 
dysregulated in various malignancies (Wenzel et al., 2007). A more recent study successfully 
identified PPP1R14C as the substrate for serine/threonine kinase 24 (MST3) and 
serine/threonine kinase 26 (MST4), resulting in phosphorylation of threonine 73, inhibition of 
MLCP and reduced cancer cell migration (Madsen et al., 2015). The authors also went on to 
show that PPP1R14C was rapidly phosphorylated in response to serum stimulation, promoting 
its inhibitory impact on MLCP. In a separate study, PPP1R14C was shown to translocate to the 
nucleus upon phosphorylation, resulting in impaired dephosphorylation of the tumour 
suppressor retinoblastoma 1 (RB1), a known MLCP substrate (Kiss et al., 2008; Dedinszki et al., 
2015). Although limited, preliminary evidence exists for PPP1R14C to act as a signal 
transduction molecule for a number of signalling cascades that may become of significance 
within the context of this thesis. Besides the role of PPP1R14C in the inhibition of MLCP, no 
other functions have been identified, and as such, the interplay between PPP1R12A and 
PPP1R14C in the regulation of MLCP activity will be assessed in the context of AR activity. In 
this chapter I aim to validate the impact of PPP1R14C and PPP1R12A RNAi depletion on AR 
transcriptional activity identified from the phosphatase RNAi screen. 
3.2 Results 
3.2.1 PPP1R14C depletion reduces androgen receptor transcriptional activity 
Following RNAi transfection of LNCaP cells for 72 hours with 3 independent RNAi oligos 
targetting PPP1R14C (denoted siPPP1R14C-1, 2 and 3), a significant reduction (p-value <0.05) 
of approximately 80% in the mRNA expression of PPP1R14C was observed with all RNAi duplex 
sequences and is depicted in figure 3.3. LNCaP cells were stimulated with 10nM DHT for 24 
hours in order to elicit an androgenic response prior to RNA extraction. Knockdown of 
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PPP1R14C with all 3 oligos resulted in statistically significant repression of the AR target genes 
PSA, TMPRSS2 and KLK2 (p-value < 0.05). siPPP1R14C-1 had the most pronounced effect on 
PSA mRNA expression, reducing its relative quantity normalised to HPRT1 by 90% compared 
to the scrambled control. siPPP1R14C-2 had the most profound impact on TMPRSS2 mRNA 
expression, again, reducing gene expression by approximately 90% when compared to the 
scrambled control. siPPP1R14C-3 was capable of statistically reducing all 3 AR target genes by 
over 50% compared to the scrambled control. Crucially, all 3 RNAi oligos recapitualte the 
impact observed in relation to AR activity within the RNAi screen described in section 3.2 
where PPP1R14C RNAi depletion resulted in a 60% reduction in luciferase activity compared 
to the scrambled control.  Due to the consistency of knockdown and repression of AR target 
genes, particularly PSA, siPPP1R14C-1 was taken forward for future characterisation assays.  
 
In the absence of androgen, depicted in figure 3.4, RNAi knockdown of PPP1R14C resulted in 
statistically significant repression of AR target gene mRNA expression (p-value < 0.05). In 
contrast to the androgen stimulated arm, all 3 target genes were repressed by approximately 
80% when compared to the scrambled control. Unfortunately it was not possible to succesfully 
quantify the extent of PPP1R14C knockdown at the protein level. However, following RNAi 
depletion of PPP1R14C, it was possible to evaluate any alterations in MLCP activity through 
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Figure 3.3 – PPP1R14C Depletion Reduces AR Transcriptional Activity in the Presence of Androgen. PPP1R14C was depleted 
in LNCaP cells using 3 independent RNAi oligos for 48 hours in DCC media prior to 24 hour 10nM DHT stimulation. AR regulated 
gene mRNA expression was quantified by RT-qPCR. Data represents n=3 mean ± sem. Unpaired student t test performed using 
graphpad.. 
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the detection of phosphorylated MLC-S19. As such, in figure 3.5 a modest reduction in the 
detection of pMLC-S19 is observed when quantified by western blot using a phospho-specific 
antibody regardless of the presence or absence of androgen. This would suggest that the 
activity of MLCP has increased in response to the depletion of its endogenous inhibitory 
protein, PPP1R14C. It was also possible to quantify the protein expression of both the AR and 
PPP1R12A following knockdown, and no significant difference was observed compared to the 
scrambled control, albeit with the expected stabilization of the AR following androgen 
stimulation compared to the androgen deprived arm. 
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Figure 3.5 - PPP1R14C Depletion Increases the Activity of Myosin Phosphatase. The impact of PPP1R14C 
depletion on MLCP activity was assessed by western blot analysis of the MLCP substrate pMLC20 in both the 
presence and absence of androgen. 
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Figure 3.4 - PPP1R14C Depletion Reduces AR Transcriptional Activity in the Absence of Androgen. 
PPP1R14C was depleted in LNCaP cells for 72 hours in DCC media. AR regulated gene mRNA expression was 
quantified by RT-qPCR. Data represents n=3 mean ± sem. Unpaired student t test performed using 
graphpad. 
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3.2.2 PPP1R12A depletion enhances androgen receptor transcriptional activity 
Conversely, RNAi knockdown of PPP1R12A was quantifiable at the protein level, and at 72 
hours post-transfection the protein expression of PPP1R12A were greatly reduced as observed 
in figures 3.6B and 3.6D. Indeed, only upon long exposure of the x-ray film were endogenous 
levels detected. Interestingly, AR protein levels increased dramatically following siPPP1R12A 
transfection, particularly in the absence of androgen (figure 3.6D). AR mRNA expression also 
increased significantly following PPP1R12A depletion. In the presence of androgen, AR mRNA 
expression increased by ~2.5-fold (p-value < 0.05, figure 3.6A), however, in the absence of 
androgen, a dramatic ~15-fold (p-value < 0.05, figure 3.6C) increase is observed and as such, 
AR mRNA levels complement AR protein expression. When investigating the impact of 
Figure 3.6 - PPP1R12A Depletion Increases AR mRNA and Protein Expression in the Presence and Absence 
of Androgen. A-B) PPP1R12A was depleted by RNAi knockdown in LNCaP cells stimulated with 10nM DHT for 
24 hours. C-D) PPP1R12A was depleted by RNAi knockdown in LNCaP cells in the absence of androgen. mRNA 
expression was quantified by RT-qPCR. Data represents n=3 mean ± sem. Unpaired student t test performed 
using graphpad. 
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PPP1R12A RNAi knockdown on AR transcriptional activity in the presence of androgen (figure 
3.7A), an increase in PSA, TMPRSS2 and KLK2 mRNA expression was observed, albeit with only 
PSA mRNA expression increasing statistically significantly (p-value < 0.05) by approximately 4-
fold. However, this increase in AR targetted gene transcription falls in line with the 
observations made from the RNAi screen. In contrast, the induction of AR activity in relation 
to the mRNA expression of PSA, TMPRSS2 and KLK2 in the absence of androgen wa 
significantly enhanced (p-value < 0.05). A 2-fold induction of TMPRSS2, 7-fold induction of 
KLK2, and a 15-fold induction of PSA mRNA expression is observed in figure 3.7B. 
Figure 3.7 - PPP1R12A Depletion Increases AR Transcriptional Activity in the Presence and Absence of 
Androgen. A) PPP1R12A was depleted by RNAi knockdown in LNCaP cells stimulated with 10nM DHT for 
24 hours. B) PPP1R12A was depleted by RNAi knockdown in LNCaP cells in the absence of androgen. mRNA 
expression was quantified by RT-qPCR. Data represents n=3 mean ± sem. Unpaired student t test 
performed using graphpad. 
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3.2.3 PPP1R14C increases androgen receptor transcriptional activity 
Over-expression of PPP1R14C was performed in HEK293T cells as described in section 2.4 and 
quantified by luciferase reporter assay as described in section 2.15. In the presence of 
androgen, AR activity increased non significantly in correlation with increasing amounts of 
transfected PPP1R14C (figure 3.8A). In contrast, transfection of both 50ng and 100ng 
PPP1R14C in the absence of androgen (figure 3.8B), significantly increases  the transcriptional 
activity of the AR compared to the 0ng transfected arm, reciprocating the results observed in 
figure 3.7B following PPP1R12A knockdown.  
 
 
Interestingly it was observed that PPP1R14C mRNA expression increased following 10nM DHT 
treatment in LNCaP cells over a 96 hour time period (figure 3.9). Maximal induction of 
PPP1R14C mRNA expression was observed at the 72 hour time point, corresponding to a 4.5 
Figure 3.8 - PPP1R14C Over-Expression Increases AR Transcriptional Activity. A) In a luciferase reporter 
assay, HEK293T cells were transfected with increasing amounts of PPP1R14C plasmid DNA and 
stimulated with 10nM DHT for 24 hours prior to analysis. B) In a luciferase reporter assay, HEK293T cells 
were transfected with increasing amounts of PPP1R14C plasmid DNA in DCC for 72 hours. Data 
represents n=3 mean ± sd. Unpaired student t test performed using graphpad. 
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fold increase (p-value < 0.05). PSA mRNA expression increased rapidly as expected, reaching 
maximal induction of approximately 14-fold 48 hours post 10nM DHT stimulation. Similarly, 
upon RNAi knockdown of the AR, confirmed in figure 3.10B, PPP1R14C mRNA expression was 
significantly reduced at the 72 hour time-point (p-value < 0.05, figure 3.10A). The mRNA 
expression of PSA was also quantified to use as a surrogate for AR activity, and a significant 
reduction (p-value < 0.05) in PSA mRNA expression is observed as early as 24 hours, whilst 
PPP1R14C mRNA expression remained largely unchanged. Together this would suggest 
PPP1R14C is androgen regulated, but may represent a secondary effect of androgen signalling. 
Figure 3.9 - PPP1R14C mRNA Expression Increases Following DHT Stimulation. LNCaP cells were stimulated with 10nM 
DHT and subject to RNA extraction at 0, 0.5, 1, 2, 4, 8, 12, 24, 48, 72 and 96 hour time-points. mRNA expression was 
quantified by RT-qPCR. Data represents n=3 mean ± sem. Unpaired student t test performed using graphpad. 
Figure 3.10 - AR Depletion Reduces PPP1R14C mRNA Expression. A) LNCaP cells were transfected with AR RNAi for 72 
hours in full media and subsequently harvested for RT-qPCR analysis. B) Western blot analysis of AR RNAi depletion. mRNA 
expression was quantified by RT-qPCR. Data represents n=3 mean ± sem. Unpaired student t test performed using 
graphpad. 
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3.3 Discussion 
As discussed in section 1.2.1, the cellular effects of androgens are mediated through 
transactivation of the AR and its subsequent impact on gene transcription. In turn, prostate 
metabolism, survival, growth and differentiation are dependent upon the transcriptional 
activity of the AR. As such, targeting the AR has proven to be an effective strategy in the 
treatment of PC. ADT is initially very effective at preventing the progression of PC by limiting 
the availability of circulating ligands for the AR, however, invariably the disease progresses 
from an initial state of sensitivity to a state termed CRPC. However, it has been proven that 
the AR signalling axis remains active and is capable of driving disease progression, and as such, 
studies have proven that disruption of AR transactivation remains a viable therapeutic option, 
and indeed, 2nd generation antiandrogens display modest efficacy. Despite positive responses 
in a large proportion of patients, this too invariably fails. It is known however, that co-
regulators of the AR are frequently dysregulated in advanced PC and are capable of inducing 
AR activity in both the presence and absence of androgens, and such are likely to contribute 
to treatment resistance, representing potential therapeutic targets. In this section, an AR 
inducing PP1 regulatory subunit, PPP1R14C, identified from an RNAi screen described in 
chapter 1, was validated at the qPCR level with 3 independent RNAi oligos (figure 3.3). 
Similarly, an AR repressing PP1 regulatory subunit, PPP1R12A, was also validated (figure 3.6). 
Crucially, these two subunits are components of the same PP1 holoenzyme, MLCP. PPP1R12A 
is the regulatory subunit that provides substrate specificity to PP1, whilst PPP1R14C is an 
inhibitory subunit that upon phosphorylation by a range of independent signalling effectors, 
behaves as a pseudo-substrate and transiently inhibits MLCP activity. In the context of AR 
signalling, when MLCP activity is retained through the RNAi depletion of PPP1R14C, a dramatic 
reduction in the expression of AR regulated gene expression was observed in both the 
presence and absence of androgens (figure 3.3 and figure 3.4). This provides an initial piece of 
evidence for the ligand independent regulation of the AR by MLCP. Furthermore, it is 
demonstrated that PPP1R14C mRNA expression increases following androgen stimulation, 
albeit at prolonged time-points compared to primary AR target genes such as PSA (figure 3.9). 
This may suggest that PPP1R14C expression increases as the levels of intracellular androgens 
are reduced. With the half-life of DHT being 24 hours, it is plausible that PPP1R14C mRNA 
expression increases under androgen depleted conditions to enhance AR transcriptional 
activity under diminished androgen levels. In addition, ectopic expression of PPP1R14C 
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enhanced the transcriptional activity of the AR, particularly in the absence of androgen (figure 
3.8). Interestingly, the maximum induction of PPP1R14C mRNA expression coincided with the 
negative expression of PSA mRNA (figure 3.9). This would suggest that PPP1R14C may be 
involved in a delayed positive feedback loop, potentiating the AR signalling axis under reduced 
androgen levels. Interrogation of the most recent publicly available PC datasets using 
CBioportal has revealed that PPP1R14C is frequently dysregulated in PC samples. PPP1R14C 
was found to undergo both genomic amplification and deletion, but the most common form 
of dysregulation was increased mRNA expression, suggesting increased expression of 
PPP1R14C may play a role in disease progression. PPP1R14C was found to be dysregulated in 
6-26% of patients from 6 publicly available datasets (Barbieri et al., 2012; Baca et al., 2013; 
'The Molecular Taxonomy of Primary Prostate Cancer,' 2015; Dan et al., 2015; Beltran et al., 
2016; Kumar et al., 2016)  
Conversely, when the formation of MLCP was prevented through RNAi knockdown of 
PPP1R12A, a dramatic increase in AR transcriptional activity was observed (figure 3.6). This 
too was more pronounced in the absence of androgen. It could be possible that AR activity in 
the presence of androgen is already maximal and therefore any induction following PPP1R12A 
depletion may in fact not be physiologically possible, hence explaining in part why the effect 
is less pronounced following androgen stimulation. However, the extent of AR transcriptional 
induction from both arms does appear to correlate with the level of induction of AR mRNA 
and protein expression (figure 3.7). As such, the ratio of AR mRNA and protein expression 
following PPP1R12A RNAi knockdown compared to the scrambled control is much higher in 
the absence of androgen than in the presence of androgen. However, despite the increases in 
AR protein expression, it may be expected that any induction in AR activity in the absence of 
androgens would be minimal, due to LNCaP cells being androgen responsive. This adds 
additional evidence that MLCP plays a role in AR regulation in a ligand independent manner. 
Furthermore, in contrast to the impact on AR expression by PPP1R12A knockdown, no 
observable impact on AR protein expression was witnessed following PPP1R14C knockdown 
(figure 3.5). This would suggest that MLCP is capable of regulating both AR expression, and 
activity at the post-translational level. A schematic diagram representing this chapters findings 
can be found in figure 3.12. 
 
81 
 
 
 
 
 
Figure 3.12 – Schematic Summary of Section 3 Results. The PP1 holoenzyme MLCP was found to be a negative 
regulator of AR function, whilst the endogenous MLCP inhibitory subunit, PPP1R14C, was found to be a positive 
regulator of AR function. RNAi depletion of PPP1R14C resulted in enhanced MLCP activity, which correlated 
with a reduction in AR transcriptional activity. Conversely, upon RNAi depletion of PPP1R12A, AR 
transcriptional activity increased. 
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4.1 Introduction 
Depletion of PPP1R14C by RNAi transfection has proven to result in significant repression of 
AR transcriptional activity. However, the underlying mechanisms of enhanced MLCP activity 
on independent signalling cascades in the context of this project remain unknown, and as such, 
known substrates of MLCP will be discussed in this section, and their relevance discussed in 
correlation with a global gene signature obtained by RNA sequencing following PPP1R14C 
RNAi depletion in LNCaP cells.  
Classically, MLCP has been investigated within the context of actomyosin contractility. 
Increases in intracellular Ca2+ leads to the activation of calmodulin and subsequent activation 
of myosin light chain kinase (MLCK) (Allen and Walsh, 1994). MLCK specifically phosphorylates 
MLC-S19, resulting in cross bridging between myosin and actin filaments, and ultimately 
contractile force (Allen and Walsh, 1994). Reversible phosphorylation of MLC-S19 is essential 
for cytoskeletal rearrangements (Somlyo and Somlyo, 1994). pMLC-S19 dephosphorylation is 
catalysed by MLCP (Ito et al., 2004). However, it is emerging that MLCP plays a critical role in 
the dephosphorylation of a number of clinically important proteins, particularly in relation to 
oncogenic malignancies.   
Initial studies observed that PP1 was capable of dephosphorylating the tumour suppressor 
RB1 in-vitro, with subsequent research demonstrating that inhibition of PP1 with either 
okadaic acid or tautomycin led to sustained C-terminal hyperphosphorylation of RB1 (Alberts 
et al., 1993; Ludlow et al., 1993). More recent studies were able to confirm that PP1 and 
indeed PPP1R12A co-immunoprecipitate with RB1 and co-localize together in the nucleus 
(Vietri et al., 2006; Kiss et al., 2008). Furthermore, structural analysis of the PP1-RB1 
interaction revealed that the binding of PP1 to RB1 blocked kinase access to the CDK docking 
sites on RB1 whilst retaining RB1 activity (Hirschi et al., 2010). However, the most relevant 
publication to date demonstrated that over-expression of PPP1R14C results in the 
maintenance of hyperphosphorylated RB1, and upon stimulation with the PKC activator, PMA, 
increases in the phosphorylation of the inhibitory threonine of PPP1R14C, threonine 73, 
correlate with increases in the phosphorylation of RB1 (Dedinszki et al., 2015). It should be 
noted that the phospho-specific antibody used to detect the phosphorylation of PPP1R14C is 
84 
 
in fact an antibody raised against phosphorylated PPP1R14A and although the peptide 
sequences are highly homologous, specificity should be a concern, particularly as a suitable 
negative control was not presented. Crucially, it is known that dephosphorylation of RB1 leads 
to enhanced activity (Manning and Dyson, 2011), and as such, MLCP is a positive regulator of 
RB1 tumour suppressor function. 
Another tumour suppressor known to be dephosphorylated and subsequently activated by 
MLCP is merlin (NF2) (Jin et al., 2006). The authors went on to show that MLCP specifically 
dephosphorylates the inhibitory phosphorylation residue serine 518, and that over-expression 
of the MLCP inhibitory protein PPP1R14A is sufficient to induce tumorigenic transformation in 
NIH 3T3 mouse embryonic fibroblast cells. NF2 is a well-documented tumour suppressor and 
is known to repress multiple oncogenic signalling cascades including the RAS, MTOR and 
HIPPO pathways (Morrison et al., 2007; James et al., 2009; Yu and Guan, 2013). 
Additional MLCP substrates include polo like kinase 1 (PLK1) and HDAC7 (Parra et al., 2007; 
Yamashiro et al., 2008). During mitosis PPP1R12A binds to PLK1, antagonising its catalytic 
activity at centrosomes. Depletion of PPP1R12A leads to a pronounced increase in the 
phosphorylation of the PLK1 activating phospho-residue threonine 210, resulting in aberrant 
cell cycle progression (Yamashiro et al., 2008). HDAC7 is a known AR transcriptional repressor 
(Karvonen et al., 2006) and it was demonstrated that MLCP is responsible for the 
dephosphorylation of HDAC7 leading to enhanced nuclear localization and transcriptional 
repression (Parra et al., 2007).   
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4.2 Results 
4.2.1 PPP1R14C depletion leads to the differential expression of 826 genes ± 2-fold 
To determine the impact of sustained MLCP activity, through PPP1R14C RNAi depletion, on 
the global LNCaP transcriptional program, RNA sequencing was performed using the Illumina 
HiSeq 2500 platform following 3 independent transfections of LNCaP cells, maintained 
separately for a minimum of 5 passages, with either siPPP1R14C-1 or the non-silencing 
scrambled control. RNA sequencing was employed as it results in low background signal, no 
hybridization issues and ultimately possesses the capacity to quantify absolute transcript 
expression levels as well as relative expression levels (Wang et al., 2009). In order to maintain 
relativity to the RT-qPCR and luciferase data presented in section 3, LNCaP cells were cultured, 
maintained and siRNA transfected in the same manner as previously described in sections 2.1 
and 2.3. Quality control and reads per lane can be found in supplementary figure 1. 
Significant depletion of PPP1R14C was confirmed by RNA sequencing following RNAi 
transfection of LNCaP cells when compared to the scrambled control as presented in figure 
4.1. RNAi knockdown of PPP1R14C resulted in no significant alterations in the mRNA 
expression of PPP1R12A or the AR as also depicted in figure 4.1. In a global context, PPP1R14C 
knockdown resulted in the statistically significant differential expression of 826 genes ± 2-fold 
compared to the scrambled control (figure 4.2). Crucially, the AR regulated genes PSA (KLK3), 
KLK2 and TMPRSS2 were all significantly down-regulated, and indeed, were amongst the top 
20 down-regulated genes depicted in figure 4.3A. This validated the results obtained by RT-
Figure 4.1 - PPP1R14C is significantly down-regulated following RNAi knockdown as 
quantified by RNA Sequencing. PPP1R12A, PPP1R14C and AR mRNA expression in 
LNCaP cells following PPP1R14C depletion and subsequent analysis by RNA sequencing 
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qPCR and presented in section 3. Interestingly, there were more significantly up-regulated 
genes compared to down-regulated genes, with the top 20 up-regulated genes presented in 
figure 4.3B. This would suggest that PPP1R14C depletion does not impact on cellular 
transcription as a whole, but rather, impacts on a subset of transcriptional programs.  
Figure 4.3 - PPP1R14C Depletion leads to the significant induction and repression of 
clinically relevant proteins. A) Top 20 Down-Regulated genes following PPP1R14C depletion 
in LNCaP cells B) Top 20 Up-Regulated genes following PPP1R14C depletion in LNCaP cells. 
Figure 4.2 - PPP1R14C Depletion leads to the Differential Expression of 826 Genes ± 2-Fold. 
Figure generated using Microsoft Excel 
A B 
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Figure 4.4 - Gene Set 
Enrichment Analysis of the 
PPP1R14C Knockdown Gene 
Signature I A) GSEA Hallmark 
Androgen Response B) 
REACTOME Generic 
Transcription C) REACTOME 
Cell Cycle D) REACTOME G1-S 
Transition E) REACTOME M-G1 
Transition. Gene set sizes can 
be found in brackets under the 
gene set name. 
A 
B 
C D E 
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4.2.2 Myosin phosphatase is a negative regulator of the cell cycle 
In order to elucidate the cellular pathways impacted, gene set enrichment analysis (GSEA) was 
performed using annotated gene sets from ‘The Molecular Signatures Database’. Again, 
following GSEA it was possible to confirm the impact of PPP1R14C depletion on androgen 
signalling. The siPPP1R14C-1 data set negatively correlated with the hallmark ‘Androgen 
Response’ gene set, resulting in a normalised enrichment score (NES) of -2.99, and a false 
discover rate (FDR) q-value of <0.001 (figure 4.4A). First, GSEA was performed against 
REACTOME datasets in the attempt to identify the most significantly impacted cellular 
pathways. The top 50 positively and negatively correlating datasets can be found in 
supplementary tables 1 and 2, however, it was clear that the positively correlating datasets 
were much less significant and possessed higher FDRs compared to the negatively correlating 
datasets, suggesting the down-regulated genes were of more biological significance. Indeed, 
the only pathway of note that positively correlated with the siPPP1R14C-1 dataset was the 
‘generic transcription’ pathway (NES=3.04, FDR<0.001, figure 4.4B), confirming that cellular 
transcription was not being impeded at a global level and cells were still capable of driving 
active transcriptional programs. Many pathways negatively correlate with the siPPP1R14C-1 
gene set, particularly those involved in cell cycle progression. The REACTOME cell cycle 
pathway as a whole had a NES of -8.84, p value <0.001 and FDR <0.001 (figure 4.4C). More 
specifically, genes from the REACTOME G1-S transition dataset are repressed, possessing a 
NES of -6.05, p value <0.001 and FDR <0.001 (figure 4.4D). Similarly, genes from the 
REACTOME M-G1 transition dataset are highly repressed, resulting in a NES of -5.51, p value 
<0.001 and FDR <0.001 (figure 4.4E). This strongly suggest that the increase in MLCP activity 
is significantly repressing the expression of genes required for cell cycle progression, or indeed, 
the activity of proteins required for cell cycle progression. Further interrogation of the GSEA 
hallmark datasets (supplementary table 3) revealed that E2F transcription factor target genes 
represent the most significantly repressed genes from the siPPP1R14C-1 data set (figure 4.5A). 
Enrichment plots result in a NES of -9.325, p value <0.001 and FDR <0.001. Other significantly 
enriched hallmark datasets were v-Myc avian myelocytomatosis viral oncogene homolog 
(MYC) and mechanistic target of rapamycin complex 1 (MTORC1) target genes, represented in 
figure 4.5B and 4.5C respectively. The next GSEA collection to be interrogated was ‘oncogenic 
signatures’; data sets defined directly from  
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Figure 4.5 - Gene Set Enrichment Analysis of the PPP1R14C Knockdown Gene Signature II A) Hallmark E2F Targets B) 
Hallmark MYC Targets V1 C) Hallmark MTORC1 Targets D) RB P107 DN.V1 UP E) E2F1 UP.V1 UP F) PTEN DN.V1 UP 
A 
B C 
D E F 
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microarray gene expression data from cancer gene perturbations. Interestingly, the 
siPPP1R14C-1 dataset positively correlated with genes up-regulated following PTEN RNAi 
depletion in A431, HCC827 and SKBR-3 cell lines (epidermoid carcinoma, lung adenocarcinoma 
and breast carcinoma, respectively, figure 4.5F). As previously mentioned, LNCaP cells are 
PTEN null, and therefore it is of some reassurance that a gene set obtained from LNCaP cells 
positively correlates with gene sets obtained following RNAi knockdown of PTEN. However, it 
is the negatively correlating data sets that represent the most promising insight into MLCP 
function in the context of this thesis. The siPPP1R14C-1 dataset negatively correlates with 
genes up-regulated following RB1 and RB-like 1 knockdown in keratinocytes (NES=-4.24, p 
value <0.001, FDR <0.001, figure 4.5D), whilst also negatively correlating with genes up-
regulated following over-expression of E2F1 in mouse fibroblasts (NES=-4.00, p value <0.001, 
FDR <0.001, figure 4.5E), strongly suggesting PPP1R14C depletion impacts on the negative 
regulation of E2F1 by RB1. Increases in gene expression following over-expression of E2F3, 
enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), MYC, platelet-derived 
growth factor (PDGF), interleukin 15 and MTOR also negatively correlated with the gene set 
obtained following PPP1R14C RNAi depletion and are outlined in supplementary table 4. 
Interrogation of ‘motif based gene sets’, based on the conserved cis-regulatory motifs from a 
comparative analysis of the human, mouse, rat and dog genomes, revealed that 15 of the top 
20 negatively correlating data sets belonged to genes containing E2F binding motifs 
(supplementary table 5), again reinforcing the negative impact of PPP1R14C depletion on the 
activity of the E2F family of transcription factors.  
4.2.3 PPP1R14C depletion restores a non-malignant gene expression profile 
Finally, the siPPP1R14C-1 data set was run against gene sets obtained from studies 
investigating differential gene expression between benign prostate tissue and PC tissue. 
Genes found to be down-regulated in PC samples vs matched benign samples from two 
independent studies positively correlated with the PPP1R14C RNAi knockdown gene set. 
These are represented in figure 4.6. Conversely, 5 independent gene sets representing genes 
over-expressed in PC tissue vs benign prostate tissue all negatively correlated with the gene 
set following PPP1R14C depletion. These too are represented in figure 4.6. 
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4.2.4 PPP1R14C depletion enhances the dephosphorylation of RB1, NF2 and PLK1 by myosin 
phosphatase 
In order to validate the impact of PPP1R14C depletion on the phosphorylation status of MLCP 
substrates, cell lysates were harvested from LNCaP cells transfected as previously described. 
Cells were stimulated with 10nM DHT for 24 hours following 48 hours of exposure to the 
siPPP1R14C transfection mix, as performed for previous assays. Using phospho-specific 
antibodies, the phosphorylation status of RB1 serine 807/811 and PLK1 threonine 210 were 
investigated by western blot. The phosphorylation status of NF2 was also investigated by 
western blot, but was analysed by a shift in protein migration as previously described (Jin et 
al., 2006). In figure 4.7A it is possible to observe a pronounced reduction in the 
phosphorylation of RB1 serine 807/811 following PPP1R14C depletion compared to the 
scrambled control. Figures 4.7A also demonstrates that there is a reduction in the protein 
levels of E2F1, contributing to the repression of E2F1 target genes. Figure 4.8B demonstrates 
that the phosphorylation of PLK1 at its activational residue, threonine 210, was reduced upon 
PPP1R14C RNAi depletion. Using a total NF2 antibody it is possible to demonstrate a shift in 
Figure 4.6 - PPP1R14C Depletion Restores a Non-Malignant Prostate Gene Expression Profile. Following knockdown of 
PPP1R14C by RNAi, genes identified as being up-regulated in PC vs Normal (matched tissue) were down-regulated. 
Conversely, genes identified as being down-regulated in PC vs Normal (matched tissue) were found to be up-regulated 
following PPP1R14C RNAi depletion. Normalised enrichment scores were calculated following gene set enrichment analysis. 
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the signal of NF2 from the phosphorylated band to the dephosphorylated band, depicted in 
figure 4.8A, confirming that NF2 undergoes enhanced dephosphorylation following PPP1R14C 
knockdown.  
 
 
 
 
Figure 4.7 - PPP1R14C Depletion Reduces the Phosphorylation Status of RB1 A) Western Blot analysis 
reveals a reduction in RB1 phosphorylation status at serine 807/811 following PPP1R14C depletion in 
LNCaP cells B) RB1 and E2F1 mRNA expression following PPP1R14C depletion in LNCaP cells quantified 
by RNA sequencing 
Figure 4.8 – PPP1R14C Depletion Reduces the Phosphorylation Status of NF2 and PLK1 A) 
Western Blot analysis reveals reduced  NF2 phosphorylation in LNCaP cells following PPP1R14C 
depletion B) Western Blot analysis reveals reduced PLK1 threonine 210 phosphorylation status 
following PPP1R14C depletion 
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4.2.5 PPP1R14C depletion results in G1 cell cycle arrest 
Finally, the impact of PPP1R14C on cell cycle progression was investigated by FACs analysis as 
previously described and is presented in figure 4.9. A statistically significant increase of cells 
in the G1 phase of the cell cycle was observed following PPP1R14C depletion (mean ± sem, 
69±1.22% vs. 84±0.46%, p-value < 0.05), coinciding with a statistically significant reduction of 
cells in the G2/M phase of the cell cycle (mean ± sem, 21±0.96% vs. 9±0.54%, p-value < 0.05). 
No significant alteration in the number of cells in sub G1 was observed (mean, 4.6% vs. 5.8%). 
This would suggest that depletion of PPP1R14C is cytostatic as opposed to cytotoxic, falling in 
line with the down-regulation of cell cycle associated gene sets observed in figures 4.4 C-E.  
 
 
Figure 4.9 - PPP1R14C Depletion Causes G1 Cell Cycle Arrest. Cells depleted of PPP1R14C were 
subject to FACS analysis as previously described. Figure represents mean n=3. PPP1R14C RNAi 
depletion results in G1 cell cycle arrest. Representative gating examples are also provided. 
Scrambled siPPP1R14C 
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4.3 Discussion 
Crucially, within this section it was possible to confirm RNAi depletion of PPP1R14C by RNA 
sequencing, thus validating the results obtained by RT-qPCR in section 4. In addition, no 
significant impact on the mRNA expression of PPP1R12A and AR was observed, confirming any 
alterations in the activity of MLCP and indeed the AR must be imposed at the post-
translational level. Importantly, down-regulation of PSA, TMPRSS2 and KLK2 mRNA expression 
was also observed, and indeed, they were within the top 20 most significantly repressed genes 
following PPP1R14C depletion. Considering it has been demonstrated that MLCP does not 
directly interact with the AR, to achieve such a dramatic reduction in AR transactivation would 
suggest the increase in MLCP activity is repressing pathways crucial for AR function. Indeed, 
the hallmark androgen response gene set negatively correlated with the PPP1R14C 
knockdown gene set, possessing a highly significant NES of -2.99, confirming MLCP as a 
negative regulator of the global AR transcriptional program.  
Upon taking a more general approach to investigating the role of MLCP in AR signalling, it 
became apparent that the cell cycle associated pathways were significantly down-regulated. 
These include some of the more general cell cycle associated gene sets from REACTOME such 
as ‘Cell Cycle’, ‘Mitotic Cell Cycle’ and ‘Cell Cycle Checkpoints’, as well as more specific gene 
sets from phases of the cell cycle including ‘S-Phase’, ‘G1-S Transition’ and ‘M-G1 Transition’ 
(Supplementary Table 2). Crucially, this can be recapitulated phenotypically following FACs 
analysis of LNCaP cells depleted of PPP1R14C. LNCaP cells are predominantly found in the G1 
phase of the cell cycle, and following PPP1R14C RNAi knockdown, a significant increase in G1 
cell cycle arrest is observed when compared to the scrambled control (69% vs. 84%, p-value < 
0.05). The increase in cells within the G1 phase of the cell cycle appear to be predominantly 
drawn from the G2/M phase of the cell cycle, which is significantly reduced, whilst the 
percentage of cells within the sub G1 gating remains consistent, suggesting knockdown of 
PPP1R14C is cytostatic as opposed to cytotoxic. More specific analysis revealed that E2F target 
genes are significantly down-regulated, coinciding with repression of genes known to be up-
regulated following E2F1 over-expression as well as genes up-regulated following RB1 and 
P107 knockdown. As introduced in this section, RB1 is dephosphorylated and activated by 
MLCP. Indeed, confirmation of a reduction in the phosphorylation of the inhibitory phospho-
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sites RB1 serine 807/811, was observed by western blot following knockdown of PPP1R14C in 
both the presence and absence of androgen. The opposing impact of PPP1R12A knockdown 
on RB1 phosphorylation was not investigated in this thesis, but has been published by another 
research group, where significant induction of RB1 serine 807/811 phosphorylation upon 
depletion of PPP1R12A is observed, further confirming the involvement of PPP1R14C in RB1 
regulation (Cho et al., 2011). In addition, no significant alteration in the mRNA expression of 
RB1 and E2F1 was detected by RNA sequencing. RB1 is a well-studied tumour suppressor and 
is known to be implicated in a number of human malignancies, including PC (Macleod, 2010). 
A recent multi-collaborative study identified loss of RB1 in 21% of metastatic CRPC, whilst 
previous studies have suggested loss of heterozygosity can be observed in up to 60% of PC 
patients (Phillips et al., 1994; Dan et al., 2015). RB1 plays a key role in supressing the 
transcriptional activity of E2F transcription factors, which in turn, are best known for their 
regulation of cell cycle related genes (Macleod, 2010). Phosphorylation of RB1 is mediated by 
CDKs in a cell cycle/cyclin dependent manner. Indeed, over-expression of CDK2 and CDK4 as 
well as cyclin D1 is also frequently observed in PC, suggesting inhibition of RB1 occurs at both 
the genomic and post-translational level (Dan et al., 2015). However, the activity and 
expression of the AR is intrinsically linked to the activity of the E2F transcription factors, and 
as such, RB1.  In 2010, it was reported that depletion of RB1 led to enhanced AR mRNA and 
protein expression, increased AR transactivation and dramatic increases of PC cell and tumour 
growth both in-vitro and in-vivo (Sharma et al., 2010). Crucially, it was demonstrated that the 
increases in AR signalling occurred in the absence of androgen, and was mediated by E2F1, 
strongly suggesting RB1 inhibition is a major contributor to castrate resistant disease. 
Importantly, the increases in AR mRNA, protein and transcriptional activity observed following 
PPP1R12A RNAi depletion correlate with the data presented by Sharma et al following RB1 
depletion, suggesting the impact of MLCP activity on AR signalling is in part mediated by RB1.  
Using an antibody previously described to investigate the phosphorylation status of NF2, it 
was possible to identify increased levels of NF2 dephosphorylation following PPP1R14C 
knockdown by western blot (Jin et al., 2006). The role of NF2 in PC progression is relatively 
understudied but preliminary evidence exists for its genomic loss and/or mutational 
inactivation (Kawana et al., 2002; Malhotra et al., 2013). Indeed, the expression of NF2 is low 
in a number of PC cell lines including LNCaP cells, and is often found in a hyperphosphorylated 
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state (Horiguchi et al., 2008). Activation of the PI3K/AKT/MTOR pathway is frequently 
observed in PC, particularly at advanced stages (approximately 50% metastatic CRPC), and is 
predominantly characterised by PTEN loss (Dan et al., 2015). As such, there is growing interest 
in targeting the PI3K pathway alongside ADT (Bitting and Armstrong, 2013). Following 
PPP1R14C RNAi knockdown, MTOR target gene expression is significantly down-regulated, 
coinciding with the increase in activated NF2. NF2 is a known MTORC1 inhibitor, however, the 
underlying mechanism remains to be elucidated (James et al., 2009). Interestingly, it was 
found that NF2 inhibits MTORC1 downstream from AKT, partially explaining why AKT 
phosphorylation levels were not reduced by increased NF2 activity. Indeed, the increase in 
phosphorylated AKT observed following PPP1R14C knockdown in section 5 cannot be 
explained by any impact on the expression of the AKT phosphatases PHLPP1 and PHLPP2 as 
these were unchanged following PPP1R14C knockdown as quantified by RNA sequencing (data 
not shown). However, it has recently been reported that PHLPP mediated dephosphorylation 
of AKT requires the presence of a scaffolding protein called FK506 binding protein 5 (FKBP5), 
which was shown to be down-regulated following PPP1R14C depletion (Log2FC -0.225, p-
value < 0.05)(Pei et al., 2009). This would suggest that the increase in AKT phosphorylation 
may be mediated through down-regulation of FKBP5 in addition to de-repression of the 
negative feedback loop between the PI3K and MAPK signalling cascades, however, 
destabilization of the PHLPPs at the protein level cannot be ruled out at this stage and may 
require further investigation.  
As mentioned in the introduction to this section, PLK1 is a substrate for MLCP, and 
dephosphorylation of PLK1 threonine 210 by MLCP results in inhibition of PLK1 activity 
(Yamashiro et al., 2008). With this in mind, it was possible to demonstrate that through 
depletion of PPP1R14C, sustained MLCP activity has led to increased dephosphorylation of 
PLK1 observed in figure 6.8B possibly contributing to the repression of AR target genes, as well 
as the inhibition of E2F1 target genes. Therefore a more in depth investigation into the impact 
of PPP1R14C knockdown on PLK1 activity is warranted. 
As such, it has been possible to confirm that PPP1R14C knockdown results in significant 
repression of the AR, E2F1 and MTOR signalling cascades amongst others, highlighting possible 
routes of AR modulation by MLCP. Crucially, genes up-regulated following PPP1R14C 
depletion positively correlated with genes down-regulated in PC vs benign prostate tissue, 
97 
 
whilst genes down-regulated following PPP1R14C depletion negatively correlated with genes 
up-regulated in PC vs benign prostate tissue. This would suggest that knockdown of PPP1R14C 
may partially restore a non-malignant genotype in PC cells, further reinforcing its validity as a 
therapeutic target.  
In conclusion, characterising and validating a global LNCaP gene signature following PPP1R14C 
RNAi knockdown has confirmed repression of AR transactivation, has demonstrated increased 
RB1 activity through enhanced dephosphorylation leading to significant repression of the E2F1 
transcriptional program, as well as resulting in significant repression of the MTOR signalling 
pathway characterised by an increase in the dephosphorylation of NF2. Collectively this has 
resulted in significant repression of cell cycle associated genes, in turn, leading to G1 cell cycle 
arrest. The involvement of PLK1 dephosphorylation was confirmed but its role in repression 
of the AR signalling cascade remains to be fully elucidated. Thus the data presented in this 
section convincingly implicates enhanced dephosphorylation of MLCP substrates in the 
regulation of AR function, contributing to the partial restoration of a non-malignant genotype 
associated with benign prostate tissue compared to PC. Figure 4.10 depicts a schematic 
summary of this chapters findings. 
 
Figure 4.10 – Schematic Summary of Section 6 Results. Sustained MLCP activity following PPP1R14C RNAi 
depletion leads to enhanced dephosphorylation of the MLCP substrates RB1, NF2 and PLK1. RNA sequencing 
confirms down-regulation of the AR signalling axis as well as E2F1 and MTORC1 activity. Depletion of PPP1R14C 
leads to G1 cell cycle arrest, partially contributed by the repression of PLK1. 
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Chapter 5. 
Myosin Phosphatase Modulation Impacts on the 
Phosphorylation Status of the Androgen Receptor 
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5.1 Introduction 
As described in section 1.2.3, the AR is a phosphoprotein heavily influenced by the action of 
kinases, and as such, phosphatases. Phosphorylation of the AR has been described to occur in 
both the absence and presence of androgens. Crucially, a number of phosphorylation sites 
have been shown to be induced by androgen stimulation, and functionally enhance 
transactivation of the AR. Conversely, there are phospho-residues that have been shown to 
be phosphorylated by non-androgenic signalling cascades that are capable of driving increased 
AR activity, and thus are of interest in a castrate-resistant setting. In this section I will discuss 
the impact of MLCP modulation on AR phosphorylation status, and its subsequent functional 
outcome.  
5.2 Results 
5.2.1 Myosin phosphatase does not interact with the androgen receptor 
In order to attempt to dissect the mechanism of regulation between MLCP and the AR, it was 
necessary to identify any potential interactions to elucidate if the means of regulation was 
direct or indirect. Any interaction would suggest that MLCP may act to dephosphorylate the 
AR directly and enhance our knowledge on the interplay between AR modifying kinases and 
phosphatases. As such, exogenous AR cDNA was transfected into the AR-null HEK293T cell line 
so that the non-transfected arm of the experiment could be used as a negative control. The 
AR was then immunoprecipitated as described in section 2.17 with an AR N-terminal targeting 
antibody (N-20) and purified using protein-G sepharose beads. The collected lysate was then 
probed by western blot for both AR and PPP1R12A. Results from this experiment, depicted in 
figure 5.1, demonstrate that indeed the protein levels of AR were enriched following 
immunoprecipitation compared to the input controls. It was also possible to identify the 
presence of endogenous PPP1R12A within the input samples, however, no apparent 
PPP1R12A was co-immunoprecipitated with the AR, regardless of the presence or absence of 
androgens. This suggests that the role MLCP plays within AR regulation is indirect, or 
extremely transient, and as such, no endogenous interactions were pursued.  
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Despite no direct interaction between MLCP and the AR being observed, characterisation of 
the phosphorylation status of the AR was performed to gain a greater insight into the 
functional outcome of MLCP modulation on AR PTM. This in turn would provide valuable 
knowledge on any potential upstream signalling cascades impacted by MLCP modulation, and 
as such, aid in elucidating to some extent the underlying mechanisms involved.  
5.2.2 PPP1R14C depletion alters the phosphorylation status of the androgen receptor 
Following PPP1R14C RNAi transfection, endogenous AR was immunoprecipitated from LNCaP 
cells by protein-G sepharose as described in section 2.17, and the phosphorylation status of 3 
residues, serine 81, serine 213 and serine 515 of the AR, were investigated using two 
commercially available phospho-specific antibodies (serine 81 and serine 213) and one custom 
phospho-specific antibody (serine 515, a kind gift from Dr. Joanne Edwards). Due to difficulties 
in detecting the phosphorylation status of the AR by western blot using whole cell lysates as 
previously described (McEwan et al., 2010). AR protein levels were enriched by 
immunoprecipitation prior to western blot analysis. Again, enrichment of the AR protein was 
observed following immunoprecipitation when compared to the input samples, presented in 
figure 5.2. Secondly, a dramatic reduction was observed in the phosphorylation status of 
serine 81 following PPP1R14C RNAi knockdown compared to the scrambled control, to the 
point where no level of phosphorylation can be detected. Similarly, a reduction in the 
phosphorylation of serine 515 was observed in the siPPP1R14C-1 experimental arm, albeit to 
Figure 5.1 - Myosin Phosphatase does not interact with the AR. HEK293T cells were 
transfected with AR plasmid DNA and immunoprecipitated as previously described. AR-
PPP1R12A interactions were then investigated by western blot. 
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a lesser extent that serine 81. Conversely, enhanced phosphorylation of serine 213 was 
observed following RNAi depletion of PPP1R14C. As described in section 1.2.3, 
phosphorylation of these 3 residues is known to impact dramatically on the transactivation of 
the AR, and as such, enabled subsequent AR functionality assays to be designed.  
 
5.2.3 PPP1R14C depletion impairs ligand induced nuclear translocation of the androgen receptor 
Serine 81 and serine 515 phosphorylation is considered to enhance AR transactivation, 
mediated through enhanced nuclear localization, chromatin binding and ultimately increased 
transcriptional activity (Gioeli et al., 2002; Chen et al., 2012; Willder et al., 2013). As described 
in section 4.2, RNAi depletion of PPP1R14C resulted in a statistically significant repression of 
AR regulated gene transcription. This correlated with the reduction in the phosphorylation 
status of serines 81 and 515 observed in figure 5.2. In complement of this, figure 5.3 
demonstrates AR nuclear/cytoplasmic localization following transfection with siPPP1R14C-1 
compared to the scrambled control in the presence of androgen. Indeed, the AR was found in 
both the cytoplasm and nucleus in the scrambled arm of the assay as expected (Kuiper et al., 
Figure 5.2 - PPP1R14C Depletion Impacts on the Phosphorylation Status of the AR. 
Endogenous AR was immunoprecipitated from LNCaP cells depleted of PPP1R14C 
and analysed by western blot using phospho-specific antibodies. 
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1993), but in the PPP1R14C knockdown arm, the AR was predominantly found in the 
cytoplasm, with minimal levels detected in the nucleus. This correlates with the literature 
surrounding phosphorylation of serine 81 and 515, as well as reinforcing initial findings from 
section 4.2. Similarly, LNCaP cells transfected with siPPP1R14C-1 were subjected to 
immunofluorescent analysis 30 minutes post 10nM DHT stimulation (figure 5.4). Crucially, a 
reduction in nuclear AR was detected following androgen stimulation in the siPPP1R14C-1 
treated cells compared to the scrambled arm, further reinforcing the results obtained 
following nuclear-cytoplasmic fractionation. It was also possible to visually detect pMLC-S19 
by immunofluorescence and a reduction in this mark was detected following depletion of 
PPP1R14C, consistent with enhanced MLCP activity. However, what was not evident by 
western blot in figure 4.5, was that androgen stimulation dramatically increases 
phosphorylation of MLC-S19 at the cellular periphery, an effect that is abolished following 
PPP1R14C knockdown. This would suggest that androgen stimulation leads to rapid 
phosphorylation of MLC-S19 mediated by the inhibition of MLCP by PPP1R14C.  
 
Figure 5.3 - PPP1R14C Depletion Impairs AR Nuclear Translocation. LNCaP cells were 
depleted of PPP1R14C as previously described and subjected to 30 mins 10nM DHT 
stimulation prior to nuclear-cytoplasmic fractionation. Knockdown of PPP1R14C resulted in 
impaired androgen induced AR nuclear translocation vs the scrambled control. 
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Figure 5.4 - PPP1R14C Depletion Prevents Androgen Mediated MLC20 Phosphorylation. LNCaP 
cells were depleted of PPP1R14C as previously described and subjected to 30 mins 10nM DHT 
stimulation prior to immunofluorescent analysis. Cell nuclei were stained with DAPI, AR (Green) 
and pMLC20 (Red) were detected using alexa-fluor conjugated secondary antibodies. PPP1R14C 
depletion prevents androgen induced MLC20 phosphorylation and reduces AR nuclear 
translocation compared to the scrambled control. 
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5.2.4 PPP1R14C depletion reduces MAPK activation 
As it has been previously reported that MAPK signalling is in part responsible for the 
phosphorylation of AR serine 515, the impact of PPP1R14C depletion on MAPK activation was 
investigated. LNCaP cells depleted of PPP1R14C as previously described were subject to 
10ng/ml EGF stimulation for 0, 5, 10 and 15 minutes prior to lysis and western blot analysis. 
Figure 5.5 demonstrates that a marked reduction in the phosphorylation of MAPK1/3 occurs 
in response to EGF stimulation following PPP1R14C knockdown compared to the scrambled 
control arm of the experiment, however, PPP1R14C depletion also leads to a marginal increase 
in the basal phosphorylation status of MAPK1/3.  
5.2.5 PPP1R14C depletion results in enhanced AKT mediated proteasomal degradation of the 
androgen receptor 
The other phosphorylation site investigated was serine 213. This is a repressive phospho-mark 
described to lead to enhanced MDM2 mediated proteasomal degradation, and as such, 
repression of AR target gene expression. Indeed, figure 5.6 demonstrates that the AR 
undergoes enhanced degradation over an 8-hour period in the presence of cycloheximide 
following RNAi depletion of PPP1R14C compared to the scrambled control. AR protein levels 
decreased over time as expected in the scrambled arm of the assay, confirming the 
accelerated AR degradation observed in the siPPP1R14C-1 arm is legitimate. In further support 
of this, LNCaP cells transfected with siPPP1R14C-1 were exposed to 1µM of the proteasomal 
inhibitor MG132 and AR regulated gene expression was quantified by RT-qPCR. Figure 5.7 
Figure 5.5- PPP1R14C Depletion Reduces MAPK Activation Following EGF Stimulation. LNCaP cells 
were depleted of PPP1R14C as previously described and stimulated with 10ng/ml EGF. LNCaP cells 
were harvested at 0, 5, 10 and 15 minutes post stimulation and analysed by western blot. Depletion 
of PPP1R14C reduces EGF induced MAPK phosphorylation compared to the scrambled control. 
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demonstrates that PPP1R14C gene expression is indeed repressed following RNAi depletion 
compared to the scrambled control, and as in section 4.2, significant repression of the AR 
target gene PSA was observed. However, upon addition of MG132, AR transcriptional activity 
can be partially rescued, confirming that in part some degree of the repressive regulation of 
Figure 5.6 - PPP1R14C Depletion Accelerates AR Degradation. LNCaP cells were depleted of 
PPP1R14C and incubated with 20µg/ml cycloheximide (CHX) for increasing time-periods. Cell 
lysates were analysed by western blot. 
Figure 5.7 - AKT and Proteasomal Inhibitors rescue AR Transcriptional Activity following 
PPP1R14C Depletion. A) LNCaP cells depleted of PPP1R14C were exposed to increasing doses 
of MG132 and underwent RT-qPCR analysis. B) LNCaP cells depleted of PPP1R14C were 
exposed to increasing doses of MK2206 and underwent RT-qPCR analysis. Data represents n=3 
mean ± sem. 
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the AR by MLCP is indeed mediated through enhanced proteasomal degradation. Furthermore, 
the increase in serine 213 phosphorylation observed in figure 5.2 would suggest that the 
accelerated proteasomal degradation is mediated by AKT. Indeed, figure 5.7 demonstrates 
that upon exposure to the AKT inhibitor MK2206, partial rescue of PSA mRNA expression was 
observed following RNAi depletion of PPP1R14C.  
 
As an increase in AR serine 213 phosphorylation was observed, the phosphorylation status of 
AKT 1/2/3 serine 473 was investigated by western blot using a phospho-specific antibody 
following PPP1R14C depletion. Figure 5.8 demonstrates that an increase in the 
phosphorylation status of AKT was observed following PPP1R14C knockdown compared to the 
scrambled control, correlating with the increase in AR serine 213 phosphorylation 
5.3 Discussion 
Deciphering the role PP1 regulatory subunits play in the regulation of the AR will be crucial in 
building on the current literature surrounding the impact of PP1 on the AR and ultimately 
generating more targeted approaches to targeting PP1 in the treatment of AR driven diseases 
including PC. Indeed, PP1 has been shown to directly interact with the AR (Chen et al., 2009), 
but as of yet no PP1 regulatory subunits have been described to interact with the AR. As such, 
PPP1R12A is the substrate specifying subunit of MLCP, and no interaction with the AR was 
detectable through co-immunoprecipitation assays, strongly suggesting that MLCP does not 
Figure 5.8 - PPP1R14C Depletion Increases AKT Phosphorylation. LNCaP 
cells depleted of PPP1R14C for 72 hours in full media were subject to 
western blot analysis using an AKT phospho-specific antibody. Depletion 
of PPP1R14C results in increased AKT phosphorylation. 
70 
70 
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interact directly with the AR (figure 5.1). Unfortunately it has not been possible to validate a 
commercially available PPP1R14C antibody, and as such, it cannot be ruled out that PPP1R14C 
interacts with the AR and is capable of imposing some form of regulation via this mechanism. 
However, further characterisation of the phosphorylation status of the AR following PPP1R14C 
RNAi depletion revealed that 2 pro-androgenic phospho-residues are down-regulated, whilst 
1 repressive phospho-residue is induced, suggesting that indeed MLCP regulates the AR 
indirectly via upstream mechanisms, which correlates with the results from the co-
immunoprecipitation assay (figure 5.2).  
As described in section 1.2.3, serine 81 phosphorylation has been shown to be induced by 
androgen (Gioeli et al., 2002) and in the scrambled arm from figure 5.2 it was possible to 
detect this phosphorylation mark. Phosphorylation of serine 81 was described to stabilize the 
AR, contributing to enhanced AR transcriptional activity. Following PPP1R14C RNAi depletion, 
reduced AR stability and transcriptional activity was observed, correlating with a reduction in 
the phosphorylation of serine 81 (figure 5.2). In addition, phosphorylation of serine 81 also 
correlates with enhanced nuclear localization and chromatin binding. Figure 5.3 highlights that 
PPP1R14C RNAi knockdown also leads to a pronounced reduction in the ability of the AR to 
translocate to the nucleus following androgen induction. This in turn provides a rationale for 
the reduced AR transcriptional activity observed in section 4.2. Indeed, chromatin 
immunoprecipitation assays have not been performed to confirm decreased deposition of the 
AR at AREs following MLCP modulation, but figures 5.3 and 5.4 provide sufficiently strong 
enough evidence to suggest that as AR nuclear localization is significantly impaired, this too 
would be the case. The kinases responsible for modification of serine 81 have been identified 
as CDK1, CDK5 and CDK9 (Gioeli et al., 2002; Chen et al., 2006; Gordon et al., 2010; Hsu et al., 
2011). Crucially, it has been demonstrated that phosphorylation of serine 81 predominantly 
occurs in the nucleus (Kesler et al., 2007; Gordon et al., 2010). Due to the 30 minute androgen 
stimulation time-scale used in the nuclear-cytoplasmic extraction and AR 
immunoprecipitation assays, the results obtained in relation to serine 81 phosphorylation and 
impaired nuclear localization following PPP1R14C RNAi knockdown would strongly suggest 
that MLCP modulation prevents androgen induced nuclear translocation prior to 
phosphorylation by the CDKs in the nucleus (figure 5.2 and figure 5.3), which would suggest 
the activity of CDK1 towards the AR is being reduced. Indeed, as described in chapter 4, RNAi 
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depletion of PPP1R14C resulted in G1 cell cycle arrest, characterised by a reduction in the 
phosphorylation status of RB1. As CDK1 is most active in the G2/M phase of the cell cycle, the 
reduction in serine 81 phosphorylation may be attributed to the G1 arrest observed. 
Furthermore, due to the time-scale used, enhanced nuclear export is unlikely to impact on 
serine 81 phosphorylation, but may contribute to the overall reduction in AR transcriptional 
activity following siPPP1R14C-1 transfection and therefore should be interrogated. Similarly 
serine 515 is also phosphorylated in the nucleus, also by CDK1 as well as CDK7 (Chymkowitch 
et al., 2011; Willder et al., 2013). The reduction in phosphorylation of this residue following 
PPP1R14C depletion may also be as a result of increased G1 cell cycle arrest and subsequent 
down-regulation of CDK1 activity. Again, phosphorylation of this residue is reported to 
increase AR transcriptional activity. Therefore it would appear that the reduction in serine 515 
phosphorylation following PPP1R14C knockdown is also likely to be caused by a reduction in 
the nuclear translocation of the AR. However, the reduction in the phosphorylation of serine 
515 following MLCP modulation compared to the scrambled control was less pronounced than 
the reduction in serine 81 phosphorylation, and is still in fact detectable (figure 5.2). This could 
be attributed to the other kinases known to phosphorylate this residue, MAPK1 and MAPK3 
(Gregory et al., 2004; Mellinghoff et al., 2004; Ponguta et al., 2008). Indeed, androgen 
stimulation has been documented to induce the phosphorylation and subsequent activation 
of MAPK1 and MAPK3 within sub-minute time-scales, providing a rationale for serine 515 
phosphorylation observed in figure 5.2 (Foradori et al., 2008). Identification of MAPK 
activation by androgen in the sub-minute time-scale proved difficult to identify, however, 
activation by the canonical EGFR pathway following EGF stimulation was detectable. As such, 
following PPP1R1C RNAi depletion, a pronounced reduction in the phosphorylation of 
MAPK1/3 was observed in figure 5.5, suggesting that MLCP activity also plays a repressive role 
in MAPK signalling. The results would suggest that the MAPK pathway is still capable of being 
activated, albeit to a lesser extent, and such still capable of phosphorylating AR serine 515. 
Indeed, it has been previously reported that ectopic expression of PPP1R14C in the breast 
cancer cell line MCF-7 induces MAPK activation but the authors draw no conclusion on MLCP 
activity, nor any specific role for PPP1R14C (Wenzel et al., 2007). However, as described in 
Chapter 4, PPP1R14C depletion results in the enhanced dephosphorylation of the tumour 
suppressor NF2. NF2 has been reported to repress the MAPK signalling cascade by directly 
inhibiting the activity of Ras (Garcia-Rendueles et al., 2015; Riecken et al., 2016) Most 
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importantly, both serine 81 and serine 515 phosphorylation are tightly associated with PC 
growth, correlate with disease progression and have been shown to hypersensitize PC cells to 
low levels of androgens. In turn, this is reflected by the frequent observation that CDK1 and 
MAPKs are dysregulated in advanced PC and represent viable therapeutic options within their 
own right. Crucially, it was observed following MLCP modulation that the downstream impact 
of CDK and MAPK action on AR phosphorylation is abolished, whilst an overall reduction in 
activation of the MAPK signalling cascade is also reduced, suggesting disruption of the MLCP-
PPP1R14C interaction may pose a viable therapeutic option in both PC and CRPC. It will be of 
great significance to investigate the direct impact of MLCP modulation on CDK activity to gain 
a greater insight into the molecular mechanisms underlying the results obtained in relation to 
serine 81 and 515 phosphorylation. 
Serine 213 was identified as a repressive phosphorylation site of the AR modified by AKT and 
PIM1-S/L (Lin et al., 2001; Linn et al., 2012). Figure 5.2 demonstrates that there was a 
considerable increase in the phosphorylation of serine 213 following PPP1R14C RNAi 
knockdown compared to the scrambled control. As phosphorylation of this site leads to the 
recruitment and ubiquitination of the AR by MDM2 and subsequent proteasomal degradation, 
AR protein stability in the presence of cycloheximide was investigated. Correlating with the 
increase in phosphorylation, accelerated AR protein degradation was observed over an 8 hour 
period (figure 5.6). This in turn will be partly responsible for the reduction in AR transcriptional 
activity observed. Phosphorylation of serine 213 by AKT predominantly occurs in the 
cytoplasm and is known to impede nuclear translocation (Palazzolo et al., 2007). This would 
correlate with the impaired nuclear localization observed in figure 5.3, however, it would be 
difficult to suggest if the increase in phosphorylation is a result of impaired nuclear 
translocation, or the cause of impaired nuclear translocation without interrogating the 
experimental setup with the inclusion of AR serine 213 mutants. Furthermore, LNCaP cells are 
PTEN null, and it would be expected that AKT is constitutively phosphorylated, and as such, 
activated (Li et al., 1997). In the scrambled arm of figure 5.8 it was possible to detect high 
levels of AKT phosphorylation, however, this was increased following PPP1R14C RNAi 
knockdown, correlating with the increase in AR serine 213 observed. The cross-talk between 
independent signalling cascades has emerged as an important area of research, particularly in 
relation to disease resistance mechanisms. As such, there is significant evidence for reciprocal 
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regulation between the PI3K and androgen signalling pathways. It was shown that AR 
repression leads to enhanced AKT phosphorylation through downregulation of the AKT 
phosphatase, PHLPP (Carver et al., 2011a). As pronounced AR inhibition is observed following 
PPP1R14C depletion (figure 4.2), downregulation of PHLPP remains a plausible reason for 
increased AKT phosphorylation, which in turn would lead to enhanced AR degradation via 
serine 213 phosphorylation, potentiating this negative feedback loop. Similarly, inhibition of 
the MAPK signalling cascade has been shown to induce activity of the PI3K pathway 
characterised by increased AKT phosphorylation (Turke et al., 2012). As a reduction in the 
phosphorylation of MAPK1/3 is observed in figure 5.5, this too is likely to contribute to 
increased AKT phosphorylation. Serine 213 phosphorylation is also mediated by both isoforms 
of PIM-1, however, these were not interrogated throughout this project, and hence their 
involvement in the modification of serine 213 in the context of MLCP modulation cannot be 
excluded. Nevertheless, phosphorylation of serine 213 by PIM1-S results in proteasomal 
degradation mediated by MDM2 in very much the same manner as AKT, and therefore would 
support the data presented in figures 5.2 and 5.6. Phosphorylation by PIM1-L on the other 
hand results in increased nuclear localization, stability and nuclear localization, and as such, 
would conflict with the data presented in this section.  
Finally, immunofluorescence analysis of LNCaP cells transfected with PPP1R14C RNAi not only 
confirmed impaired nuclear translocation of the AR, but provided significant evidence for the 
rapid involvement of PPP1R14C mediated MLCP inhibition in response to androgen 
stimulation (figure 5.4). PPP1R14C phosphorylation has previously been reported to be 
enhanced in response to serum (Madsen et al., 2015), and here it is possible to show that this 
induction is extended to androgen stimulation. Indeed, this finding could be further enhanced 
using phospho-specific antibodies raised against PPP1R14C threonine 73, but as of yet a 
specific antibody does not exist, and the use of a phosphorylated PPP1R14A threonine 43 
antibody would raise specificity issues. The MLCP inhibitor protein family display significant 
similarities both in terms of structure and regulation, and it has been previously reported that 
PPP1R14A is phosphorylated in response to androgen, further suggesting that androgen 
mediated phosphorylation of PPP1R14C is plausible (Song et al., 2010). Indeed, this raises the 
possibility that disruption of androgen mediated MLC20 phosphorylation prevents efficient 
AR nuclear translocation. A number of cytoskeletal associated proteins have been associated 
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with co-regulation of AR activity, one of which, filamin, has been associated with a crucial role 
in AR nuclear translocation (Ozanne et al., 2000). As such, the direct involvement of MLCP in 
AR cytoplasmic retention cannot be ruled out.  
In conclusion, MLCP impacts on the phosphorylation status of the AR at a number of different 
biologically important phospho-residues, resulting in impaired ligand induced nuclear 
translocation and accelerated proteasomal degradation. These can be in part explained by the 
repression and induction of the MAPK and PI3K signalling cascades respectively, but crucially, 
suggests that MLCP modulation is having a profound impact on a number of independent 
signalling cascades, and ultimately exerting repressive regulation of the AR via indirect 
mechanisms. Indeed, the impaired nuclear localization and enhanced degradation of the AR 
correlate with the reduction in AR mediated gene transcription described in section 4.2. 
Functionally, it is now possible to understand how MLCP modulation impacts on the cellular 
role of the AR, however, the underlying mechanisms linking MLCP activity to AR repression 
remain unknown. Therefore it is necessary to gain a greater understanding of MLCP function, 
and in particular, a greater understanding of its therapeutic relevance in order to assess MLCP 
modulation as a viable modality in the treatment of PC.  A schematic diagram summarising 
the findings from this chapter can be found in figure 5.9. 
Figure 5.9 – Schematic Summary of Section 5 Results. Enhanced MLCP activity via depletion of PPP1R14C reduces MAPK 
and CDK mediated phosphorylation of AR serine 81 and serine 515 resulting in impaired ligand induced nuclear 
translocation. Conversely, phosphorylation of the AR at serine 213 by AKT is enhanced following PPP1R14C depletion, 
resulting in enhanced proteasomal degradation. 
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6.1 Introduction 
As described in section 1.1.6, preventing transactivation of the AR has remained a crucial 
treatment modality in PC therapy for over 40 years. Although drugs have advanced 
pharmacologically, or indeed, novel approaches of targeting the androgen signalling axis have 
developed in parallel with our improved understanding of AR signalling, ultimately, the aim of 
preventing the biological role of the AR in the treatment of PC has remained the same. Indeed, 
disruption of the AR either by small molecule inhibition, ligand withdrawal or genetic 
modification represses PC cell and tumour growth. As the genotypic impact of PPP1R14C RNAi 
knockdown has been established in relation to the activation of clinically relevant tumour 
suppressors, and its involvement in cell cycle progression assessed, the impact of PPP1R14C 
modulation on LNCaP cell growth and migration was investigated using live cell imaging 
techniques and a Boyden chamber assay respectively. Similarly, the depletion of PPP1R14C 
was assessed in cell line models of treatment resistance. Since the discovery by Huggins et al 
(Huggins et al., 1941) in 1941 that PC is highly dependent upon the action of androgens for 
survival, growth and progression, targeting the AR signalling axis has been the mainstay of 
treatment for localised, advanced, and metastatic PC. As described in section 1.1.6, this form 
of treatment is initially very effective, achieving response rates in up to 90% of patients, 
however, after a median time of 2-3 years, it invariably fails, rendering the cancer what is 
termed castrate resistant. Whether ADT resistant clones exist prior to treatment is currently 
unknown, but undoubtedly, therapy with ADT applies a selection pressure upon the cancer, 
favouring survival and propagation of resistant cells.  
Although novel cytotoxic agents, AR targeting agents, and immunotherapies have been 
developed, demonstrating modest increases in survival outcomes, CRPC invariably progresses 
in the absence of any effective treatments, characterised by rising PSA levels, metastasis, and 
ultimately death after a median period of 16-18 months (Chen et al., 2004). The rising 
expression of PSA, combined with initial responses to novel anti-androgens, suggests CRPC 
tumours still possess an active androgen signalling axis and are sensitive to androgen blockade, 
and therefore the AR remains a viable therapeutic target. Indeed, a number of resistance 
mechanisms that allow continued AR signalling in CRPC have been identified. These include 
incomplete blockade of androgen biosynthesis pathways, AR amplification, AR mutation, 
aberrant AR co-activator activity, and the emergence of AR splice variants. 
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Emerging evidence exists that intratumoral androgen biosynthesis pathways are up-regulated 
in CRPC, enabling PC cells to increase androgen availability both within the primary tumour 
and at distant metastatic sites (Mohler et al., 2004; Locke et al., 2008; Montgomery et al., 
2008). Sensitization of the AR to low levels of androgens also occurs through over-expression 
of the AR. Indeed AR amplification has been observed in up to 50% of mCRPC cases (Dan et 
al., 2015). In addition to gene amplification, DNA hypermethylation has been shown to lead 
to reduced binding of the AR suppressor binding complex, resulting in enhanced AR mRNA 
expression (Perry et al., 2010). Multiple mutations have been detected within the AR LBD. 
Furthermore, these mutations have been demonstrated to convert anti-androgen antagonism 
to AR agonism, enhancing AR transcriptional activity (Zhou et al., 2010). Similarly, mutation of 
the AR LBD has also been documented to allow AR activation following the binding of 
alternative steroidal hormones such as progesterone and corticosteroids (Culig et al., 1993; 
Zhao et al., 2000). Finally, the emergence of AR splice-variants has been heavily linked to the 
progression of CRPC. There are a number of splice variants encoding an AR protein lacking the 
LBD, resulting in a constitutively active and nuclear localized AR molecule (Dehm et al., 2008; 
Hu et al., 2009). 
In this section, an investigation into the impact of PPP1R14C depletion on the AR signalling 
axis from anti-androgen resistant and steroid deprived resistant LNCaP cells is performed. 
Resistant and steroid deprived LNCaP cells were generated in house and have been shown to 
possess an active androgen signalling axis (O’Neill et al.).  
 
115 
 
6.2 Results 
6.2.1 PPP1R14C depletion reduces LNCaP cell growth 
In order to investigate the impact of PPP1R14C RNAi depletion on cell growth, LNCaP cells 
were monitored by live cell imaging for 96 hours following transfection. Images were taken 
every 4 hours, and the percentage confluency calculated using the Incucyte Zoom software. 
Figure 6.2 shows representative images taken at 96 hours of LNCaP cells transfected with 
scrambled and siPPP1R14C-1 RNAi oligos, respectively. It is clear from the images that 
depletion of PPP1R14C resulted in impaired cellular proliferation whilst maintaining a 
physiological phenotype. Figure 6.1 highlights the rate of proliferation for the two 
experimental arms. LNCaP cells transfected with the scrambled control siRNA increased in 
confluency by 2.8-fold over a 96 hour period, whilst cells transfected with the siPPP1R14C-1 
achieved a 2-fold increase in confluency over the same time period. This is the equivalent of 
a 45% reduction in cell proliferation. 
 
Figure 6.1 - PPP1R14C Depletion Reduces LNCaP Cell Growth. LNCaP cells 
depleted of PPP1R14C were cultured in full media for 96 hours. Growth was 
measured by live cell imaging and calculated from percentage confluency. 
Data represents n=3 mean ± sd. 
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6.2.2 PPP1R14C depletion reduces LNCaP cell migration 
To assess the impact of PPP1R14C depletion on cell migration a Boyden chamber assay was 
implemented as described in section 2.18. Figure 6.3 contains representative images from 
each of the experimental repeats for both siPPP1R14C-1 and scrambled RNAi transfection. 
Following cell fixation and staining, cells were counted and plotted in a box-plot chart 
including maximum value, minimum value, median, and 1st and 3rd quartiles. Knockdown of 
PPP1R14C resulted in a dramatic reduction of LNCaP cell migration compared to the 
scrambled control of approximately 80% (median, p-value).  
Figure 6.2 - PPP1R14C Depletion Doesn't Impact on the Morphology of LNCaP Cells. 
LNCaP cells depleted of PPP1R14C and were imaged every 4 hours. This figure is a 
representative image of LNCaP cell growth and morphology at the 96 hour time-point. 
Figure 6.3 - PPP1R14C Depletion Reduces LNCaP Cell Migration. LNCaP cells were depleted of PPP1R14C as 
previously described for 48 hours. Cells were then trypsinised and counted (N=10,000) before being placed in the 
upper chamber of a Boyden chamber in DCC media. The lower chamber contained full media. Migrated cells were 
fixed, stained and counted after a period of 24 hours. Data represents n=3 maximum, minimum, median, 1st and 
3rd quartile values. 
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6.2.3 PPP1R14C depletion reduces androgen receptor transcriptional activity in distinct cell line 
models of treatment resistance 
RNAi depletion of PPP1R14C in LNCaP-AI cells resulted in a statistically significant mean 
reduction in PPP1R14C mRNA expression of approximately 90%, as depicted in figure 6.4. In 
parallel with the parental LNCaP cell line, this resulted in a statistically significant repression 
of the AR target genes PSA and TMPRSS2 at the mRNA level as quantified by RT-qPCR. Indeed 
both genes were repressed by over 70%, reinforcing that the AR is still active in the absence 
of androgen in the LNCaP-AI cell line, and is sensitive to repression by MLCP activity. 
Figure 6.4 - PPP1R14C Depletion Reduces AR Transcriptional Activity in 
Androgen Independent LNCaP Cells. PPP1R14C was depleted in LNCaP-AI cells 
for 72 hours in DCC media. AR regulated gene mRNA expression was quantified 
by RT-qPCR. Data represents n=3 mean ± sem. Unpaired student t test 
performed using graphpad 
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Subsequent RNAi investigations took place in the anti-androgen resistant cell lines LNCaP-
CdxR and LNCaP-EnzR in the presence of the respective anti-androgen. Successful knockdown 
of approximately 80% following siPPP1R14C-1 transfection can be observed in both LNCaP-
CdxR and LNCaP-EnzR in figure 6.5 and figure 6.6 respectively. In the LNCaP-CdxR cell line this 
resulted in inhibition of both PSA and TMPRSS2 mRNA expression of over 60%. In the 
enzalutamide resistant LNCaP cell line, LNCaP-EnzR, PPP1R14C knockdown resulted in a 90% 
reduction in PSA expression, and an approximately 60% reduction in TMPRSS2 expression. 
Again, this reinforces that both resistant cells possess active AR signalling cascades in the 
Figure 6.5 - PPP1R14C Depletion Reduces AR Transcriptional Activity in 
Casodex Resistant LNCaP Cells. PPP1R14C was depleted in LNCaP-CdxR cells 
for 72 hours in FM media + 10µM casodex. AR regulated gene mRNA 
expression was quantified by RT-qPCR. Data represents n=3 mean ± sem. 
Unpaired student t test performed using graphpad 
Figure 6.6 - PPP1R14C Depletion Reduces AR Transcriptional Activity in 
Enzalutamide Resistant LNCaP Cells. PPP1R14C was depleted in LNCaP-EnzR 
cells for 72 hours in FM media + 10µM enzalutamide. AR regulated gene 
mRNA expression was quantified by RT-qPCR. Data represents n=3 mean ± 
sem. Unpaired student t test performed using graphpad 
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presence of their respective anti-androgen, and can be repressed following modulation of 
PPP1R14C expression.  
Figure 6.7 highlights the ability of PPP1R14C to impact on the cell growth of the LNCaP-AI cell 
line. Over a 96 hour period, cells within the scrambled control arm of the assay increased in 
confluency by 4.5-fold. In contrast, LNCaP-AI cells depleted of PPP1R14C increased in 
confluency by less than 3-fold, representing a 50% reduction in cell proliferation.  
 
 
7.3 Discussion 
In this section it was possible to identify the impact of PPP1R14C depletion on LNCaP cell 
proliferation and migration. LNCaP cells are androgen dependent and it has been previously 
shown that inhibition of the AR via multiple mechanisms is capable of reducing LNCaP cell 
growth and migration (Yang et al., 2005b; Zhu and Kyprianou, 2010; Guerrero et al., 2013). In 
previous sections it was demonstrated that PPP1R14C depletion leads to significant inhibition 
of the AR signalling cascade as well as impairing cell cycle progression, this now correlates 
with a 45% reduction in LNCaP cell proliferation over a 96-hour time-period. Indeed, detecting 
down-regulation of PPP1R14C at the protein level has proven difficult throughout this project 
Figure 6.7 - PPP1R14C Depletion Reduces Androgen Independent LNCaP Cell 
Growth. LNCaP-AI cells depleted of PPP1R14C were cultured in DCC media for 96 
hours. Growth was measured by live cell imaging and calculated from percentage 
confluency. Data represents n=3 mean ± sd. 
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and therefore a direct relationship between PPP1R14C protein levels and proliferation cannot 
be concluded. However, it has been possible to quantify depletion of PPP1R14C at the mRNA 
level at both the 72 and 96 hour time points, confirming repression of PPP1R14C mRNA is still 
persistent at these-time points. One negative factor of this assay would be the time-point at 
which PPP1R14C mRNA depletion is first observed is unknown, and indeed, this should be 
incorporated into future assays. If this was known it might be possible to draw a more accurate 
conclusion between PPP1R14C mRNA expression and LNCaP cell growth. In this assay, 
confluency has been used as the measurement for cell growth, which provides a suitable 
surrogate for proliferation as long as cells do not reach such a high density that they begin to 
grow in layers, and indeed that the morphology of the cells does not change following 
modulation. As can be observed in figure 6.2 the morphology of the LNCaP cells following 
PPP1R14C depletion remains consistent with the morphology of the LNCaP cells transfected 
with the non-silencing control, suggesting there is no significant detrimental effect on 
essential cellular pathways. Furthermore, the cells in either arm do not reach a confluency 
forcing overlapping growth. It is also possible to observe that there is no evidence of increased 
cell death, which is consistent with the cell cycle data presented in section 4 where no 
significant difference in the population of LNCaP cells in the sub-G1 phase was detected, 
reinforcing that PPP1R14C does not appear to be cytotoxic, but rather, cytostatic. 
Following implementation of the Boyden chamber assay, a profound reduction in the 
migration of LNCaP cells is observed following depletion of PPP1R14C of approximately 80% 
compared to the scrambled control. Therapeutically this is very advantageous, particularly as 
death from PC is typically associated with metastasis from the primary tumour to distant sites. 
PC is regarded as a slow growing cancer, and more recently the preferred treatment option 
for low-risk patients is active surveillance, therefore by combining a reduction in proliferation 
with a pronounced inhibition of migration would be well suited characteristics of future 
treatment modalities. Whilst the reduction in cell proliferation following PPP1R14C depletion 
may be associated with enhanced cell cycle regulation, the impact on migration is more likely 
to be associated with alternative signalling cascades. Cell motility is dictated via modulation 
of the actin cytoskeleton, and whilst actin polymerization pushes the plasma membrane 
forward, both the trailing membrane and stress fibres are pulled in through actomyosin 
contraction, a process that requires the reversible phosphorylation of MLC20, mediated by 
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both MLCK and MLCP (Watanabe et al., 2007). Whilst neither the phosphorylation nor 
dephosphorylation of MLC20 has been inhibited, it could be possible that enhanced MLCP 
activity following depletion of PPP1R14C prevents hyperphosphorylation of MLC20, and as 
such reduces the rate at which MLC20 phosphorylation is cycled, thus slowing the migratory 
rate of LNCaP cells. Indeed, the implication of PPP1R14C on lamellipodia formation has been 
previously published (Madsen et al., 2015). The lamellipodium is an essential cellular structure 
for cell migration and has been demonstrated to play a key role in PC invasion and metastasis. 
Upon migration, cells produce sheet-like protrusions, the lamellipodium, at the leading edge 
in order to generate cellular-matrix interactions, which upon cycling of the MLC20 
phosphorylation status, leads to cellular contraction and motility (Kato et al., 2014). Upon 
depletion of PPP1R14C, the authors noted a reduction in both the length and the peak angle 
of the lamellipodia in MDA-MDB-231 cells (breast adenocarcinoma), resulting in fewer, more 
broader extensions characterised by a reduction in pMLC20, and conclude that this phenotype 
leads to a reduction in intra-cellular hydrostatic pressure, preventing migration through 
confined spaces (Madsen et al., 2015). This would directly implicate PPP1R14C depletion in 
the repression of cell migration via increased dephosphorylation of pMLC20, but it should also 
be noted that the tumour suppressor NF2 plays a crucial role in cell motility, providing 
secondary, indirect, evidence for the repression of migration by PPP1R14C knockdown. Both 
lamellipodia formation and MLC20 phosphorylation is mediated in a Rho/Rac1 GTPase 
dependent manner (Nobes and Hall; Kimura et al., 1996). NF2 is a potent repressor of both 
Rho and Rac1 through inhibition of guanine nucleotide exchange factors, a crucial step in 
activation of both Rho and Rac1 (Morrison et al., 2007). Thus, increased dephosphorylation 
and activation of NF2 by MLCP following PPP1R14C depletion, will undoubtedly play a 
repressive role in the reduction of LNCaP cell migration observed in figure 6.3. It should also 
be noted that cells are at their most migratory during the G1 phase of the cell cycle, and 
despite the increase in cells found in G1 following PPP1R14C depletion, a dramatic reduction 
in the migration of LNCaP cells is observed, making this finding more significant. In conclusion, 
a significant reduction in the proliferation of PC cells can be attributed to the increase in G1 
cell cycle arrest observed in section 6, whilst a dramatic reduction in PC cell migration can be 
linked to increased dephosphorylation of both MLC20 and NF2 by MLCP, providing novel 
evidence that PPP1R14C depletion represents a novel approach to reduce both LNCaP cell 
proliferation and migration as well as AR transactivation. 
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The ability of the AR to function in the presence of next-generation anti-androgens and under 
castrate resistant conditions has become a hallmark feature of CRPC. Whilst next generation 
AR targeting agents only show modest efficacy in CRPC patients, it has become evident that 
targeting the AR signalling axis remains a viable therapeutic approach. In this section it has 
been possible to demonstrate that depletion of PPP1R14C results in the significant repression 
of AR transactivation as quantified by the mRNA expression of its target genes PSA and 
TMPRSS2 in 3 LNCaP derived cell lines, capable of continued AR signalling in the absence of 
androgen, and in the presence of casodex and enzalutamide, respectively. Furthermore, 
PPP1R14C knockdown reduces LNCaP-AI cell growth by 50%, demonstrating that this cell line 
is still sensitive to disruption of the AR signalling axis. In section 3 it was possible to 
demonstrate that depletion of PPP1R14C was capable of reducing AR transcriptional activity 
in both the presence and absence of androgen. Conversely, depletion of PPP1R12A resulted 
in increased AR transcriptional activity in both the presence and absence of androgen. This 
strongly suggests that MLCP is intrinsically repressive to AR function, but moreover, in a ligand 
independent manner. This is further confirmed in this section, as all 3 resistance models 
represent ligand independent resistance mechanisms, and are sensitive to depletion of 
PPP1R14C. The underlying mechanisms of resistance within each cell line remains unknown, 
and therefore it is not possible to make any direct conclusions regarding the impact of 
PPP1R14C depletion on the particular resistance mechanisms each cell line possess. However, 
as knockdown of PPP1R14C plays a pivotal role in the repression of upstream signalling 
cascades required for AR expression and signalling in both the presence and absence of 
androgen, it is likely these too are involved within the context of this section. Indeed, despite 
a reduction in AR function in both the LNCaP-CdxR and LNCaP-EnzR cell lines following 
PPP1R14C depletion, ultimately the impact on cell growth has not been assessed and as such 
requires future interrogation. Furthermore, it has been demonstrated that mutations within 
the AR LBD, enabling antagonists to act as agonists, induce a distinct transcriptional program 
to wild type AR, and as such, additional AR target gene expression should be investigated, 
particularly in relation to mutant AR target genes (O'Neill et al., 2015). This chapters findings 
are schematically represented in figure 8.5. 
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Figure 6.8 – Schematic Summary of Section 6 Results. RNAi depletion of PPP1R14C reduces 
LNCaP cell proliferation and migration. Furthermore, PPP1R14C RNAi depletion reduces AR 
transcriptional activity in LNCaP-AI, LNCaP-CdxR and LNCaP-EnzR cell lines providing 
significant evidence for viability of PPP1R14C as a therapeutic target. 
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7.1 Introduction 
Throughout this thesis a thorough analysis into the impact of MLCP activity on AR function has 
been performed following RNAi depletion of PPP1R14C, providing significant evidence for its 
viability as a therapeutic target in PC. However, limited availability of commercial reagents 
against PPP1R14C, and indeed insufficient knowledge on the therapeutic disruption of PP1 
holoenzymes, currently render PPP1R14C untargetable. As such, investigation into additional 
endogenous MLCP inhibitors represents an attractive route of further reinforcing previous 
findings within this thesis, whilst identifying potential novel therapeutic targets in the 
treatment of PC. With this in mind, PTMs of MLCP will be introduced in this chapter, with an 
emphasis on MLCP inhibition.  
As described in section 4, PPP1R12A is the substrate specifying subunit for the PP1 
holoenzyme MLCP, and is subject to a number of PTMs capable of influencing its activity. 
These include phosphorylation, ubiquitination and methylation. Phosphorylation of PPP1R12A 
occurs in response to a number of physiological stimuli, many of which result in specific spatio-
temporal regulation of MLCP activity. It has been demonstrated that PPP1R12A is 
phosphorylated specifically during mitosis at 3 serine residues; serine 432, serine 473 and 
serine 601 (Yamashiro et al., 2008). This was shown to be mediated by proline directed kinases, 
including CDK1. The authors went on to show that phosphorylation of serine 473 results in the 
formation of a PLK1 binding motif, and indeed, phosphorylated PPP1R12A at serine 473 co-
immunoprecipitates with PLK1, whilst a PPP1R12A 473A mutant does not. Further 
characterisation revealed that this interaction mediates dephosphorylation of the PLK1 
activation site, threonine 210, by MLCP. A more recent study went on to show that 
phosphorylation of PPP1R12A serine 445 by LATS1 was crucial for PLK1 inactivation by MLCP, 
suggesting there is significant interplay between the different phosphorylation sites on 
PPP1R12A (Chiyoda et al., 2012). Crucially, phosphorylation of serine 445 by large tumour 
suppressor kinase 1 (LATS1) occurred in an ataxia telangiectasia mutated (ATM) dependent 
manner following DNA damage, resulting in repression of PLK1 activity and attenuation of 
mitotic entry. Another site capable of enhancing MLCP activity upon phosphorylation is serine 
695, mediated by PKA and PKG (Wooldridge et al., 2004). It was demonstrated that 
phosphorylation of serine 695 prevents phosphorylation at threonine 696, the most 
characterised inhibitory site of PPP1R12A. Phosphorylation of threonine 696 has been 
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extensively studied in the context of cell motility and actomoyosin contractility, and has been 
demonstrated to account for RhoA mediated Ca2+ sensitization in smooth muscle. More in 
depth studies successfully demonstrated that the RhoA-associated kinases ROCKI/II were 
responsible for phosphorylation and inhibition of PPP1R12A at threonine 696 and serine 854, 
and as such these 2 residues have since been regarded as the PPP1R12A inhibitory 
phosphorylation sites (Kimura et al., 1996; Feng et al., 1999). Subsequent studies have shown 
that many kinases are capable of phosphorylating PPP1R12A at threonine 696, and indeed 
inhibit MLCP activity. These include RAF1, myotonic dystrophy kinase-related CDC42-binding 
kinase, myotonic dystrophy protein kinase, ILK and ZIPK (Muranyi et al., 2001; Broustas et al., 
2002; Kiss et al., 2002; Wilkinson et al., 2005; Takamoto et al., 2006).  
Methylation of PPP1R12A at lysine 442 has been shown to impact on its stability both in-vitro 
and in-vivo (Cho et al., 2011). Methylation was demonstrated to be mediated by SET9, which 
upon RNAi depletion, led to a pronounced destabilization of the PPP1R12A protein. 
Conversely, demethylation has been shown to be mediated by lysine demethylase 1 (LSD1), 
which upon RNAi depletion leads to enhanced PPP1R12A stability, and is characterised by 
increased dephosphorylation of MLCP substrates, specifically RB1 serine 807/811. 
Degradation of PPP1R12A has been reported to occur in an SIAH2 dependent manner 
(Twomey et al., 2010). PPP1R12A contains an SIAH2 consensus sequence, ‘RLAYVAP’, within 
its CTD, and has been shown to interact through this motif with SIAH2. As such, PPP1R12A 
acts as a signalling hub for a number of signalling pathways and plays a crucial role in 
modulating cell motility, and a number of down-stream signalling cascades associated with 
the activity of its substrates.  
However, it is the role of the adenosine monophosphate-activated protein kinase (AMPK)-
related kinases NUAK1 and NUAK2 that were pursued within the context of MLCP inhibition 
within this thesis. NUAK1/2 were identified as AMPK-related kinases through sequence 
homology with the AMPK catalytic domain (Manning et al., 2002). Indeed, NUAK1/2 can be 
activated via phosphorylation by LKB1 like AMPK (Lizcano et al., 2004). However, the known 
AMPK inducers, AICAR, phenformin and metformin, failed to induce NUAK1/2 activity, 
suggesting different regulatory mechanisms exist for NUAK1/2 (Lefebvre and Rosen, 2005). 
Both NUAKs can be activated in response to osmotic stress and nutrient deprivation including 
glucose and glutamine withdrawal, whilst NUAK2 activity can also be induced by DNA damage 
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(Suzuki et al., 2003a; Suzuki et al., 2003b). Crucially, both members have been associated with 
tumorigenesis. NUAK1 has been shown to induce tumour cell survival and suppress cell death 
during nutrient starvation, as well as being identified as an important component of AKT-
dependent cancer cell survival and migration (Suzuki et al., 2003b; Kusakai et al., 2004). 
Furthermore, over-expression of NUAK1 has been demonstrated to induce cellular aneuploidy 
and senescence (Humbert et al., 2010). Similarly, NUAK2 has been implicated with the 
migration and proliferation of melanoma cells, with NUAK2 expression being a significant risk 
factor for patient relapse (Namiki et al., 2011). In fact, NUAK2 gene amplification has recently 
been identified in a number of human cancers (Monteverde et al., 2015). Interestingly, 
PPP1R12A is the only known substrate for NUAK2 (Yamamoto et al., 2008). NUAK1 is also 
capable of phosphorylating PPP1R12A in addition to LATS1, an MLCP enhancer, contributing 
to the cell migratory and detachment roles of the NUAK kinases (Humbert et al., 2010; 
Zagorska et al., 2010).  
Phosphorylation of PPP1R12A by NUAK1/2 occurs on serine 445, serine 472 and serine 910 
(Zagorska et al., 2010). Crucially, phosphorylation at serine 472, triggers the binding of 14-3-3 
and inhibits the catalytic activity of MLCP (Koga and Ikebe, 2008). Over-expression of 14-3-3 
significantly impairs MLCP activity through enhanced binding to PPP1R12A characterised by 
an increase in the phosphorylation status of MLC20. 14-3-3ζ has also been demonstrated to 
induce AR transcriptional activity in the absence of androgens in an AR dependent manner 
(Quayle and Sadar, 2007). A subsequent study demonstrated that 14-3-3ε was involved in a 
positive feed-forward loop with the AR and capable of driving AR nuclear localization in the 
absence of androgens, whilst enhancing MAPK induced AR activity in CRPC (Titus et al., 2009). 
More recently 14-3-3ζ has been confirmed as an AR regulated gene capable of activating AR 
transcriptional activity, enhances PC cell survival and proliferation, and facilitates the 
progression of PC to CRPC, drawing considerable similarities to the impact of PPP1R14C on AR 
transactivation (Murata et al., 2012).  
With this in mind, this section aims to elucidate the impact of endogenous MLCP inhibitors on 
the AR-signalling axis using commercially available small molecule inhibitors. NUAK1/2, 
ROCKI/II and MLCK inhibitors will be employed to elucidate the means by which MLCP 
inhibition enhances AR activity. NUAK1/2 and ROCKI/II phosphorylate different PPP1R12A 
phospho-residues resulting in distinct mechanisms of MLCP inhibition, whilst MLCK directly 
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phosphorylates the MLCP substrate MLC20 serine 19, potentially revealing a novel route of 
AR regulation. Affirmation of the impact of MLCP modulation on the AR signalling cascade will 
reinforce previous findings presented in this thesis, whilst simultaneously providing additional 
therapeutic targets in the treatment of PC. 
7.2 Results 
7.2.1 Myosin light chain kinase inhibition enhances androgen receptor transcriptional activity 
To examine if direct phosphorylation of MLC20 contributes to the regulation of AR function 
by MLCP, LNCaP cells were exposed to 5µM ML-7, a specific inhibitor of MLCK. An initial 
concentration of 5µM was used as previously described in a panel of human cancer cell lines 
(Barkan et al., 2008). Inhibition of MLCK would be expected to result in impaired 
phosphorylation of MLC20, mirroring an increase in MLCP activity following PPP1R14C 
depletion. However, upon inhibition of MLCK with ML-7, a significant induction of both PSA 
and TMPRSS2 mRNA expression quantified by RT-qPCR is observed in LNCaP cells in the 
presence of androgen, contrasting to the repression of AR target gene expression observed 
following PPP1R14C knockdown. Figure 9.1 demonstrates that PSA and TMPRSS2 mRNA 
expression was increased by 1.6 and 2.5-fold, respectively. 
Figure 7.1 - Inhibition of Myosin Light Chain Kinase Increases AR Transcriptional Activity. LNCaP cells 
were subject to inhibition of MLCK with 5µM ML-7 for a period of 24 hours. mRNA expression was 
quantified by RT-qPCR. Data represents n=3 mean ± sd. Unpaired student t test performed using 
graphpad 
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7.2.2 ROCK I/II inhibition enhances androgen receptor transcriptional activity 
ROCK I/II is the known RhoA effector responsible for increased MLC20 phosphorylation. ROCK 
I/II is capable of directly phosphorylating MLC20 serine 19 as well as phosphorylating 
PPP1R12A on threonine 696 and serine 854, inhibiting MLCP activity towards phosphorylated 
MLC20. Similar to the inhibition of MLCK, upon addition of 10µM Y-27632, a specific ROCK I/II 
inhibitor, increases in AR regulated gene expression in the presence of androgen was observed 
as demonstrated in figure 7.2. 10µM Y-27632 was used as previously described for the LNCaP 
cell line (Xiao et al., 2009). Whilst the induction of PSA mRNA expression was not statistically 
significant, TMPRSS2 mRNA expression was significantly increased 2-fold. This supports the 
data presented following MLCK inhibition, and strongly suggests modulation of the 
phosphorylation status of MLC20 does not contribute to the repressive regulation of the AR 
by MLCP, but rather may suggest a positive role in AR function.  
7.2.3 NUAK 1/2 inhibition represses androgen receptor transcriptional activity 
Following on from this, LNCaP cells were exposed to NUAK1/2 inhibition in the presence of 
androgen through the addition of 100nM WZ-4003, a specific NUAK 1 and NUAK2 inhibitor 
(IC50 20nM and 100nM respectively). WZ-4003 IC50 values were calculated for both the 
LNCaP and CWR-22RV1 cell lines (6.5µM and 14µM, respectively), as depicted in 
supplementary figure 2. However, it became apparent that the AR signalling axis was 
significantly repressed at much lower concentrations of WZ-4003. Figure 7.3 demonstrates 
Figure 7.2 - Inhibition of ROCK I/II Increases AR Transcriptional Activity. LNCaP cells were subject 
to inhibition of ROCK I/II with 10µM Y-27632 for a period of 24 hours. mRNA expression was 
quantified by RT-qPCR. Data represents n=3 mean ± sd. Unpaired student t test performed using 
graphpad 
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that 100nM WZ-4003 was capable of significantly reducing AR transcriptional activity in 
relation to the mRNA expression of PSA and TMPRSS2. PSA mRNA expression was reduced by 
60% whilst TMPRSS2 expression was reduced by 40%. Further reinforcing the positive impact 
of NUAK1/2 inhibition on AR activity, a dose-dependent reduction in LNCaP cell growth can 
be observed in figure 7.4. Interestingly, at the 100nM dose shown to significantly repress AR 
transactivation, only a modest reduction in cell proliferation was observed. However, 
statistically significant repression of cell proliferation was observed upon the addition of 
300nM and 1000nM WZ-4003, respectively. Analysis of MLCP activity following NUAK1/2 
inhibition was then investigated by western blot using phospho-specific antibodies against the 
MLCP substrates phosphorylated MLC20 serine 19 and phosphorylated RB1 serine 807/811. 
Similarly the phosphorylation status of PPP1R12A at serine 472 was investigated using a 
phospho-specific antibody. Figure 7.5 demonstrates that a modest reduction in the 
phosphorylation status of PPP1R12A serine 472 occurred in a dose dependent manner, with 
the largest reduction occurring following the addition of 300nM WZ-4003. This correlated with 
a pronounced reduction in the phosphorylation status of both RB1 serine 807/811 and MLC20 
serine 19. No observable reduction in total PPP1R12A was observed, suggesting the increase 
in MLCP activity occurs at the post-translational level.  
 
Figure 7.3 - Inhibition of NUAK 1/2 Reduces AR Transcriptional Activity in LNCaP Cells. 
LNCaP cells were subject to inhibition of NUAK 1/2 with 100nM WZ-4003 for a period of 24 
hours. mRNA expression was quantified by RT-qPCR. Data represents n=3 mean ± sd. 
Unpaired student t test performed using graphpad 
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Figure 7.5- Inhibition of NUAK 1/2 Increases Myosin Phosphatase Activity. LNCaP cells were subject to 
inhibition of NUAK 1/2 with 0, 0.1, 0.3 µM WZ-4003 for a period of 24 hours. Cell lysates were then analysed 
by western blot. A reduction in the phosphorylation status of MLCP substrates RB1 and pMLC20 is observed 
following the incubation of LNCaP cells with WZ-4003 in a dose dependent manner. This correlates with a 
reduction in the phosphorylation status of PPP1R12A serine 472. 
 
Figure 7.4 - Inhibition of NUAK 1/2 Reduces LNCaP Cell Growth. LNCaP cells were subject to 
inhibition of NUAK 1/2 with 0, 100, 300 and 1000nM WZ-4003 for a period of 96 hours. Cell 
growth was measured by live cell imaging. Data represents n=3 mean ± sd. 
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7.2.4 NUAK 1/2 inhibition represses constitutively active androgen receptor variant 
transcriptional activity 
The CWR-22RV1 cell line express constitutively active AR splice variants, particularly the AR-
V7 and AR-1/2/3/2B variants (Tepper et al., 2002). As described in section 8, the emergence 
of AR variants represents a significant prognostic factor in disease progression and treatment 
resistance. Unfortunately, the CWR-22RV1 cell line do not express detectable PPP1R14C and 
therefore it has not been possible to investigate the impact of PPP1R14C depletion on AR 
splice variant activity. However, they do express NUAK1 and NUAK2, therefore using the small 
molecule inhibitor WZ-4003 it has been possible to investigate the impact of MLCP modulation 
on AR variant transcriptional activity. Figure 7.6 represents the impact of 100nM WZ-4003 
exposure on AR transcriptional activity in the CWR-22RV1 cell line cultured in full media. Upon 
inhibition of NUAK1/2 with WZ-4003, a statistically significant reduction in the mRNA 
expression of both PSA and TMPRSS2 was observed of 60% and 50% respectively. This 
correlated with a significant repression in CWR-22RV1 cell growth in the presence of 1µM WZ-
4003 of 40% as depicted in figure 7.7. This was less pronounced than the 75% reduction in 
proliferation observed for the LNCaP cell line. Another treatment resistant cell line employed 
within this section was the LNCaP-EnzR cell line described in section 6. Again, this cell line 
proved to be sensitive to the inhibition of NUAK1/2, resulting in a 60% reduction in cell growth.  
Figure 7.6 - Inhibition of NUAK 1/2 Reduces AR Transcriptional Activity in CWR22RV1 
Cells.CWR22RV1 cells were subject to inhibition of NUAK 1/2 with 100nM WZ-4003 for a 
period of 24 hours. mRNA expression was quantified by RT-qPCR. Data represents n=3 
mean ± sd. Unpaired student t test performed using graphpad 
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7.3 Discussion 
In this section the role of endogenous MLCP modulators was assessed in relation to AR 
regulation. The aim was to identify potential underlying mechanisms supporting the 
repressive role of MLCP on AR regulation previously identified in this thesis, and as such, to 
identify novel AR co-activating targets. As MLCP has been extensively studied in the context 
of MLC20 serine 19 dephosphorlyation, and MLCK directly phosphorylates MLC20 serine 19, 
inhibition of this kinase with the small molecule ML-7 would enable evaluation of this 
modification in the context of AR signalling. As observed in figure 7.1, MLCK inhibition results 
in enhanced AR transcriptional activity, suggesting that dephosphorylation of MLC20 serine 
19 by MLCP is not crucial for the repression of AR activity. In the literature, MLCK inhibition 
with ML-7 has been demonstrated to enhance the cytotoxic activity of etoposide in PC cells, 
and independently reduce the growth of PC tumours in-vivo as a single agent (Gu et al., 2006). 
However, the impact of MLCK inhibition on AR signalling was not evaluated and as such 
requires further interrogation. Similarly, ROCK I/II plays a pivotal role in the phosphorylation 
of MLC20 serine 19 by both direct phosphorylation, and via the inhibitory phosphorylation of 
MLCP. Inhibition of ROCK I/II with Y-27632 has been demonstrated to attenuate PC motility 
Figure 7.7 - Inhibition of NUAK 1/2 Reduces Enzalutamide Resistant LNCaP and CWR22RV1 Cell 
Growth. Cell lines were subject to inhibition of NUAK 1/2 1µM WZ-4003 for a period of 96 hours. 
Cell growth was measured by live cell imaging. Data represents n=3 mean ± sd. 
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and proliferation in the AR-null PC cell line, PC3 (Zhang et al., 2014). As such, both MLCK and 
ROCK I/II inhibition have been independently identified as potential therapeutic targets in the 
treatment of PC, without a thorough investigation into the impact on AR activity. In this 
section it became evident that both inhibition of MLCK and ROCK I/II in fact induce AR 
transcriptional activity, and as such, may not represent suitable targets in the treatment of PC. 
Whilst no studies investigating the impact of MLCK on AR activity have been published, one 
study has identified that MLCK expression is down-regulated in response to androgen in an 
AR dependent manner (Leveille et al., 2009). One hypothesis as to why MLCK inhibition can 
increase AR transcriptional activity would be that both MLCK and the AR form a negative 
feedback loop, and upon MLCK inhibition, AR expression and ultimately activity is increased. 
The relationship between ROCK I/II and AR activity is also understudied. However, one study 
also documents down-regulation of ROCK I/II in an AR mediated manner, again raising the 
possibility of another negative feedback loop (Kroiss et al., 2015). But more compelling is that 
Y-27632, the ROCK I/II inhibitor employed in this section, dramatically enhances signalling of 
the EGFR pathway (Nakashima et al., 2011). This results in significant induction in the activity 
of MAPK1 and MAPK3, kinases capable of inducing AR activity in both the presence and 
absence of androgens (Gioeli et al., 1999). The induction of MAPK activity with Y-27632 may 
be responsible for the increase in AR transactivation observed in figure 7.2. As such, 
preventing phosphorylation of MLC20 serine 19, either directly or indirectly, may contribute 
to the repression of PC cell growth and migration, but it would appear that it does not 
contribute to the repression of AR activity, suggesting additional MLCP substrates are 
responsible for the repression of AR function observed throughout this thesis. 
In contrast to MLCK and ROCK I/II inhibition, exposure of LNCaP cells to the NUAK1/2 inhibitor 
WZ-4003 appears to contribute to MLCP mediated repression of the AR signalling cascade 
through reduced phosphorylation of PPP1R12A. In parallel with PPP1R14C depletion, 
NUAK1/2 inhibition results in enhanced dephosphorylation of phosphorylated MLC20 serine 
19, but crucially, also results in dephosphorylation of the MLCP substrate RB1 at serine 
807/811, suggesting NUAK1/2 phosphorylation of PPP1R12A contributes to RB1 repression. 
Furthermore, NUAK1/2 inhibition prevents transactivation of the androgen independent AR 
variants in the CWR-22RV1 cell line, further reinforcing that MLCP represses AR function in a 
ligand independent manner. As discussed in the introduction to this section, phosphorylation 
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of PPP1R12A at serine 472 mediates the interaction between MLCP and the AR inducer 14-3-
3 resulting in subsequent inhibition of MLCP activity. As a reduction in PPP1R12A serine 472 
phosphorylation is observed following NUAK1/2 inhibition, it is likely the interaction between 
MLCP and 14-3-3 has been diminished, allowing for enhanced activity towards the additional 
substrates including RB1, NF2 and PLK1 outlined in section 4. 
Crucially, inhibition of NUAK1/2, like RNAi depletion of PPP1R14C, results in increased 
dephosphorylation of MLC20 serine 19. However, through the inhibition of MLCK and ROCK 
I/II, this has been shown to not represent a route of AR repression, and therefore, MLCP must 
impose its repressive role on AR function through the dephosphorylation of additional 
substrates. Fundamentally, AR repression by MLCP may be mediated by the distinct spatio-
temporal localization of its endogenous modulators. Both MLCK and ROCK I/II are localized to 
the cell periphery where they are able to respond to extracellular cues and signalling cascades, 
and ultimately modulate the phosphorylation of MLC20 directly and indirectly. Conversely, 
PPP1R14C has been shown to translocate to the nucleus upon phosphorylation following 
serum stimulation (Kiss et al., 2008; Madsen et al., 2015). Indeed, preliminary evidence 
presented in section 5 would suggest that PPP1R14C is capable of mediating a rapid response 
to androgen stimulation in the context of MLCP inhibition. In addition, NUAK1/2 have both 
been shown to predominantly localize to the nucleus and the cytoplasm, whilst PPP1R12A also 
localizes within both the cytoplasm and nucleus, targeting MLCP to its distinct substrates 
throughout varying subcellular localizations. Crucially, the MLCP substrates identified as being 
differentially phosphorylated following PPP1R14C RNAi depletion in section 4 all localize to 
the nucleus as well as the cytoplasm. Therefore, it is likely that PPP1R14C and NUAK1/2 
contribute to the repression of MLCP at subcellular locations where MLCP substrates 
important for AR regulation co-localize. 
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Figure 7.8 - Distinct Subcellular Localizations of Endogenous MLCP Inhibitors and Substrates 
– collated from Human Protein Atlas. Myosin Phosphatase is distributed throughout distinct 
subcellular localizations, whilst its substrates and endogenous inhibitors tend to localize to 
specific subcellular localizations, which in turn may provide spatio-temporal regulation of 
myosin phosphatase activity. 
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Finally, investigation into the expression of NUAK1 and NUAK2 in publicly available datasets 
revealed that both kinases undergo gene amplification in PC. In the most recent publicly 
available dataset (Beltran et al., 2016), NUAK1 was found to undergo gene amplification in 21% 
of cases (16/77), reinforcing its viability as a candidate therapeutic target. NUAK2 was found 
to be genomically amplified in 34% of cases (26/77), also confirming its validity as a target. 
Interestingly, NUAK2 amplification has been associated with PTEN deficiency in melanoma, 
promoting disease progression (Namiki et al., 2015). As described in section 1.2.3, PTEN loss 
is a major prognostic marker for PC and is frequently observed in up to 40% of cases. Therefore 
it will be of interest to see if the association between NUAK2 and PTEN observed in melanoma 
extrapolates to PC. Furthermore, NUAK2 is located on chromosome 1q32, a gene locus found 
to be amplified in 45% of advanced PC samples but unaltered in primary tumours (Holcomb 
et al., 2008). In a subsequent study, 1q32 was found to be amplified in 50% of metastatic PC 
samples (Holcomb et al., 2009). As such, NUAK2 not only represents a valuable biomarker, but 
warrants further interrogation as a potential therapeutic target in the treatment of PC. This 
chapters findings are schematically represented in figure 7.9. 
 
Figure 7.9 – Schematic Summary of Section 9 Results. Inhibition of NUAK 1/2 mediated MLCP phosphorylation 
through the addition of WZ-4003results in repression of AR and AR-V transcriptional activity characterised by 
increased MLCP activity. 
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Concluding Remarks 
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Disruption of the androgen signalling axis is initially a very effective and essential 
strategy in the treatment of localized and locally advanced PC. Unfortunately, patient 
responses to this form of treatment invariably fail after a median period of 2 years, with the 
disease progressing to castrate resistance. Crucially, it has been demonstrated that the AR is 
still responsible for driving disease progression and maintaining an active androgen signalling 
axis. Furthermore, the addition of next generation anti-androgens, such as enzalutamide, to 
the treatment regimens of CRPC patients, elicit partial responses and convey a modest survival 
advantage over placebo, demonstrating that the AR remains a viable therapeutic target even 
under androgen ablation. Indeed, resistance to next generation anti-androgens has been 
heavily linked to aberrant activation of the AR signalling axis, including AR mutation, 
emergence of AR splice variants and dysregulation of AR co-activators. The activity of AR co-
activators, particularly those that are capable of directly modifying the AR at the post-
translational level, are often found to positively correlate with disease progression, and 
reciprocally, post-translationally modified AR species can be indicative of a poor disease 
prognosis. With this in mind, a significant knowledge gap was identified surrounding the role 
of phosphatase enzymes on AR function in the progression of PC. To address this issue, an 
RNAi screen targeting 291 phosphatase enzymes and phosphatase related proteins was 
performed in the androgen responsive PC cell line, LNCaP, using AR transcriptional activity as 
an experimental end-point. This resulted in the identification of both AR co-activators and co-
repressors, representing potential therapeutic targets and biomarkers, and providing a novel 
insight into the role of phosphatase enzymes on AR transcriptional activity. Of particular 
interest was the impact of PP1 regulatory subunit depletion on AR function, providing 
compelling evidence for the differential regulation of AR activity by distinct PP1 holoenzymes. 
In contrast to the current literature surrounding the positive impact of PP1 on AR function, it 
has been possible to demonstrate for the first time that PP1 is a negative regulator of AR 
activity. Furthermore, both the positive and negative regulation of the AR by PP1 is dictated 
by association with its mutually exclusive regulatory subunits, revealing a novel layer of 
complexity to the underlying mechanisms of regulation previously established. Whilst a 
number of regulatory subunits were depleted in the RNAi screen, to date over 200 PP1 
interacting proteins have been identified, resulting in the formation of hundreds of PP1 
holoenzymes, each with distinct subcellular localizations, substrate specificity and catalytic 
activity, emphasising the current lack of knowledge regarding AR regulation by PP1 
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holoenzymes. Conversely, this thesis highlights the opportunity to further dissect the role of 
PP1 regulatory subunits on AR function, allowing for the identification of specific PP1 
holoenzymes involved in the androgen signalling axis, providing a novel route of 
therapeutically targeting the activity of PP1. As such, it was identified within this thesis that 
MLCP is a multimeric PP1 holoenzyme intrinsically repressive to AR function. Depletion of 
PPP1R12A, the substrate specifying regulatory subunit of MLCP, significantly enhanced AR 
transcriptional activity in both the presence and absence of androgen, characterised by a 
dramatic increase in AR mRNA and protein expression. This provides novel evidence for 2 
things; firstly, the identification of a specific PP1 holoenzyme capable of modulating AR activity, 
and secondly, a repressive role for PP1 in the regulation of AR function. Due to the fact that 
MLCP appears to be intrinsically repressive to AR function in a ligand independent manner, it 
might be expected that PPP1R12A could be subject to genomic loss or mutation throughout 
the progression of PC, particularly in a castrate resistant setting. However, upon interrogation 
of a publicly available dataset containing 150 sequenced mCRPC samples (Dan et al., 2015) 0% 
of samples harboured genomic loss of the PPP1R12A gene, whilst only 0.75% (1/150) of 
samples harboured a mutation (fusion gene) within the PPP1R12A gene. This strongly suggests 
that PPP1R12A is essential for cell viability, despite being identified as a repressive regulator 
of AR function. Upon dissection of the literature, it is apparent that MLCP plays a crucial role 
in cytoskeletal rearrangements, impacting on cell migration, cell cycle progression and 
ultimately cellular proliferation. However, it also becomes increasingly apparent that the 
activity of MLCP is heavily influenced at the post-translational level by a number of different 
signalling cascades in a very sensitive spatio-temporal manner. With this in mind it was 
possible to identify PPP1R14C, an endogenous inhibitory protein for MLCP, as an activator of 
AR transcriptional activity. Characterisation of the role of MLCP on AR functionality using 
robust molecular biology techniques revealed that RNAi depletion of PPP1R14C leads to 
enhanced AR proteasomal degradation and impaired ligand induced nuclear translocation, 
characterised by a repressive phosphorylation status, culminating in significantly reduced AR 
transcriptional activity in both the presence and absence of androgen. Phenotypically, RNAi 
knockdown of PPP1R14C causes G1 cell cycle arrest whilst dramatically reducing cell migration, 
but crucially, represses the proliferation of PC cells within distinct models of castrate 
resistance. However, with the increased availability of enhanced sequencing techniques, it is 
becoming increasingly apparent that the genomic landscape of CRPC is highly heterogeneous 
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and extremely complex. Aberrations within the PI3K signalling cascade and the cell cycle 
machinery are amongst some of the most frequently observed abnormalities in CRPC, 
undoubtedly contributing to disease resistance and driving disease progression. Crucially, it 
was established that MLCP inhibition of AR activity partly occurs via an indirect mechanism, 
incorporating the activation of 2 clinically relevant tumour suppressors, RB1 and NF2. 
Increasing the activity of both RB1 and NF2, via the depletion of endogenous MLCP inhibitory 
proteins, provides a novel route of repressing E2F1 and MTORC1 respectively, both 
independent PC therapeutic targets within their own right. An additional advantage of 
increasing MLCP activity via PPP1R14C depletion is increased dephosphorylation of PLK1, 
another promising therapeutic target in the treatment of PC. Targeting specific PP1 regulatory 
subunits has recently emerged as a viable route of modulating PP1 activity, providing 
significant reassurance that PPP1R14C remains a viable therapeutic target for the future. 
However, currently no tool compounds exist to directly enhance the activity of MLCP via 
disruption of endogenous inhibitory proteins. This provided the project with a rationale to 
investigate additional MLCP inhibitors where small molecule inhibitors may be available. As 
previously mentioned, PPP1R12A is heavily influenced at the post-translational level by a 
number of different signalling cascades in a specific and sensitive manner. Using a candidate 
based approach it was possible to identify NUAK1/2 as novel AR co-regulators and potential 
therapeutic targets in the treatment of PC. Inhibition of NUAK1/2 with the small molecule WZ-
4003 prevented the repressive phosphorylation of PPP1R12A by NUAK1/2, characterised by 
an increase in MLCP activity, leading to repression of AR transcriptional activity, and resulting 
in a reduction in PC cell growth. Furthermore, inhibition of NUAK1/2 was capable of repressing 
AR variant transcriptional activity in the CWR22RV1 cell line, reinforcing the finding that MLCP 
is a ligand independent repressor of the AR. In conclusion, MLCP has been characterised as a 
novel PP1 holoenzyme capable of significantly repressing castrate resistant AR transcriptional 
activity, with modulation of 2 distinct MLCP inhibitory mechanisms providing compelling 
therapeutic potential, ultimately warranting further scientific investigation. 
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Supplementary Table 1 – Top 50 positively enriched REACTOME gene sets following GSEA 
 
Gene Set NES p-Value
FDR q-
Value
REACTOME_GENERIC_TRANSCRIPTION_PATHWAY 3.04 0 0
REACTOME_BIOLOGICAL_OXIDATIONS 2.76 0 0.001
REACTOME_PHASE1_FUNCTIONALIZATION_OF_COMPOUNDS 2.63 0 0.004
REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE 2.54 0 0.005
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS 2.51 0.002 0.005
REACTOME_INTEGRIN_ALPHAIIB_BETA3_SIGNALING 2.44 0 0.007
REACTOME_AXON_GUIDANCE 2.44 0 0.006
REACTOME_GPCR_DOWNSTREAM_SIGNALING 2.38 0 0.007
REACTOME_EFFECTS_OF_PIP2_HYDROLYSIS 2.31 0 0.01
REACTOME_SIGNALING_BY_RHO_GTPASES 2.27 0 0.012
REACTOME_HS_GAG_BIOSYNTHESIS 2.12 0.002 0.03
REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION 2.01 0 0.054
REACTOME_SIGNALING_BY_ROBO_RECEPTOR 1.95 0.01 0.07
REACTOME_ION_CHANNEL_TRANSPORT 1.94 0.01 0.071
REACTOME_BRANCHED_CHAIN_AMINO_ACID_CATABOLISM 1.94 0.002 0.067
REACTOME_ION_TRANSPORT_BY_P_TYPE_ATPASES 1.9 0.01 0.077
REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY 1.82 0.008 0.111
REACTOME_SIGNALING_BY_GPCR 1.8 0.02 0.115
REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH 1.8 0.01 0.11
REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM 1.8 0.017 0.107
REACTOME_CGMP_EFFECTS 1.79 0.012 0.105
REACTOME_NCAM1_INTERACTIONS 1.78 0.025 0.109
REACTOME_NITRIC_OXIDE_STIMULATES_GUANYLATE_CYCLASE 1.77 0.023 0.105
REACTOME_DEVELOPMENTAL_BIOLOGY 1.77 0.02 0.101
REACTOME_CLASS_A1_RHODOPSIN_LIKE_RECEPTORS 1.75 0.032 0.108
REACTOME_METABOLISM_OF_STEROID_HORMONES_AND_VITAMINS_A_AND_D 1.73 0.027 0.116
REACTOME_HS_GAG_DEGRADATION 1.72 0.029 0.117
REACTOME_OLFACTORY_SIGNALING_PATHWAY 1.72 0.025 0.115
REACTOME_CELL_JUNCTION_ORGANIZATION 1.66 0.029 0.152
REACTOME_APOPTOTIC_CLEAVAGE_OF_CELLULAR_PROTEINS 1.64 0.051 0.161
REACTOME_NRAGE_SIGNALS_DEATH_THROUGH_JNK 1.62 0.042 0.172
REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS 1.59 0.055 0.19
REACTOME_COLLAGEN_FORMATION 1.57 0.059 0.199
REACTOME_NETRIN1_SIGNALING 1.55 0.047 0.212
REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS 1.55 0.056 0.208
REACTOME_STEROID_HORMONES 1.55 0.057 0.207
REACTOME_GPCR_LIGAND_BINDING 1.53 0.059 0.215
REACTOME_L1CAM_INTERACTIONS 1.5 0.072 0.243
REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES 1.49 0.077 0.243
REACTOME_PHASE_II_CONJUGATION 1.47 0.093 0.268
REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS 1.46 0.072 0.264
REACTOME_FATTY_ACID_TRIACYLGLYCEROL_AND_KETONE_BODY_METABOLISM 1.44 0.097 0.286
REACTOME_LIPID_DIGESTION_MOBILIZATION_AND_TRANSPORT 1.44 0.092 0.281
REACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS 1.39 0.128 0.334
REACTOME_GENERATION_OF_SECOND_MESSENGER_MOLECULES 1.38 0.129 0.34
REACTOME_CELL_CELL_COMMUNICATION 1.38 0.114 0.336
REACTOME_REGULATION_OF_SIGNALING_BY_CBL 1.35 0.117 0.368
REACTOME_CELL_CELL_JUNCTION_ORGANIZATION 1.35 0.137 0.362
REACTOME_GLYCOSAMINOGLYCAN_METABOLISM 1.32 0.155 0.402
REACTOME_APOPTOTIC_EXECUTION_PHASE 1.3 0.153 0.42
REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING 1.29 0.162 0.424
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Supplementary Table 2 – Top 50 negatively enriched REACTOME gene sets following GSEA 
 
Gene Set NES p-Value
FDR q-
Value
REACTOME_CELL_CYCLE -8.84 0 0
REACTOME_CELL_CYCLE_MITOTIC -7.97 0 0
REACTOME_DNA_REPLICATION -6.96 0 0
REACTOME_MITOTIC_M_M_G1_PHASES -6.72 0 0
REACTOME_METABOLISM_OF_RNA -6.6 0 0
REACTOME_CELL_CYCLE_CHECKPOINTS -6.49 0 0
REACTOME_METABOLISM_OF_MRNA -6.32 0 0
REACTOME_S_PHASE -6.26 0 0
REACTOME_MITOTIC_G1_G1_S_PHASES -6.13 0 0
REACTOME_G1_S_TRANSITION -6.06 0 0
REACTOME_METABOLISM_OF_PROTEINS -6.03 0 0
REACTOME_SYNTHESIS_OF_DNA -5.91 0 0
REACTOME_TRANSLATION -5.63 0 0
REACTOME_M_G1_TRANSITION -5.51 0 0
REACTOME_TELOMERE_MAINTENANCE -5.49 0 0
REACTOME_CHROMOSOME_MAINTENANCE -5.13 0 0
REACTOME_ER_PHAGOSOME_PATHWAY -5.04 0 0
REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE -5.02 0 0
REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETI
NG_TO_MEMBRANE
-4.97 0 0
REACTOME_G2_M_CHECKPOINTS -4.88 0 0
REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_P
ROTEINS
-4.84 0 0
REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AN
D_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EAR
LY_G1
-4.84 0 0
REACTOME_MRNA_PROCESSING -4.82 0 0
REACTOME_MRNA_SPLICING -4.81 0 0
REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_M
RNA
-4.79 0 0
REACTOME_ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX -4.78 0 0
REACTOME_INFLUENZA_LIFE_CYCLE -4.74 0 0
REACTOME_ORC1_REMOVAL_FROM_CHROMATIN -4.73 0 0
REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_REGULATION -4.69 0 0
REACTOME_P53_DEPENDENT_G1_DNA_DAMAGE_RESPONSE -4.69 0 0
REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_
BIND_AU_RICH_ELEMENTS
-4.69 0 0
REACTOME_DNA_STRAND_ELONGATION -4.56 0 0
REACTOME_CDT1_ASSOCIATION_WITH_THE_CDC6_ORC_ORIGIN_CO
MPLEX
-4.54 0 0
REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_S
TRESS
-4.5 0 0
REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_P27_P21 -4.47 0 0
REACTOME_AUTODEGRADATION_OF_CDH1_BY_CDH1_APC_C -4.43 0 0
REACTOME_EXTENSION_OF_TELOMERES -4.43 0 0
REACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_TRANSITI
ON_
-4.42 0 0
REACTOME_CDK_MEDIATED_PHOSPHORYLATION_AND_REMOVAL_OF
_CDC6
-4.41 0 0
REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESE
NTATION
-4.39 0 0
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Supplementary Table 3 – Most significant negatively enriched MSigDB ‘Hallmark’ gene sets following GSEA 
 
 
 
 
 
 
 
Gene Set NES p-Value
FDR q-
Value
HALLMARK_E2F_TARGETS -9.33 0 0
HALLMARK_G2M_CHECKPOINT -7.53 0 0
HALLMARK_MYC_TARGETS_V1 -6.75 0 0
HALLMARK_MTORC1_SIGNALING -4.51 0 0
HALLMARK_UNFOLDED_PROTEIN_RESPONSE -4.09 0 0
HALLMARK_DNA_REPAIR -3.58 0 0
HALLMARK_MYC_TARGETS_V2 -3.43 0 0
HALLMARK_OXIDATIVE_PHOSPHORYLATION -3.36 0 0
HALLMARK_ANDROGEN_RESPONSE -2.99 0 0
HALLMARK_UV_RESPONSE_UP -2.58 0 0
HALLMARK_MITOTIC_SPINDLE -2.43 0 0.001
HALLMARK_PI3K_AKT_MTOR_SIGNALING -2.18 0.002 0.004
HALLMARK_NOTCH_SIGNALING -1.78 0.024 0.038
HALLMARK_WNT_BETA_CATENIN_SIGNALING -1.73 0.029 0.045
HALLMARK_GLYCOLYSIS -1.44 0.108 0.164
HALLMARK_TGF_BETA_SIGNALING -1.17 0.257 0.434
HALLMARK_CHOLESTEROL_HOMEOSTASIS -1.11 0.303 0.496
HALLMARK_P53_PATHWAY -1.06 0.347 0.536
HALLMARK_ALLOGRAFT_REJECTION -1.05 0.373 0.525
HALLMARK_PROTEIN_SECRETION -0.99 0.457 0.611
HALLMARK_HEME_METABOLISM -0.98 0.449 0.584
HALLMARK_SPERMATOGENESIS -0.98 0.436 0.559
HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY -0.94 0.503 0.602
HALLMARK_ADIPOGENESIS -0.85 0.645 0.727
HALLMARK_APOPTOSIS -0.84 0.662 0.704
HALLMARK_HEDGEHOG_SIGNALING -0.84 0.658 0.677
HALLMARK_APICAL_SURFACE -0.72 0.809 0.823
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Supplementary Table 4 – Most significant negatively enriched MSigDB ‘Cancer Gene Perturbations’ gene sets following 
GSEA 
 
 
 
Gene Set NES p-Value
FDR q-
Value
CSR_LATE_UP.V1_UP -4.9 0 0
RB_P107_DN.V1_UP -4.24 0 0
E2F1_UP.V1_UP -4 0 0
GCNP_SHH_UP_LATE.V1_UP -3.46 0 0
GCNP_SHH_UP_EARLY.V1_UP -3.33 0 0
CAMP_UP.V1_UP -3.29 0 0
E2F3_UP.V1_UP -2.86 0 0
HOXA9_DN.V1_DN -2.85 0 0
PRC2_EDD_UP.V1_UP -2.77 0 0
RPS14_DN.V1_DN -2.71 0 0
PRC2_EZH2_UP.V1_UP -2.65 0 0
PTEN_DN.V2_DN -2.6 0 0
VEGF_A_UP.V1_DN -2.57 0 0
MYC_UP.V1_UP -2.51 0 0.001
RB_DN.V1_UP -2.43 0 0.001
TBK1.DF_DN -2.38 0 0.002
PDGF_UP.V1_UP -2.34 0 0.003
RB_P130_DN.V1_UP -2.24 0 0.005
EIF4E_UP -2.11 0 0.011
SNF5_DN.V1_UP -1.93 0.008 0.031
CORDENONSI_YAP_CONSERVED_SIGNATURE -1.91 0.008 0.031
ESC_J1_UP_LATE.V1_DN -1.9 0.01 0.031
TBK1.DF_UP -1.88 0.01 0.034
CSR_EARLY_UP.V1_UP -1.87 0.01 0.034
TBK1.DN.48HRS_DN -1.76 0.017 0.062
IL15_UP.V1_UP -1.74 0.025 0.064
PDGF_ERK_DN.V1_DN -1.73 0.022 0.065
LTE2_UP.V1_UP -1.7 0.018 0.074
RB_P107_DN.V1_DN -1.7 0.017 0.072
NRL_DN.V1_UP -1.66 0.049 0.086
TBK1.DN.48HRS_UP -1.6 0.036 0.111
MTOR_UP.N4.V1_UP -1.5 0.085 0.171
ESC_V6.5_UP_LATE.V1_DN -1.47 0.056 0.192
GCNP_SHH_UP_LATE.V1_DN -1.46 0.075 0.193
SIRNA_EIF4GI_DN -1.46 0.092 0.189
SRC_UP.V1_UP -1.39 0.101 0.252
BMI1_DN_MEL18_DN.V1_UP -1.38 0.112 0.255
ESC_J1_UP_EARLY.V1_DN -1.38 0.11 0.251
KRAS.DF.V1_UP -1.37 0.115 0.252
IL2_UP.V1_UP -1.33 0.147 0.29
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Supplementary Table 5 – Most significant negatively enriched MSigDB ‘Motif Based’ gene sets following GSEA 
 
 
 
 
 
Gene Set NES p-Value
FDR q-
Value
GGGCGGR_V$SP1_Q6 -6.96 0 0
SCGGAAGY_V$ELK1_02 -6.31 0 0
V$E2F4DP1_01 -5.69 0 0
V$E2F1_Q6 -5.59 0 0
GCCATNTTG_V$YY1_Q6 -5.53 0 0
V$E2F1DP1RB_01 -5.53 0 0
V$E2F_Q4 -5.45 0 0
V$E2F_Q6 -5.45 0 0
V$E2F_03 -5.39 0 0
V$E2F1DP1_01 -5.34 0 0
RCGCANGCGY_V$NRF1_Q6 -5.32 0 0
V$E2F1DP2_01 -5.31 0 0
V$E2F4DP2_01 -5.31 0 0
V$E2F_02 -5.29 0 0
GATTGGY_V$NFY_Q6_01 -5.2 0 0
V$E2F_Q4_01 -5.08 0 0
V$E2F1_Q6_01 -5.05 0 0
V$E2F_Q3 -4.96 0 0
V$E2F_Q6_01 -4.95 0 0
V$E2F1_Q4_01 -4.91 0 0
V$E2F1_Q3 -4.86 0 0
CACGTG_V$MYC_Q2 -4.79 0 0
SGCGSSAAA_V$E2F1DP2_01 -4.75 0 0
V$E2F_Q3_01 -4.48 0 0
MGGAAGTG_V$GABP_B -4.06 0 0
V$NFMUE1_Q6 -3.94 0 0
GTGACGY_V$E4F1_Q6 -3.9 0 0
V$E2F1_Q3_01 -3.83 0 0
V$E2F1_Q4 -3.82 0 0
TGCGCANK_UNKNOWN -3.76 0 0
V$GABP_B -3.76 0 0
V$YY1_02 -3.75 0 0
V$USF_Q6 -3.58 0 0
V$CREB_01 -3.56 0 0
V$NRF2_01 -3.53 0 0
V$HIF1_Q3 -3.52 0 0
V$YY1_Q6 -3.51 0 0
V$MYCMAX_03 -3.45 0 0
V$CETS1P54_01 -3.42 0 0
GGGAGGRR_V$MAZ_Q6 -3.42 0 0
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Supplementary figure 1 – Results from RNA integrity analysis and reads per sample upon RNA sequencing. Extracted RNA 
was subjected to anaylsis using the bioanalyzer as described in chapter 2. All samples possess a RIN value > 9 and were 
therefore taken forward for RNA sequencing. Upon sequencing, the amount of reads per sample was calculated by Aros 
Biotechnology and can be observed above. 
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Supplementary figure 2 – WZ-4003 IC50 in LNCaP and CWR-22RV1 cell lines. LNCaP and CWR-22RV1 cells were exposed to 
increasing concentrations of WZ-4003 over a 120 hour period. Cell growth was measured using the BioEssen Incucyte live cell 
imager as described in chapter 2. IC50 values were calculated using GraphPad Prism. 
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